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Abstract 
 
Background: RNA splicing is a crucial process for delivering the appropriate 
message for protein synthesis. Most genes are affected by alternative splicing, 
and among these is CHRNA7. This gene encodes for the nicotinic acetylcholine 
Į UHFHSWRU subunit that is involved in the cholinergic anti-inflammatory 
pathway. This anti-inflammatory pathway is considered an important part of the 
human body¶V defence line against tissue injury or infection and causative 
mechanism in COPD.  
Aim: The aim of the present study was to investigate the role of alternative 
splicing on the nature of the transcripts generated by CHRNA7 gene and its 
partial duplicate, CHRFAM7A. 
Methods: Airway epithelial cell lines, A549 and BEAS2B, were mainly used 
as targets for testing alternative splicing. RT-PCR, TA cloning and gel 
extraction methods were used for testing CHRNA7 and CHRFAM7A 
transcripts. Following RT-PCR, the resulting product band intensities were 
analysed using densitometric analysis tools. This was followed by the use of 
several bioinformatics analysis tools to predict the protein structure for the 
resulting transcripts. For one of the detected transcripts, minigene methods were 
used to test for the source of expression. 
Results: A novel transcript missing exon 9 is reported for the first time. Both 
genes showed the expression of full length and the novel transcripts (missing 
exon 9) at similar ratios (~2:1). These results could be detected in immortalised 
cell lines from human alveolar and bronchial epithelial cells (A549 and 
BEAS2B, respectively) and in BE (2)-c cells (neuroblastoma cells with bone 
  
marrow metastasis). The same results were shown when primary human 
peripheral blood monocytes cells (PBMC) were tested. This means that the 
effect of missing exon 9 is not tissue-specific, and is not only found in 
cancerous cells, indicating that it could be a common feature of splicing for 
these two genes. Furthermore, another novel transcript was detected which is 
inserted exon 9b. The initial RT-PCR experiments seemed to suggest that this 
was derived from CHRFAM7A only. The use of minigene methods showed that 
this transcript could be expressed from both genes, CHRNA7 and 
CHRFAM7A, but a single nucleotide base within the inserted sequence (at 
position 77 from the 5` end) could play a role in enhancing of exon 9b in the 
mRNA transcripts. This base is C allele in CHRFAM7A sequence of exon 9b, 
while its corresponding base in CHRNA7 is G allele that has less prominent 
effect on exon 9b inclusion. 
Conclusion: CHRNA7 and CHRFAM7A express novel transcripts in different 
human cells that are missing exon 9. This could be due to inactive splicing 
factors that are required for recognition of exon 9 as a constitutive exon. For 
exon 9b transcripts, these lie within the common sequence of CHRNA7 and 
CHRFAM7A, and it seems that the presence of C allele at position 77 could 
enhance the inclusion of exon 9b in CHRFAM7A more than the presence of G 
allele in CHRNA7 sequences. The results shown in this study implicate a 
possible regulatory role of the transcripts detected on the control mechanism 
exerted by CHRFAM7A on CHRNA7. These results help to suggest a possible 
role of in the development of COPD in the form of inflammatory/anti-
inflammatory control imbalance. 
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1.1 Chronic Obstructive Pulmonary Disease (COPD):  
COPD is a chronic inflammatory disease interrupted by episodes of acute 
exacerbation. A major feature of the disease is the partial loss of reversibility of 
airflow obstruction. Although smoking is the major risk factor contributing to 
the disease, there is strong evidence for the role of genetic factors, which are 
not understood completely. Chronic inflammation is a hallmark of COPD, a 
process that may be controlled via the cholinergic anti-inflammatory pathway. 
7KHĮQLFRWLQLFDFHW\OFKROLQHUHFHSWRUVXEXQLWQ$&K5KDVDFHQWUDOUROHLQ
this anti-inflammatory pathway. This chapter will cover a short introduction to 
COPD and the potential role of CHRNA7 in this disease. 
 
1.1.1 Definition 
COPD is a preventable and treatable disease with pulmonary and extra 
pulmonary components. The pulmonary component is characterized by airflow 
limitation that is not fully reversible, progressive, and associated with an 
abnormal inflammatory response of the lungs to noxious particles or gases 
(GOLD, 2013). 
 
1.1.1.1 Chronic bronchitis and emphysema 
The term COPD is becoming more frequently used for describing patients 
having chronic bronchitis and emphysema. Chronic bronchitis is defined 
(symptomatically) as chronic productive cough for three successive months per 
year for more than one year, while emphysema is defined (pathologically) as 
abnormal permanent dilatation of airways distal to the terminal bronchioles 
(Kumar, c2012). 
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1.1.2 Classification 
A simple spirometric classification of COPD based on lung function is 
recommended by GOLD (Table 1-1). 
Table 1-1: Spirometric Classification of COPD Severity Based on Post-
Bronchodilator FEV1 % predicted. 
COPD stage FEV1/FVC FEV1% predicted 
1: Mild < 0.70  > 80 %  
2: Moderate < 0.70 50%  < and < 80% 
3: Severe < 0.70 30%  < and < 50% 
4: Very severe < 0.70 < 30 % 
FEV1: forced expiratory volume during the first second, FVC: forced vital capacity, 
Adopted from (GOLD, 2013). 
 
For simple classification, spirometry is used. This method includes the use of 
short-acting bronchodilators to test for reversibility and to minimize variation 
in the results between different individuals tested. Following the use of a 
bronchodilator, the individual is asked to apply forceful expiration using the 
spirometer tool. This will help assessing the forced expiratory volume during 
the first second as a percentage of the predicted value (FEV1% predicted). 
 
1.1.3 The burden of COPD: 
COPD is a known cause of worldwide morbidity and mortality and it is 
expected to be the third leading cause of worldwide mortality and the fifth 
leading cause of morbidity by the year 2020 (Buist et al., 2007). This 
worldwide recognized burden on health and treatment costs is increasing due to 
the increased prevalence of the aging population which is contributing to the 
increasing prevalence of the disease in older age groups. The estimated 
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population prevalence in adults is about 10% (Lopez et al., 2006, GOLD, 
2013), but this may be an underestimate as it will take more than a decade for a 
COPD to be established and it is difficult to diagnose COPD in the early stages 
(Lokke et al., 2006). Recent prospective cohort studies revealed that after 25 
years of smoking, more than 20% of smokers will develop COPD, two-thirds 
of which will develop severe forms of this disease (stages 3 and 4 according to 
GOLD classification) (Mannino et al., 2003, Lokke et al., 2006). 
 
1.1.4 Pathogenesis 
COPD is a disease of complex etiology, and there are several factors that play a 
role in its pathogenesis. Early pathological findings in chronic bronchitis 
include mucus glands hypertrophy with resultant increased mucus secretion. If 
the condition continued to progress, the bronchi would be inflamed, and 
inflammatory cells would infiltrate the bronchial walls. This may end up with 
fibrosis and narrowing of the airways. On the other hand, the changes in 
emphysema includes dilatation of the small bronchioles leading to air trapping 
and limitation of airflow, which may progress and cause loss of the elastic 
recoil of the lung tissue (Barnes et al., 2003) (Figure 1-1). 
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Figure 1-1: Pathological features of COPD. 
Chronic bronchitis and emphysema, the two major component parts of COPD, are 
compared with healthy lung tissue. A: Chronic bronchitis showing the inflamed 
bronchi precipitated with the inflammatory products and excess mucus thus decreasing 
the lumen size of the bronchi (as compared to the healthy bronchi). B: Emphysema 
showing alveoli with loss of the alveolar membranes and thus decreasing the gas-
exchange surface area (as compared to the healthy alveoli). 
Taken from (nurseslabs, 2012). 
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1.1.5 Development of COPD:    
There are a number of factors that can contribute individually or collectively to 
the development of COPD (Barnes et al., 2003) (Table 1-2).  
Table 1-2: Risk factors for COPD. 
Smoking 
Protease/anti-protease imbalance 
Genetic factors 
Oxidative stress 
Other factors (occupational exposure, outdoor pollution, age, infections, inflammation 
and other factors). 
 
 
1.1.5.1 Smoking 
Although there are several risk factors for COPD, cigarette smoking remains to 
be the predominant one (GOLD, 2013). There are many factors that determine 
the decline in lung function and subsequent development of COPD amongst 
smokers, like age at starting and pack-years of smoking. Although cessation of 
smoking is an effective strategy to slowdown this decline in experimental 
animals (Li et al., 2007), it requires a long period to resolve the established 
inflammatory changes in the human lungs (Barnes et al, 2003; Rutgers et al, 
2000)(Lokke et al., 2006). Despite the significant role of smoking in 
developing COPD, only about 20 % of smokers develop COPD and the disease 
also occurs in nonsmokers (Mannino et al., 2003, Lokke et al., 2006, Celli et 
al., 2005). However, when using the new criteria based on the GOLD 
classification of COPD, it seems that up to half of smokers develop COPD 
(Lundback et al., 2003). 
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1.1.5.1.1 How does smoking cause COPD? 
In response to prolonged inhalation of cigarette smoke and other noxious 
particles, inflammation can start in the lung tissue. In some smokers, this 
response is exaggerated, leading to chronic inflammation and damage to the 
lung parenchyma (with subsequent emphysema).  In addition, small airway 
fibrosis may result from disturbed immune mechanisms. Both effects cause air 
trapping and airflow limitation leading to the development of COPD (Barnes et 
al., 2003). These effects are mediated by activation of inflammatory cells 
(tissue macrophages and neutrophils in the lung). Similarly, smoking leads to 
increased oxidants released from these cells, and may cause decreased levels of 
DQWLR[LGDQWV LQ &23' SDWLHQWV UHVXOWLQJ LQ ZKDW LV FDOOHG µ2[LGDWLYH VWUHVV¶
Smoking can affect the protease/antiprotease balance, an effect that is mediated 
by inflammatory cells, leading to dominant protease effects and subsequent 
damage to the lung tissue (Figure 1-2). 
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Figure 1-2: The role of smoking in COPD pathogenesis. 
Smoking can lead to the activation of inflammatory cells like macrophages and 
epithelial cells. The activation of tissue macrophages can cause the start of 
inflammatory-like conditions in the lungs, which serve to recruit neutrophils to the 
inflamed area. This can further be complicated by the release of protease enzymes 
from the inflammatory cells (macrophages, neutrophils, and epithelial cells). On the 
other hand, another consequence of smoking is the imbalance of oxidants and anti-
oxidants in the lungs leading to oxidative stress. Collectively, all these factors can 
cause lung inflammation. 
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1.1.5.2 Genetic factors 
Can genetic factors predispose to COPD?  
COPD is an example of interaction between genetic and environmental factors 
(Kalsheker and Chappell, 2008). Although smoking has been shown to be the 
most important environmental factor, family based studies suggest a role for 
genetic factors in the development of COPD (Silverman et al., 1998, GOLD, 
2013). The best recognized genetic factor that contributes to the development 
of COPD is alpha-1-antitrypsin (A1AT) deficiency. The fact that COPD tends 
to cluster in families was the first evidence of association of genetic factors 
with the development of COPD that interplay with environmental factors. 
 
1.1.5.2.1 Familial aggregation of COPD: 
Family studies provided evidence for genetic factors contributing to COPD 
(COPD tends to be clustered in families). Silverman and coworkers used 
spirometric measurements to compare lung function between families of early 
onset COPD smoker probands and a control group. They showed that in 
families of COPD probands the FEV1% and FEV1/FVC levels were both 
significantly lower than those in the healthy controls. Similarly, the former 
group had higher risk for developing chronic bronchitis than the control group, 
highlighting the importance of genetic factors predisposing to the development 
of COPD in certain families (Silverman et al., 1998). Higher risk (by two to 
three times) for developing COPD in siblings of patients with COPD was 
shown by other studies indicating the importance of familial clustering of 
COPD within the smoking relatives of COPD probands (Kueppers et al., 1977, 
McCloskey et al., 2001).   
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Further evidence of familial aggregation of COPD was evident from twin 
studies, showing that monozygotic twins are at high risk for developing COPD 
if one of them develops the disease. This concordance was not complete, and it 
shared almost equally with environmental factors for developing COPD in 
these patients (Hubert et al., 1982, Redline et al., 1987, McClearn et al., 1994). 
 
1.1.5.2.2 Alpha-1-antitrypsin (A1AT) deficiency: 
A1AT is a serine protease inhibitor. It irreversibly inhibits serine proteases 
secreted by neutrophils (neutrophil elastase (NE), proteinase 3 and cathepsin 
G), with NE being its principal substrate (Barnes et al., 2003). This action 
protects the lung against proteolytic damage.  In 1963, Laurell and Eriksson  
ZHUHWKHILUVWWRQRWHWKHDEVHQFHRIWKHĮ-band on protein electrophoresis in 
samples from patients with early-onset emphysema (Laurell and Eriksson, 
1963). The A1AT deficiency accounts for only 1-2% of all COPD cases 
(Ganrot et al., 1967, Silverman et al., 1998, Kalsheker and Chappell, 2008), 
and the disease affects individuals from different racial groups worldwide (de 
Serres, 2002). 
 
1.1.5.2.3 Candidate gene studies: 
Determination of genetic susceptibility for COPD remains a big challenge. 
There are many genetic associations with COPD identified by candidate genes. 
These have been inconsistently replicated (Castaldi et al., 2010). The only 
exception for this is the SERPINA1 gene (that encodes for A1AT), that has 
been proven to affect susceptibility of COPD (Stoller and Aboussouan, 2005). 
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Candidate gene studies showed no association with COPD in many genes. This 
was basically due to ethnic group selection and the number of participants 
(Celedon et al., 2004, Hersh et al., 2005, Castaldi et al., 2010). In a recent 
meta-analysis of candidate gene studies for COPD, it was suggested that the 
genes involved with COPD development can be classified into three main 
pathways: the inflammatory, protease/antiprotease and the oxidative stress 
pathways (Smolonska et al., 2009). However, among the variations studied, 
only SERPINA1 variations showed a well recognised association with COPD.  
 
1.1.5.2.4 GWAS studies for COPD 
These are non-hypothesis driven studies, designed to identify association of 
genetic variants with common diseases in a given population. This type of 
study uses somewhat evenly distributed variation across the genome which 
helps to identify specific areas of the gene that are significantly associated with 
the disease phenotypes (Pearson and Manolio, 2008).  It was suggested that 
GWAS for COPD could be a valuable tools to reveal further genetic 
association to this disease other than the A1AT deficiency (Kalsheker and 
Chappell, 2008). 
The first GWAS for COPD reported by Pillai and colleagues in 2009 identified 
D VWURQJ DVVRFLDWLRQ RI &23' ZLWK WZR Į-nicotinic acetylcholine receptor 
(nAChRs) loci on chromosome 15 (rs1051730 and rs8034191 on CHRNA3/5 
gene locus). This locus was suggested to represent a major susceptibility for 
COPD in the general population (Pillai et al., 2009). Furthermore, the same 
alleles of this locus have been reported recently to be associated with lung 
cancer and nicotine addiction (Amos et al., 2008, Hung et al., 2008, 
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Thorgeirsson et al., 2008). Another GWAS of pulmonary function in the 
Framingham Heart Study identified a SNP on chromosome 4q31 (rs13147758) 
that was strongly associated with FEV1/FVC ratio (Wilk et al., 2009). 
Recently, a study by Repapi and colleagues in 2010 reported a meta-analysis of 
GWAS of pulmonary function in individuals of European ancestry (Repapi et 
al., 2010). This study confirmed the previously reported association of 
pulmonary function with SNPs detected at 4q31 locus by the Wilk et al. study, 
and showed that five novel, previously unreported, loci were robustly 
associated with pulmonary function that represent good candidate genes for 
lung development or renewal pathways. 
 
It is worth mentioning that the results for the two SNPs at CHRNA3/5 locus 
reported by Pillai et al could not be replicated by the other two GWAS studies 
of Wilk et al and Repapi et al, possibly due to investigating different 
phenotypes of COPD. Interestingly, in a recent meta-analysis study to test for 
susceptibility to COPD, SNP (rs1051730) (in the CHRNA3/5 locus) was found 
to have a strong correlation with COPD development, showing an association 
with lower FEV1 % predicted values and increased the risks of developing 
emphysema (Zhang et al., 2011). $OWKRXJKĮ nAChR gene (CHRNA7) was 
not in LD with the CHRNA3/5 locus, it is still functionally related to the 
disease (as will be discussed later in this chapter). 
  
1.1.5.3 Inflammation 
Inflammation is one of the defense mechanisms used by the immune system to 
protect the human body against pathogens. Normally this is well orchestrated 
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by the immune system in a precise and rapid manner. The process involves 
many cells, such as tissue macrophages, neutrophils and epithelial cells. These 
cells will release several inflammatory mediators (like Tumor necrosis factor 
(TNF), Interleukin-ȕ,/-ȕ ,/ ,/ ,/DQG+LJK-mobility group box1 
(HMGB1)), causing the start and progression of inflammation (Tracy, 2002; 
Pavlov and Tracy, 2004; Wang et al, 2004).  
It is well known that TNF (previously known as TNF-Įis one of the earliest 
pro-inflammatory cytokines released during inflammation. It mainly functions 
to control invasion and help promote healing (Tracey, 2002). TNF was 
identified by Beutler and colleagues in 1985 as a hormone causing cachexia, 
who later on that same year identified its key role in mediating septic shock in 
response to  infection (Beutler et al., 1985a, Beutler et al., 1985b). TNF is 
produced by many cell types, like macrophages, monocytes and neutrophils. 
TNF activates and prolongs the inflammatory response by activating other cells 
to release cytokines (such as HMGB1) (Wang et al., 1999, Wang et al., 2004). 
In the typical and successful inflammatory response, the TNF release is kept to 
the minimally effective level and period of secretion without progression to 
systemic TNF release. After stimulation with gram negative bacterial 
endotoxin/lipopolysaccharide (LPS) (0.1 mg/kg), the levels of TNF in 
experimental animals were elevated in the serum, the liver and the spleen, 
confirming that TNF is secreted by components of the mononuclear phagocyte 
system (formerly known as the reticuloendothelial tissue) (Wang et al., 2003).  
Cytokines and interleukins (IL) are small molecules with a profound activity 
exerted at very low concentrations (Picomolar or femtomolar) (Ulloa and 
Tracey, 2005).   
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The Central nervous System (CNS) on the other hand, will limit this response 
from spreading via stimulating the vagus nerve (Borovikova et al., 2000) (this 
part will be discussed further in the anti-inflammatory pathway). 
 
1.1.5.3.1 COPD and inflammation: 
What role does inflammation plays in COPD?  
The bronchial epithelium is one of the important lines of defense against 
infections, and is enriched for inflammatory mediators. COPD was suggested 
to be a chronic inflammatory disease (Nathan, 2002, Barnes et al., 2003). This 
was supported by the presence of large numbers of alveolar macrophages and 
neutrophils within the lung tissues and secretions. This was shown to be 
concomitant to increased release of inflammatory mediators, such as TNF, IL8 
and other inflammatory cytokines. However, the release of these mediators 
may be modified by cigarette smoking which may be the case in COPD. The 
alveolar macrophages seem to have a central role in the start of inflammatory 
changes of the lungs which may subsequently precipitate COPD. These 
changes include recruiting neutrophils and other inflammatory cells, release of 
pro-inflammatory cytokines and release of elastase enzyme. The latter can 
affect the lung parenchyma and alveolar cell walls leading to the development 
of emphysema. This effect together with the presence of chronic inflammation 
of the bronchi (chronic bronchitis) will form the components of COPD (Barnes 
et al., 2003). Thus, several pulmonary cell types (the bronchial epithelial cells, 
alveolar epithelial cells, neutrophils and the pulmonary macrophages) seem to 
contribute to the development of COPD. It is well established that the chronic 
inflammatory condition in COPD is affecting the respiratory epithelial cell 
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remodeling and regeneration which can further complicate the tissue texture 
(Maouche et al., 2009). These inflammatory changes in COPD function via a 
pathway that involves the nicotinic acetylcholine receptors (as mentioned 
below). 
 
1.2 Nicotinic acetyl choline subunits: a family of receptors 
The nicotinic acetyl choline receptors (nAChRs) are a group of receptors that 
form part of the superfamily of ligand-gated ion channels. The nAChRs are 
characterised by ion selectivity to cations (Seguela et al., 1993). 
In humans, the nAChRs constitutes 16 members (discovered so far) and these 
are H[SUHVVHGLQGLIIHUHQW WLVVXHV7KHVHLQFOXGHĮ-subunits (1-H[FHSWĮ
ȕ-subunits (1-LQDGGLWLRQWRȖįDQGİ subunits (Albuquerque et al., 2009). 
7KHĮ-subunits differ from the other subunits in having two cysteine residues in 
close proximity within the amino terminal end. This will form the cysteine loop 
which is part of the agonist binding site helping to establish the functional role 
of the receptor (Boyd, 1997, Albuquerque et al., 2009). Generally, these 
subunits bind to acetylcholine (ACh) and to nicotine as agonists. The nAChR 
VXEW\SHV Į-6 bind ZLWKKLJKDIILQLW\ WRQLFRWLQH DQG UHTXLUHVȕ-subunits 2-4 
for forming heteropentameric receptors 2Q WKH RWKHU KDQG Į-10 has lower 
affinity to bind nicotine but have high affinity to bind alphabungarotoxin 
(Į%7;), and tend to form homopentameric receptors2IWKLVJURXSĮQ$&K5 
is the most abundant in the mammalian brain tissuH ZKLOH Į ZDV RQO\
recognised in FKLFNHQVDQGĮ	ZHUHVKRZQWR have limited expression in 
a range of human tissues, such as outer hair cells of the inner ear (Ulloa, 2005, 
Albuquerque et al., 2009). 
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This receptor family (nAChRs) was identified in mammals, including Humans. 
However, it was suggested that this family developed in Humans IURPWKHĮ-
nAChRs which involved gene duplications and mutations over time to yield 
this group of receptors (Le Novere and Changeux, 1995, Hurst et al., 2013).  
 
1.2.1 General structure for nAChR subunits: 
All these members share a common structure formed of three major domains: 
the extracellular domain, the intracytoplasmic domain and the transmembrane 
domain (Tsetlin et al., 2011). Generally, the extracellular domain is composed 
of a long amino terminal end (N-terminus) of more than 200 amino acid chain 
and a short carboxy terminal end (C-terminus). The transmembrane domain is 
composed of several transmembrane domains (1-4) and the intracellular 
cytoplasmic domain is composed of the relatively long (more than 100 amino 
acids) intracytoplasmic loop between transmembrane domains 3 and 4 (Figure 
1-3) (Brejc et al., 2001). 
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Figure 1-3: General structure for nAChRs. 
A: single subunit of nAChRs showing composition of three main parts: extracellular 
part (including N-terminus (N) and C-terminus (C)), transmembrane parts (black 
cylinders) and intracytoplasmic loop (between TMD3 and 4, TMD1 is the farthest 
left).  
B: schematic representation of five nAChR subunit assembly enclosing ion channel 
(the pore of which is indicated above the channel-arrowed-).  
Figure was modified from (Millar, 2003, Hurst et al., 2013). 
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The N-terminus constitutes the major part of the receptor and includes the 
signal peptide, the agonist binding sites and the glycosylation sites. This part is 
followed by the transmembrane domains (TMDs 1-4) that help stabilise the 
receptor into the cell membrane (Unwin, 2005). The TMD2 lines the core of 
the ion channel, while TMD 1 and 3 separate TMD2 from the lipid layer of the 
membrane, with TMD 4 being the farthest from the rest (Taly et al., 2009). The 
intracytoplasmic loop connects between TMD 3 and 4 and includes three 
phosphorylation sites (Jansen et al., 2008, Kracun et al., 2008).  
A summary of the parts forming the nAChRs is shown in (Table 1-3). 
Table 1-3:  The nAChRs domains. 
nAChR Part Included sites aa  Position 
N-terminus Contains SP, LB, GLY 200 extracellular 
TMDs 1-4 - 19-24 transmembrane 
Intracellular loop 3P >100 cytoplasmic 
C-terminus - - extracellular 
N-terminus: amino terminal end, SP: signal peptide, LB: ligand binding site, GLY: N-
glycosylation site, P: phosphorylation site, C-terminus: carboxy terminal end, aa: 
number of constituting amino acids. 
 
1.2.2 Subunit assembly and posttranslational modifications: 
The nAChR subunits can assemble into homomer or heteromer pentameric 
receptors that surround a ligand-gated ion channel pore. Almost all nAChR 
subunits can form heteropentamer receptors ZKLOH Į DUH UHFRJQL]HG LQ
Humans to form a homopentamer receptor (Corringer et al., 2000, Millar, 
2003, Wu and Lukas, 2011). However, heteropentameric UHFHSWRUV RI Į
FRPELQHG ZLWK ȕ VXEXQLWV could be detected from rodent brain (Figure 1-4) 
(Liu et al., 2009). 
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Figure 1-4: Schematic representation of some of nAChRs pentamers. 
$Į-nAChR subunits assembled into homopentameric receptor expressed on 
the cell surface of neuronal and non-QHXURQDOFHOOV%Įȕ-nAChR subunits 
assembled into heteropentameric receptor expressed on the cell surface of 
QHXURQDO FHOOV & ĮȕįȖ Q$&K5 VXEXQLWV DVVHPEOHG DW WKH QHXURPXVFXODU
junction (muscle type nAChRs). The ACh (agonist) binding sites are shown as 
EODFNRYDOVEHWZHHQĮ-VXEXQLWVRUEHWZHHQĮ-DQGQRQĮ-subunits. 
Adapted from (Corringer et al., 2000, Albuquerque et al., 2009, Wu and Lukas, 
2011). 
 
$OWKRXJK Į-nAChRs are the best described homopentameric receptors, they 
are not the only ones, and similar homopentamers were described IURPĮDQG
ĮVXEXQLWV (Hurst et al., 2013). +RZHYHUWKHIDFWWKDWĮ-nAChRs are widely 
GLVWULEXWHG LQ KXPDQ WLVVXHV ZKLOH Į DQG Į nAChRs are less widely 
expressed in human tissues (Į DQG Į were shown to be expressed by the 
outer hair cells of the inner ear ZKLOH RQO\ Į ZDV H[SUHVVHG E\ neurons 
involved in pain perception) LVGHWHUPLQLQJWKHĮ-nAChRs as the prototype for 
such a group of receptors, at least so far. In addition, the wide expression of 
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Į-nAChRs enabled researchers to use this subunit for studies involving the 
ion channels¶ function, drug design experiments and signaling pathways testing 
(Bertrand D., 1995, Bertrand et al., 2008). 
Following the translation of nAChR subunits mRNAs, the polypeptide formed 
will be subjected to a number of posttranslational modifications that take place 
within the endoplasmic reticulum (ER) till the receptors are expressed on the 
cell surface (Green and Millar, 1995). First, the polypeptide chains would fold 
in a way that helps establish the correct secondary structure of nAChR protein. 
Then, the folded subunits would gather to assemble and form the pentamer 
receptor. This will include establishing the agonist binding sites at the subunit 
LQWHUIDFHV EHWZHHQ Į VXEXQLWV for homopentamer receptors, or between both 
the Į- DQG ȕ- subunits for heteropentamer receptors). This preference would 
leave heteropentamer receptors with two agonist binding sites compared to five 
for homopentamer ones (Unwin, 2005, Hurst et al., 2013). Finally, the N-
glycosylation sites and the disulfide bonds are added to the N-terminus (Gehle 
et al., 1997). 
Different parts of the nAChRs protein contribute to the assembly and function 
of the receptor. It has been established that the N-terminus is responsible for 
the receptor assembly and formation of the agonist binding sites in nAChRs 
(Verrall and Hall, 1992, Brejc et al., 2001). Similarly, the cytoplasmic loop is 
involved in subunit folding, assembly, trafficking and efficient membrane 
insertion of the protein in addition to ensuring the formation of functional 
receptors  (Jansen et al., 2008, Kracun et al., 2008). This may be partly due to 
the effect of three phosphorylation sites that are essential for stimulating the 
subunit assembly and for the control of receptor expression, desensitization and 
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function of the receptor (Green et al., 1991, Guo and Wecker, 2002).  Although 
the C-terminus is relatively short and represents a small part of the protein, its 
presence within the nAChRs protein is essential for enhancing the protein 
transport to the surface and subsequent binding site function (Pons et al., 
2004). 
7KHH[SUHVVLRQRIĮ-nAChR proteins was found to be not always correlated 
with their corresponding mRNA levels (Blumenthal et al., 1997). This effect 
was shown to affect some of the normal and cancerous respiratory cells and 
cell lines that might explain a defective translation, assembly or the relatively 
scarce protein concentrations (Carlisle et al., 2004, Plummer et al., 2005, 
Carlisle et al., 2007). 
 
1.2.3 Agonist binding and channel opening: 
The nAChR receptors function mainly as ligand-gated ion channels, lining 
cation channels that permit calcium, and to some extent sodium. This results in 
the influx of calcium (or sodium) inside the cell which will help upregulate 
certain genes (Dani and Bertrand, 2007). Acetylcholine (ACh) is well known 
for acting as an endogenous agonist for nAChRs. During the resting condition 
of these receptors, the ion channel is closed and no ions are permitted to enter 
the cell. Once ACh or nicotine binds to the agonist binding site of the receptor, 
a conformational change of the receptor results in opening the channel and ion 
influx inside the cell (Wu and Lukas, 2011). This effect tends to be short-lived 
(for few milliseconds) and the receptor will return to the resting state (Dani and 
Bertrand, 2007, Taly et al., 2009). However, a prolonged stimulation of 
nAChRs with ACh or nicotine ZLOOFDXVHµGHVHQVLWL]DWLRQ¶Rf the channel (non-
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responsive state of the channel) (Figure 1-5) (Galzi et al., 1992, Hurst et al., 
2013).  
 
Figure 1-5: A Diagram showing the different phases of nAChR functions. 
After agonist binding, the channel opens and the ions influx inside the cell (A). 
During the resting phase, no agonist is bound to the receptor and the channel is 
closed (B). This will cause the start of a cascade of events ending up with 
upregulation of a gene or stimulation of a second messenger-signalling 
pathway. This stimulatory effect will last only for short time, and will be 
followed subsequently by a desensitisation phase of the channel (the state of 
non-responsiveness) (C). Adapted from (Hurst et al., 2013).  
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The nAChRs channels function in a similar mode by allowing cation infusion 
inside the cell and lead to the upregulation of certain genes or cascades of 
pathways (Albuquerque et al., 2009). The ion selectivity of nAChRs is 
dependent on few amino acids that form part of the TMD 2 and TMD 2-TMD 
3 loop and changes in such amino acids could change the channel into an anion 
selective channel (Galzi et al., 1992, Lummis et al., 2005). In contrast, an 
LPSRUWDQW FRPSHWLWLYH DQWDJRQLVW IRU Q$&K5V LV WKH DOSKD EXQJDURWR[LQ Į-
BGT). This chemical compound is a component of snake venom that binds in 
an irreversible reaction with nAChRs leading to inhibition of the ion flux inside 
the cell (Albuquerque et al., 2009))RUWKLVUHDVRQĮ-BGT was used by many 
studies to precipitate these receptors for further investigations. The nAChRs 
were classified according to their pattern of binding with this compound inWRĮ-
BGT sensitive or insensitive receptors, with expression intensities varying from 
no or mild to moderate or even high expression (Kracun et al., 2008). Nicotine 
was used experimentally in high concentrations to EORFN Į-BGT irreversible 
binding to nAChRs (Wang et al., 2003, Govind et al., 2009). The need for high 
QLFRWLQHGRVHVZDVMXVWLILHGE\WKHIDFW WKDWĮ-nAChRs have low affinity for 
nicotine. Interestingly, nicotine seems to have a role in activating these 
receptors via several methods, including competitive agonist binding and 
EORFNLQJIDFWRUVWKDWVXSSUHVVĮ-nAChRs expression (Araud et al., 2011). 
 
1.2.4 Association with human diseases: 
The major association of nAChRs with human diseases was via nicotine 
addiction. Nicotine is a known agonist to nAChRs, but a prolonged exposure to 
nicotine, as the case for chronic cigarette smokers, can lead to increased 
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receptor desensitization to nicotine over time. This will result in the up-
regXODWLRQRIUHFHSWRUVZLWKKLJKDIILQLW\WRQLFRWLQHVXFKDVĮȕnAChRs in 
an attempt to increase receptor sensitization (Govind et al., 2009). Similarly, 
chronic exposure WRQLFRWLQHOHDGVWRXSUHJXODWLRQRIWKHĮ-nAChRs (Peng et 
al., 1999, Wang et al., 2001, Fu et al., 2009).  
It was documented that more than two thirds of the nAChRs are retained within 
intracellular pools, and that only one third was allowed to be transported to the 
cell surface for expression and functioning (Albuquerque et al., 2009). During 
this intracellular pooling, many subunits will be degraded, a mechanism that is 
counteracted by nicotine. In cases of increased nicotine concentrations, fewer 
subunits are subjected to degradation, and thus more subunits are allowed to be 
expressed on the surface allowing for the receptor upregulation. Thus, the 
effect of chronic nicotine exposure, as the case for chronic smoking, can 
interfere with the proportion of expressed receptors, and leading to the 
development of certain diseases (Albuquerque et al., 2009) (This part will be 
discussed in the final discussion). 
,WLVZRUWKPHQWLRQLQJWKDWWKHVWLPXODWRU\HIIHFWRIQLFRWLQHRQĮ- nAChRs is 
more than that exerted by ACh making the former a favorable drug target for 
stimulating this subset of receptors (Ulloa, 2005). 
 
1.3 Į-nAChR subunit: 
This is the only nAChR that is known to assemble into homopentameric 
receptors, with the earlier studies reporting this in chicken brain tissues 
(Couturier et al., 1990). 7KH FRPSDULVRQ RI WKH FKLFNHQ DQG UDW Į-nAChRs 
VKRZHGKLJK VLPLODULW\ ZLWKKXPDQĮ-nAChRs at mRNA and protein levels 
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(Lynn Doucette-Stamm, 1993, Chini et al., 1994, Peng et al., 1994). This 
receptor was studied extensively due to its unique homopentameric 
composition in human and animal tissues. It was speculated that due to this 
SURSHUW\ DQG GXH WR WKH KLJK GHJUHH RI VLPLODULW\ RI Į-nAChRs with other 
mammalian nAChRs, that this receptor forms the ancestor of all nAChRs and 
during evolution, the other types of nAChRs developed by duplication, 
inversion and deletion (Albuquerque et al., 2009, Le Novere and Changeux, 
1995). It is important to know that RIC-3 (resistance to inhibitors of choline 
esterases) protein is an essential chaperone for Į-nAChRs to enhance their 
functional receptor expression. This effect is lost with other heteropentameric 
UHFHSWRUVVXFKDVĮȕRUĮȕ(Halevi et al., 2002). 
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1.3.1 CHRNA7: 
7KLVJHQHFRGHVIRU WKHĮ-nAChR subunits in human tissues. It is located at 
chromosome 15q13 region and constitutes ten exons embedded within more 
than 140 kb of intronic sequences (Gault et al., 1998). The promoter region of 
this gene was shown to be about 77% GC-rich sequence which is lacking the 
TATA box and includes binding sites for transcription factors, such as SP1, 
AP-2, CREB and Egr-1 (Carrasco-Serrano et al., 1998). Not all these 
WUDQVFULSWLRQ IDFWRUV VHHP WR FRQWULEXWH WR WKH XSUHJXODWLRQ RI Į-nAChR. A 
good example is the transcription factor AP-Į ZDV found to be negatively 
FRQWUROOLQJWKHĮ-nAChRs mRNA expression (Finlay-Schultz et al., 2011).  
The CHRNA7 exons 1-10 are relatively short exons spanning around 100 bp or 
less in size except exon 10 (Figure 1-6).  
 
 
 
Figure 1-6: CHRNA7 exons. 
Exons (E) 1-10 demonstrated with the nucleotide sequence (at the start of each exon) 
shown alternating on the upper and lower panels. 
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However, the introns connecting these exons vary widely in size from 
relatively short introns of 300 bps up to large introns of more than 25 kb size 
(Table 1-4). 
Table 1-4: CHRNA7 exons and introns nucleotide number and cDNA position. 
 Exon details Downstream intron details 
Exon no. Exon size (bp) cDNA position Intron no. Intron size (bp) 
1 55 1-55 1 248 
2 140 56-195 2 70,265 
3 45 196-240 3 10,440 
4 110 241-350 4 42,007 
5 80 351-430 5 3,621 
6 168 431-598 6 636 
7 195 599-793 7 962 
8 87 794-880 8 3,570 
9 110 881-990 9 4,604 
10 519 991-1509 - 
- 
CHRNA7 accession number NM_00074, NCBI and from (Gault et al., 1998). 
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1.3.2 Į-protein: 
This protein showed similar structure to other nAChRs proteins. However, 
uQOLNHPRVWKHWHURSHQWDPHULFQ$&K5VĮ-nAChRs are characterized by their 
low affinity to ACh and nicotine but with KLJK DIILQLW\ WR ELQG Į%7; (Orr-
Urtreger et al., 1997, Ulloa, 2005). This characteristic was used extensively to 
SUHFLSLWDWH Į-nAChRs to study the physical properties of the receptor 
(Couturier et al., 1990, Rangwala et al., 1997, Drisdel and Green, 2000). 
However, using nicRWLQH LQ KLJK FRQFHQWUDWLRQV SULRU WR DGGLQJ Į%7; FDQ
block the latter binding to these receptors (Wang et al., 2003).   
 
1.3.2.1 The significance of specific amino acid seTXHQFHIRUPLQJĮ-
nAChRs: 
7KH DPLQR DFLGV RI WKH Į-nAChR are arranged in a complex conformation 
which directs the cation selectivity of the channel. Besides cation selectivity 
SURSHUWLHV Į-nAChRs are much more permeable to calcium ions than to 
sodium and potassium ions depending on the unique amino acid structure 
(Seguela et al., 1993). This high permeability to calcium ions is a unique 
SURSHUW\RIĮ-nAChRs and it was correlated with cellular protection. Changes 
that can affect these receptors can affect the calcium ion balance that is 
necessary for vital cell processes and thus affecting the cell survival (Uteshev, 
2012).  
7KLV DUFKLWHFWXUH RI Į-nAChRs is important for maintaining the receptor 
function and changes to certain amino acids with others of different properties 
can change the ion channel properties (Bertrand et al., 1993, Dani and 
Bertrand, 2007). The use of site-directed mutagenesis made it easier for 
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predictions of the effect of amino acid changes on the protein structure, 
assembly and channel function. Consequently, it was shown that the change of 
a single amino acid near the extracellular space from the TMD2 can alter the 
ion selectivity of the channel from cationic into anionic (Galzi et al., 1992). 
Similar results were detected when substituting charged amino acids at the 
amino terminal end of TMD 2 of the receptor with a hydrophobic side-chain 
amino acid decreased the ion channel permeability to calcium ions (Bertrand et 
al., 1993). Furthermore, the substitution of two amino acids of the same group, 
both with hydroxyl side chains, led to gain-of-IXQFWLRQ HIIHFW RQ WKH Į-
nAChRs (Placzek et al., 2005). On the other hand, a loss-of-function of the 
receptor was detected when substituting an amino acid within the 
intracytoplasmic loop with an uncharged amino acid. This change caused 
prolonged and reversible GHVHQVLWL]DWLRQRIWKHPXWDQWĮ-nAChRs in response 
to protein kinase C activators (Tsuneki et al., 2007). 
 
1.3.2.2 Posttranslational modification of Į-nAChR: 
There are a number of posttranslational modifications that affect the assembly 
DQGIXQFWLRQDOH[SUHVVLRQRIWKHĮ-nAChRs (Blumenthal et al., 1997, Rakhilin 
et al., 1999). Among these is RIC-3 protein encoded by the gene hric-3 in 
humans (Halevi et al., 2003). This chaperone protein plays an important role by 
HQKDQFLQJWKHĮ-nAChRs folding, assembly and functional expression (Halevi 
et al., 2002, Halevi et al., 2003, Lansdell et al., 2005, Williams et al., 2005). 
6RPHĮ-nAChRs might escape this necessity and form receptors on the cell 
surface in the absence of RIC-3. Such receptors were proved to be 
nonfunctioning, a condition that was concomitant to increased intracellular 
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accumulation of nAChRs. This effect was shown either in cells expressing low 
levels of RIC-3 or in cells with mutated nonfunctioning form of the protein 
(Cooper and Millar, 1997, Rakhilin et al., 1999, Halevi et al., 2002, Williams et 
al., 2005).  
Interestingly, the N-glycosylation sites within the N-WHUPLQXVRIWKHĮ-nAChR 
subunits ZHUHVKRZQWRDIIHFWWKHĮ-nAChRs function without interfering with 
the receptor surface expression in spite of being located away from the ligand 
binding site and thus are not directly affecting the agonist binding process 
(Chen et al., 1998, Avramopoulou et al., 2004). 7KH IROGLQJ RI Į-nAChRs 
may also play a role in the receptor assembly and function. As far as the 
disulfide bond is concerned, receptors assembled into single conformation were 
shown to form non-functional receptors compared to the functional ones 
formed by the double conformation receptors (Rakhilin et al., 1999, Drisdel 
and Green, 2000). Moreover, the phosphorylation of certain tyrosine residues 
ZLWKLQWKHLQWUDF\WRSODVPLFORRSFDQOHDGWRLQDFWLYDWLRQRIWKHĮ-nAChRs and 
thus affecting the ion channel function negatively. This is supported by the 
ILQGLQJVRILQFUHDVHGĮ-nAChRs activity after dephosphorylation (Charpantier 
et al., 2005, Fu et al., 2009). It is worth noting that another posttranslational 
SURFHVV WKH SDOPLWR\ODWLRQ FDQ HQKDQFH WKH Į-nAChRs assembly and the 
ligand binding site formation, leading to the formation of functional nAChRs 
(Drisdel et al., 2004, Alexander et al., 2010). 
By comparing the results obtained for CHRNA7 in humans to that in chicken 
DQG UDWV LWZDV VKRZQ WKDWĮ-nAChR is similar to other nAChRs in general 
structure (Table 1-5), (Figure 1-7). 
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Table 1-5: The parts of the Human Į-nAChR.  
Exon Protein part encoded aa 
5' UTR 77 % GC rich, lack TATA box, contains consensus SP1, AP2, 
Egr1 and CREB transcription binding sites 
- 
1 SP (aa 1-22) 18 
2 last part of signal peptide, GLY (aa 46) 46 
3 - 15 
4 GLY (aa 90), LB (aa 107-117) 36 
5 GLY (aa 133) 26 
6 LB (aa 169-175) 56 
7 LB (aa 207-219), TMD1(aa 231-254)  65 
8 TMD2 (aa 261-283) 29 
9 TMD3 (aa 293-315) 36 
10 TMD4 (aa 472-494), 3 P (aa 367, 417, 444), intracytoplasmic 
loop (aa 318-469), C-terminus (aa 495-502) 
173 
N-terminus: amino terminal end, SP: signal peptide, LB: ligand binding site, GLY: N-
glycosylation site, P: phosphorylation site, C-terminus: carboxy terminal end. Two 
disulfide bonds present between aa at positions: 150-164 and 212-213. 
aa: number of constituting amino acids. 
Adapted from (Gault et al., 1998, de Jonge and Ulloa, 2007). 
 
 
 
7KHĮ-nicotinic acetylcholine receptors                                       Chapter 1 
 
32 
 
 
Figure 1-7VFKHPDWLFUHSUHVHQWDWLRQRIĮ-nAChR protein domains. 
A: showing secondary structure for nAChRs using PSIPRED software. The 
major parts of the protein are indicated (N-terminal and C-terminal ends 
extracellularly, TMDs 1-4 (S1-4), and intracytoplasmic loop between TMD 3 
and 4). The intracytoplasmic loop between TMD 1 and 2 is small and has a less 
important role on the receptor¶s assembly and function than the loop between 
TMD 3 and 4 and the term intracytoplasmic loop refers usually to the latter. 
B: schematic representation of nAChR protein structure using CSS palm 3.0 
software program. The terms NH3 and CO2 are referring to the N-terminus and 
C-terminus, respectively. TMDs1-4 are indicated above the figure. SP: signal 
peptide, cytoplasmic: intracytoplasmic loop, BD: binding domains 
(corresponding to agonist binding sites), N-Gly: N-glycosylation sites (with 
amino acid sequence within the protein indicated), S: refers to sulphur atom 
within cysteine amino acids, P: refers to phosphorylation sites. The amino acid 
positions of the corresponding parts are indicated on the lower panel of the 
figure. 
Adapted from (Gault et al., 1998) and (Millar, 2003). 
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1.3.2.3 7KHĮ-nAChRs expression in different cells: 
There were several VWXGLHV WKDW WHVWHG IRU WKH H[SUHVVLRQ RI Į-nAChRs at 
mRNA and/or protein level in different tissues. The homo-oligomeric nature of 
this receptor helped to shed light on this receptor as a model for heterogeneous 
expression in cells that do QRWH[SUHVVĮ-nAChRs. The first successful attempt 
was made by using human reFRPELQDQWĮ-nAChR DNA transfection into cells 
that do not express nAChRs (Peng et al., 1999). This was followed by many 
VWXGLHVWRH[SUHVVĮ-nAChRs in different types of human and animal tissues. 
Among the human tissues that expressed Į-nAChRs (mRNA and protein) are 
SH-SY5Y (human neuroblastoma cell line) (Peng et al., 1994), human brain 
tissue (Gault et al., 1998, Severance and Yolken, 2008) human bronchial 
epithelial and aortic epithelial cells (Wang et al., 2001), human fibroblast cells 
(Carlisle et al., 2004), and different human lung cancer cell lines, including 
A549 cell line (Carlisle et al., 2004, Plummer et al., 2005, Carlisle et al., 2007, 
Lam et al., 2007, Paleari et al., 2008). Recently, human mature adipocytes were 
VKRZQWRH[SUHVVIXQFWLRQDOĮ-nAChRs (Cancello et al., 2012). 
Similar work on animal tissues showed that it was expressed in different 
tissues, such as rat phaeochromocytoma cells from adrenal medulla (Rangwala 
et al., 1997), bovine adrenal chromaffin cells (García-Guzmán et al., 1995, El-
Hajj et al., 2007), mouse brain tissue (Saragoza et al., 2003) and rat autonomic 
neurons (Severance et al., 2004). 0RVWRIWKHZRUNGRQHRQĮ-nAChRs could 
GHWHFW KRPRSHQWDPHULF UHFHSWRUV +RZHYHU KHWHURSHQWDPHULF Į-nAChRs 
were recently identified in animal tissues such as bovine chromaffin cells (El-
Hajj et al., 2007) or rodent brain cells (Liu et al., 2009). These results are 
VLPLODUWRHDUOLHUWULDOVWKDWLQYROYHGH[SUHVVLRQRIĮ-Q$&K5VDQGȕ-nAChRs 
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in Xenopus oocytes or human epithelial kidney cell line (tsA201) that yielded 
heteropentameric functional receptors (Khiroug et al., 2002). 
 
1.3.3 CHRFAM7A: 
This gene represents partially duplicated CHRNA7 on chromosome 15, 
(upstream of CHRNA7) with exons 5-10 of CHRNA7 duplicated in the same 
or opposite orientation to the CHRNA7 (as will be described below). The 
GXSOLFDWLRQ IRUPVDQHZJHQHFDOOHG WKHK\EULGĮ RU WKH IXVLRQJHQHRU WKH
cholinergic receptor family with sequence similarity 7A (CHRFAM7A)) after 
combination with four novel exons (D to A) upstream of exons 5-10, so that 
the orientation of the duplicated gene is in the following order: exons D, C, B, 
A, then exons 5-10 (Gault et al., 1998) (Figure 1-8) (Table 1-6). 
 
Figure 1-8: CHRFAM7A exons. 
Exons (E) D-10 demonstrated with the nucleotide sequence (at the start of each exon) 
shown alternating on the upper and lower panels. 
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Table 1-6: CHRAFM7A exons and introns nucleotide number and cDNA 
position. 
 
 Exon details Downstream intron details 
Exon no. Exon size (bp) cDNA position Intron ID Intron size (bp) 
D 297 1-162 D 6,264 
C 125 163-287 C 3,480 
B 64 288-351 B 2,919 
A 47 352-398 A 3,243 
5 80 399-478 5 3,884 
6 168 479-646 6 636 
7 195 647-841 7 962 
8 87 842-928 8 3,570 
9 110 929-1038 9 4,606 
10 519 1039-1557 - - 
CHRFAM7A accession number NM_139320.1, NCBI and from (Gault et al., 1998, 
Araud et al., 2011). 
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This gene was suggested to originate at some point during evolution due to a 
number of duplication and deletion steps that involved several genes at this 
locus (15q13-14) (Zody et al., 2006, Makoff and Flomen, 2007). Among these 
steps, duplication of CHRNA7 and associated or subsequent deletion of its first 
four exons (1-4) gave rise to the partial duplication segment of exons 5-10 
(Riley, 2002). This partial duplication step was suggested to be located 
following another partial duplication of ULK4 gene on chromosome 15. The 
ULK4 gene original copy is located on chromosome 3p22, and several copies 
were detected partially duplicated (exons C-A) on chromosome 15. In all the 
partial duplication sites, another exon of unknown origin termed ³H[RQ'´ZDV
located upstream of the duplication giving rise to the composition of exons D-
A (Riley, 2002, Araud et al., 2011). 7KLV ³IXVLRQ´ RI JHQHV combined with 
partial CHRNA7 duplication was suggested to aid the formation of the fusion 
or hybrid gene (the CHRFAM7A). This fusion was shown clearly when 
investigations on the break point that joins the two genes (CHRNA7 
duplication and WKH³IXVLRQ´H[RQV'-A) where part of intron 4 (of CHRNA7) 
and part of intron A (of ULK4) were found merged to form a hybrid intron 
connecting exons A and 5 within CHRFAM7A sequence. Most individuals 
seem to have the CHRFAM7A gene but some might miss one or both copies of 
the gene (Gault et al., 1998, Riley, 2002, Gault et al., 2003). It is not known if 
this geneotype difference of CHRFAM7A is associated with phenotypes of 
psychiatric disorders as the case is with CHRNA7 (Figure 1-9).  
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Figure 1-9: chromosome 15q13-14 locus genetic composition. 
a) The location of CHRNA7 and CHRFAM7A on chromosome 15. Exons 1-10 of CHRNA7 shown as red bars, ULK4 exons C-A shown as blue bars, 
exon D is shown as pink bar and  CHRNA7 promoter region is shown as a yellow bar while the 3`UTR of CHRNA7 is shown as a green bar. Exons 
D-A are duplicated on chromosome 15 several times, one of which is just upstream of partial duplication of CHRNA7 (CHRFAM7A). CHRNA7 
located on the right represent the original copy of the gene and is located within a duplicated cassette on chromosome 15, about 1.6 Mb downstream 
of the other duplicated cassette that harbours CHRFAM7A; both cassettes are about 300 kb in size. Note that the locus D15S1360 is unique to 
CHRNA7 within intron 2, locus L76630 is located downstream of 3` end of CHRNA7 exons 5-10,  locus WI13983 is located after two of exons D-A 
duplications while locus D15S143 is located just upstream of these exons in CHRFMA7 gene locus only. 
b) The exon composition of CHRNA7 (exons 1-10) and of CHRFAM7A (exons D-A, then exons 5-10). 
Taken from (Araud et al., 2011), and information adapted from (Gault et al., 1998, Riley, 2002, Araud et al., 2011, de Lucas-Cerrillo AM, 2011). 
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Interestingly, this fusion gene is unique to humans and could not be detected in 
animals (Locke et al., 2003). 
1.3.4 CHRNA7 and CHRFAM7A: similarities and differences 
1.3.4.1 At gene level: 
Both genes, CHRFAM7A and CHRNA7, are located on chromosome 15 
(15q13 and 15q14, respectively) with a 1.6 Mb intervening segment. Both 
genes have exons 5-10 within their sequence with almost 100% similarity 
(Gault et al., 1998). Gault et al showed that the orientation of the CHRNA7 is 
in the sense direction (Gault et al., 1998). This was the first study to show the 
CHRFAM7A duplication and constitutive exons and suggested that the 
orientation of the duplicated gene is in the same direction of CHRNA7. A 
subsequent study by Riley and co-workers conflicted with these results and 
showed that both genes were in the opposite direction (Riley, 2002). 
Subsequent studies showed that both results were correct and that the presence 
of a common polymorphism (2 bp deletion in exon 6 (Gault et al., 1998)) could 
be used as a marker for CHRFAM7A inversion (opposite to CHRNA7 
orientation) (Flomen et al., 2006, Flomen et al., 2008). The identification of the 
2bp deletion leads to categorisation of two major alleles of CHRFAM7A (with 
and without the deletion) that were suggested to have almost equal expression 
within populations expressing the gene. This means that CHRNA7 and 
CHRFAM7A are in the same or opposite orientation in almost equal 
proportions of the population harbouring them. 
The copy number variants of both genes, CHRNA7 and CHRFAM7A, gave 
rise to different allelic constitution among different populations. Most 
populations have both copies of CHRNA7, but missing one or both copies can 
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lead to neuropsychiatric disorders (will be discussed shortly in the final 
discussion) (Shinawi et al., 2009, Endris et al., 2010, Masurel-Paulet et al., 
2010, Spielmann et al., 2011, Hoppman-Chaney et al., 2013). Again, most 
populations have both copies of CHRFAM7A, with around 10% missing one 
copy and rarely missing both copies (Araud et al., 2011, de Lucas-Cerrillo AM, 
2011). Missing both copies of CHRFAM7A was suggested to represent an 
ancestral genomic structure that persisted over time and escaped the 
duplication process (Makoff and Flomen, 2007). Interestingly, both genes 
originate from the sense strand (Severance and Yolken, 2008). 
 
1.3.4.2 At genomic sequence level: 
The reference sequences for both genes were arranged on separate files for 
further analysis. The exons, introns and SNP sites were allocated using three 
databases: NCBI, UCSC genome browser and Ensembl. It was documented that 
the similarities between both genes (between exons 5 and 10) are exceeding 
99% (Gault et al., 1998). Our results were similar to those, indicating only 
three nucleotide differences within exons 7, 9 and 10, respectively (Table 1-7). 
Table 1-7: The three nucleotide base difference within exons 5-10 sequence 
between the two genes. 
Gene Exon7 (56) * Exon 9 (53)* Exon 10 (126)* 
CHRNA7 C A C 
CHRFAM7A T G T 
*: the nucleotide position on the sense strand is shown between brackets representing 
the position within each exon (starting from the 5` end of the exon). 
All the sequence alignments were applied using ClustalW software program. 
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Using the NCBI database shows that there are three main transcripts deposited 
for CHRNA7. These include full length, inserted 87 bp of intron 1 and missing 
exons 4 & 5. However, for CHRFAM7A, only two transcripts were deposited 
which include the full length and missing exon B transcripts (Table 1-8). There 
are other mRNA transcripts of CHRNA7 and CHRFAM7A that were reported 
in Human and animal tissues but were not deposited in the NCBI database. 
These transcripts will be discussed in detail in chapter 2. 
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Table 1-8: Summary for the main transcripts deposited in the NCBI database for CHRNA7 and CHRFAM7A. 
Gene Transcript 
NCBI 
Accession 
mRNA accession 
mRNA size 
(bp) 
Size of coding 
sequence (bp) 
Protein accession 
Protein 
size (aa) 
comments 
CHRNA7 
 
Variant 1 - NM_000746 3356 bp 1509 NP_000737   502  Full length 
Variant 2 - NM_001190455.2 3443 bp 1596 NP_001177384.1 531  87 bp of intron 1 inserted 
Variant 3 NR_046324 - 3166 bp 1319 non-coding RNA  Missing exons 4&5 
CHRFAM7A 
Variant 1 - NM_139320.1 2858 bp 1557 NP_647536.1 412  Full length 
Variant 2 - NM_148911.1 2794 bp     1493 NP_683709 321  Missing exon B 
Bp: base pairs, aa: amino acids, NCBI database accession numbers:  NM (for protein coding mRNA), NP(for protein), NR (for noncoding RNA) 
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1.3.4.3 At translation level: 
Based on the differences in the first four exons of CHRFAM7A, the 
corresponding protein (GXSĮSURWHLQ) would have some differences from the 
Į SURWHLQ 7KHVH LQFOXGH ODFN RI WKH VLJQDO SHSWLGH HQFRGHG E\ H[RQ  and 
lack of part of the agonist binding domain encoded by exons 2-4 (de Lucas-
Cerrillo AM, 2011, Araud et al., 2011). However, there still some similarities 
between both proteins in the TMDs, IC loop and C-terminus parts as the exons 
coding for them (exons 7-10) are shared between the two genes (Figure 1-10). 
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Figure 1-107KHĮ-7 nAChRs structure. 
a) CHRNA7 and CHRFAM7A genes are presented with their corresponding protein parts. Upper panel: CHRNA7 is composed of ten exons (blue boxes) 
WKDWFRGHVIRUDPLQRDFLGVĮ-7 nAChRs protein. The first exon of CHRNA7 codes for 18 of 22 amino acids that form the signal peptide (SP) part of 
the protein, exons 2-6 code for the ligand binding part (LBD) and exons 7-10 code for TMDs 1-4, respectively. In addition, exon 10 codes for IC loop (L) 
and C-terminus (C) parts of the protein. Middle panel: PDLQSDUWVRIĮSURWHLQ7KHSURWHLQSDUWVDUHOLQNHGZLWKH[RQVFRGLQJIRUWKHPIURPERWKJHQHV
Lower panel: CHRFAM7A is composed of ten exons, exons D-A (orange boxes) and exons 5-10 are almost the same of CHRNA7 (blue boxes). Note that 
the GXSĮSURWHLQLVODFNLQJWKH63DQG/%'EXWVWLOOFRQVHUYHs the TMDs, IC loop, and C-terminus. 
b) 6FKHPDWLFUHSUHVHQWDWLRQRIWKHQ$&K5VDQGRIWKHĮ-nAChRs) structure. Single subunit parts and their arrangement on the cell membrane are shown. 
c) Schematic repUHVHQWDWLRQRIWKHQ$&K5VDQGRIWKHĮ-nAChRs) structure. Five subunit parts and their arrangement on the cell membrane are shown to 
represent the pentameric receptor.  
Note: for b) and c), N: refers to N-terminus, C: refers to C-terminus and numbers 1-4 referring to TMDs 1-4. TheTMD 2 that is forming the ion channel pore 
is coloured in blue. The IC loop is shown between TMDs 3 and 4. 
Adopted from (Verrall and Hall, 1992, Rakhilin et al., 1999, Moss and Smart, 2001). 
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In addition, the sequence alignment of proteins of both genes showed a 100% 
sequence similarities for the part encoded by exons 5-10, which means that 
these three base differences between the two genes does not affect the amino 
acids encoded (synonymous nucleotide changes).   
The differential expression of both proteins in different human cells and cell 
lines was reported in many studies. Human tissue macrophages were shown to 
have higher sensitivity for stimulation by cholinergic agonists than PBMCs 
(Borovikova et al., 2000). Another study showed that human tissue 
macrophages can express mRNA and functional proteins on their surface from 
both genes (CHRNA7 and CHRFAM7A) (Wang et al., 2003). These results 
were conflicted partially by the findings of a subsequent study showing that 
PMBCs can express mRNA from the CHRFAM7A only (Severance et al., 
2009). Other studies tested for the expression of same (monocytes and PBMCs) 
and other similar types of cells (human leukemia cell lines) and proved that all 
these cells express only CHRFAM7A mRNA and protein, although CHRNA7 
mRNA was detected from bone marrow cells of the same individuals (Villiger 
et al., 2002). These results were supported later by the findings of another 
study on the same cells and cell line (Benfante et al., 2011). However, the latter 
study showed that human macrophages and monocytes can express low 
amounts of CHRNA7 mRNA and protein. Taking the latter two study results, it 
seems that when the cells are in the bone marrow they express both genes, but 
with different differentiation involved later, with CHRNA7 expression seeming 
to be lowered according to certain mechanisms. This discrepancy in gene 
expression within the same cell type can also be attributed to different methods 
of collection and separation of the cells from the whole blood samples, health 
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status of the selected individuals (schizophrenia patients or healthy volunteers) 
or the use of different methods with different detection sensitivity.  
When comparing both proteins, it is important to remember the fact that GXSĮ
lacks the signal peptide forming part. This would subject the protein to 
subcellular localization and partial retention within the ER (Gault et al., 1998, 
de Lucas-Cerrillo AM, 2011).  Furthermore, it is expected to have a truncated 
N-terminus that is lacking the important agonist binding site. This can give rise 
to a difference in the function IURPWKDWRIWKHĮSURWHLQ7KLVZDVFRQILUPHG
ZKHQ WHVWLQJ 3%0&V ZLWK GXS Į SURWHLQ GHWHFWHG WKH SURWHLQ EXW ZLWK
nonfunctional receptors formed (Villiger et al., 2002).  
  
1.4 The regulatory role of CHRFAM7A: negative regulation of 
CHRNA7 
8QWLOUHFHQWO\WKHUROHRIWKHGXSĮSURWHLQZas only a matter of speculation. 
Research on CHRNA7 and CHRFAM7A during the last decade revealed what 
was described as non-functLRQDO Į-nAChRs expressed on human PBMCs 
(Villiger et al., 2002). Further research work revealed that these `receptors` 
ZHUHDFWXDOO\GXSĮSURWHLQVXEXQLWVDssembled together. This fact raised the 
IROORZLQJ TXHVWLRQ LI GXS Į protein can act like other nAChRs and form 
SHQWDPHUV VLPLODU WR Į-nAChRs), is there is a possibility of production of 
heteropentameric receptors IURPĮDQGGXSĮSURWHLQV" 
Subsequent studies aimed at answering this question and to test some of the 
VSHFXODWLRQVDERXWGXSĮSURWHLQ)LUVWWKHVXEFHOOXODUORFDOL]DWLRQRIGXSĮ
protein (as a result of lacking the signal peptide part) was tested (de Lucas-
Cerrillo AM, 2011). This was concomitant with confirming the expression of 
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ĮQ$&K5V on the cell surface. The second finding included the fact that the 
GXS Į SURWHLQ FDQ FR-DVVHPEOH ZLWK WKH Į7-nAChRs forming 
heteropentameric receptors ZLWK OHVV DIILQLW\ IRU Į-BTX and less functional 
DFWLYLW\ WKDQ KRPRSHQWDPHULF Į-nAChRs (Benfante et al., 2011, de Lucas-
Cerrillo AM, 2011). It is worth noting that similar results were obtained when 
FRPSDULQJ IRUGXSĮKHWHURSHQWDPHUVRULJLQDWing from missing or including 
2bp in exon 6 (Araud et al., 2011). Accordingly, this highlights a regulatory 
UROH IRU GXS Į SURWHLQ RQ Į-nAChRs (or for CHRFAM7A on CHRNA7). 
This role was evident when testing for the effect on inflammation using the 
inflammatory model cells (such as primary human monocytes and 
macrophages). In such a model, it was shown that by using LPS for stimulating 
pro-inflammatory cytokine release and start of inflammation, the CHRFAM7A 
was down regulated at transcriptional and translational levels, while CHRNA7 
was transcriptionally upregulated (Benfante et al., 2011, de Lucas-Cerrillo AM, 
2011). It is well established that once inflammation has started, in response to 
LPS or other pro-inflammatory mediators, it will be localized and limited to the 
affected area via many mechanisms. Among these is the cholinergic anti-
inflammatory pathway, which functions principally through activation of the 
Į-nAChRs (Borovikova et al., 2000, Wang et al., 2003). However, it was not 
clear until recently how the body controls this effective and possibly damaging 
anti-inflammatory mechanism. It is evident now that under resting conditions, 
WKH&+5)$0$DQGLWVGXSĮSURWHLQNHHSWKH&+51$DQGLWVĮSURWHLQ
in a minimal expression level thus allowing for inflammation to proceed in 
response to tissue invasion or injury. When inflammation starts, inflammatory 
mediators act to suppress CHRFAM7A role and thus allowing for CHRNA7 
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expression and activation. Among the anti-inflammatory roles of CHRNA7 is 
the suppression of LPS and other pro-inflammatory mediators. Again, this 
reverses the CHRFAM7A blocking, paving the way for CHRNA7 down 
regulatory role, and helping the tissue to go back to the resting stage 
(Borovikova et al., 2000, Wang et al., 2003, Benfante et al., 2011, de Lucas-
Cerrillo AM, 2011) (Figure 1-11). 
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Figure 1-11: The control mechanism for CHRFMA7A on CHRNA7.  
Upper panel: in normal condition, CHRFAM7A is down regulating CHRNA7 
expression. Lower panel: during inflammation. 1: LPS and other inflammatory 
mediators cause CHRFAM7A suppression. 2: CHRFAM7A effect on CHRNA7 is 
dimiQLVKHGFDXVLQJ WKH ODWWHU¶VXSregulation. 3:  CHRNA7 activation leads to down 
regulating LPS expression. 4: CHRFAM7A is upregulated again, indicating the 
resolution of inflammatory phase and return to the normal condition (as in the upper 
panel). 
 Red arrows and boxes: are showing the down regulation effects. Green arrows and 
boxes are showing the upregulation effects. Interrupted arrows: diminishing effects. 
Adopted from (Borovikova et al., 2000, Tracey, 2002, Wang et al., 2003, Benfante et 
al., 2011, de Lucas-Cerrillo AM, 2011). 
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It is worth noting that this relationship between the two genes is different in 
different human tissues. The relative ratio of mRNA expression of 
CHRNA7:CHRFAM7A was 5:1 in cerebral cortex while the opposite is true 
for macrophages (de Lucas-Cerrillo AM, 2011). This might highlight the 
different roles this receptor is playing in different human tissues, where in the 
brain it was correlated with neuronal transmission that have an effect on 
cognition and memory, while in the peripheral tissues, such as tissue 
macrophages, it seem to have a role in the anti-cholinergic pathway. 
 
1.5 7KH UROH RI Į-nAChR in cholinergic anti-inflammatory 
pathway: 
Human health and disease is balanced by control mechanisms. Human tissues 
survive repeated insults from infections, inflammatory conditions, injury and 
cancer. These conditions are dealt with continuously via the immune system. 
This is fundamentally achieved, in part, through the production of pro-
inflammatory mediators (cytokines) that encounter the invading pathogens or 
particles in a controlled manner (Ulloa and Tracey, 2005). Inflammation is 
controlled, in part, via the stimulation of the anti-inflammatory pathways, and 
once the anti-inflammatory pathway is diminished or lost it can give rise to the 
progression of inflammatory conditions ultimately resulting in human 
morbidity and mortality (de Jonge and Ulloa, 2007).  It is well established that 
the human body keeps the pro-inflammatory and the anti-inflammatory 
pathways balanced. These pathways interchange their roles during tissue injury 
and/or infection helping to keep the tissue damage to a minimum (Tracey, 
2002). Disturbances to this balance can lead to anti-inflammatory part 
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dominance causing infections, sepsis and even cancer. On the other hand, 
dominance of the inflammatory pathway can precipitate a wide range of 
chronic inflammatory conditions (Pavlov et al., 2003). This might be, in some 
cases, more damaging than the original insult. Besides the humoral anti-
inflammatory pathway (that forms one of the immune barriers of the human 
body), another pathway was described that is functioning mainly via the 
efferent vagus nerve (cholinergic nerve that functions by ACh release). This 
SDWKZD\ ZDV WHUPHG ³7KH cholinergic anti-LQIODPPDWRU\ SDWKZD\´
(Borovikova et al., 2000) (Figure 1-12). 
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Figure 1-12: The cholinergic anti-inflammatory pathway. 
Efferent vagus nerve stimulation leads to the release of ACh in organs of the 
mononuclear phagocyte system (the previously known as the reticuloendothelial 
system), such as the heart, liver, spleen and gastrointestinal (GI) tract. The released 
ACh stimulates WKH Į-nAChRs on the surface of tissue macrophages leading to 
inhibition of TNF,/ȕDQGRWKHULQIODPPDWRU\F\WRNLQHV 
Taken from (Tracey, 2002). 
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This pathway was shown to be mediated (in experimental animal and human 
macrophages as models of endotoxemia) through Į-nAChR activation and 
could suppress the release of pro-inflammatory mediators, such as TNF,/ȕ
IL6, IL18 and HMGB1 in response to LPS stimulation (Borovikova et al., 
2000, Wang et al., 2003, Wang et al., 2004). Similar results were shown in 
experimental animal models of acute lung injury (Su et al., 2007) (Figure 
1-13). 
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Figure 1-137KHUROHRIĮ-nAChRs in inflammation. 
The inflammation starts with tissue injury or infection (1). This causes the release of 
pro-inflammatory cytokines from the inflammatory cells (2), such as the tissue 
macrophages, via translational (A) (for cytokineV 71)Į ,/ȕ DQG ,/ RU SRVW-
translational mechanisms (B) (for HMGB1). This effect is supposed to be localized to 
the site of inflammation and with limited inflammatory pro-cytokine release. To 
ensure this limit is not exceeded, the cholinergic anti-inflammatory pathway starts 
SHUIRUPLQJ LWV HIIHFW YLD $FK VWLPXODWLRQ RI WKH Į-nAChRs. This pathway will 
eventually inhibit the cytokine release at both translational and post-translational 
levels (3). 
Black arrows indicate stimulatory effect while red arrows indicate inhibitory effect.  
Adapted from (Borovikova et al., 2000, Wang et al., 2003, Wang et al., 2004, Ulloa, 
2005). 
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However, this anti-inflammatory pathway function extends far beyond 
suppressing pro-inflammatory mediator release into the suppression of 
endothelial cell activation during inflammation. This suppression will prevent 
leukocyte migration to the inflamed tissue. The sum of these effects causes 
further suppression of the inflammatory chemokines used for recruiting other 
inflammatory cells (Saeed et al., 2005). Furthermore, the spleen was found to 
be crucial for activation of the cholinergic anti-LQIODPPDWRU\SDWKZD\DQGĮ-
nAChRs mediate this pathway through suppression of TNF release from the 
macrophages within the spleen (Huston et al., 2006, Rosas-Ballina et al., 
2008). Surprisingly, this effect was found to be mediated via memory T-cell 
population that can synthesize and release ACh in response to vagus nerve 
stimulation (Rosas-Ballina et al., 2011). This role for the spleen proved to be 
crucial for the anti-inflammatory pathway as most of the TNF released during 
endotoxemia in experimental animals was originated in this organ (Wang et al., 
2003, Huston et al., 2006, Olofsson et al., 2012). 
Although the cholinergic anti-inflammatory pathway depends on the vagus 
QHUYHWKHĮ-nAChRs are considered as a vital part of the pathway, and using 
Į-nAChRs antagonists or knockdown techniques was enough to render the 
pathway ineffective in counteracting inflammation. The term ³WKH
LQIODPPDWRU\ UHIOH[´ ZDV GHVFULEHG IRU WKH ILUVW WLPH E\ 7UDFH\ LQ  ,W
showed a relay pathway that involves an afferent pathway for informing the 
central nervous system (CNS) that an injury or infection is starting at certain 
parts of the human body (Pavlov and Tracey, 2004, Pavlov and Tracey, 2006). 
This afferent signaling is mediated mainly via the vagus nerve in response to 
the release of inflammatory cytokines (Olofsson et al., 2012). This represents 
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the beginning of inflammation. The opposite (cholinergic) anti-inflammatory 
pathway is reSUHVHQWHG E\ WKH HIIHUHQW YDJXV QHUYH WKDW ZLOO VWLPXODWH Į-
nAChRs and suppress inflammation (Pavlov et al., 2003, Olofsson et al., 
 7KLV µUHIOH[¶ UHFUXLWV LPPXQH FHOOV WKDW FDQ GHIHQG WKH ERG\ DJDLQVW
invading pathogens and keep an imprint of such a pathogen for possible 
repeated invasion (Figure 1-14). 
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Figure 1-14: The inflammatory reflex. 
 
The inflammatory reflex represents a bi-directional communication between the 
central (CNS) and peripheral (PNS) nervous systems to accommodate inflammation. 
During inflammation, the tissue macrophages start releasing pro-inflammatory 
cytokines. This is followed by the stimulation of a number of pathways that 
inform the CNS (such as the afferent vagus nerve). The CNS response comes 
through the activation of the neuronal anti-inflammatory pathway represented 
by the cholinergic anti-inflammatory pathway (via the efferent vagus nerve 
VWLPXODWLRQRIWKHĮ-nAChRs on the surface of tissue macrophages and other 
inflammatory cells). 
Taken from (Tracey, 2002, Rosas-Ballina and Tracey, 2009). 
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It is worth noting that both the neuronal and immune cells release ACh and 
thus play a common role in controlling inflammation by delivering the vagus 
nerve signal to activate the cholinergic pathway. The use of acetylcholine 
esterase inhibitors helped prevent inflammatory cytokine release and could be 
used as a potential drug target for treating inflammatory diseases (Ulloa, 2005, 
Pavlov et al., 2009).  
Results from nicotine exposure experiments suggested that chronic nicotine 
H[SRVXUH FDQ LQDFWLYDWH Į-nAChRs which may be the basis for defective 
inflammation suppression in chronic smokers and in COPD (Kawashima et al., 
2012). However, stimulation of this pathway might not always be beneficial. 
For instance, COPD is a chronic inflammatory disease and the chronic 
exposure of nicotine in these patients suppresses inflammation, but helps 
precipitation of infection in such patients (de Jonge and Ulloa, 2007). 
,QWHUHVWLQJO\ Į-nAChRs were shown to have a critical role in suppressing 
inflammatory mediators in an inflammatory lung model in humans (Kox et al., 
2011). 
AlthoXJKWKHGXSĮSURWHLQHQFRGHGE\WKH&+5)$0$JHQHSOD\VDUole in 
FRQWUROOLQJ WKH Į-nAChR expression, its role in the anti-inflammatory 
pathway requires further exploration (Araud et al., 2011). It was shown that the 
CHRFAM7A mRNA transcript (but not protein) was down regulated in 
response to inflammatory cytokine stimulation. This suggested a possible 
QHJDWLYH UHJXODWRU\ UROH IRU WKLV JHQH XSRQ Į-nAChRs expression during 
resting condition which can be abolished once inflammation has started and 
Į-nAChRs expression is required (Benfante et al., 2011, de Lucas-Cerrillo 
AM, 2011).  
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1.5.1 The role of Į-nAChR agonists in treatment of chronic 
inflammatory diseases: 
More than a decade passed after the first trials of using nicotine for treatment 
of chronic inflammatory diseases. The earlier attempts for using nicotine 
treatment was employing nicotine transdermal patches for the treatment of 
ulcerative colitis (Guslandi, 1999). However, the effect of nicotine toxicity and 
the less than expected clinical improvement had a role on limiting the use of 
such treatment. It was shown in many studies that ACh and nicotine can be 
XVHG DV DJRQLVWV IRU WKH Į-nAChRs in suppressing inflammation. However, 
nicotine proved to have a much more powerful effect than ACh in such sets of 
experiments (Wang et al., 2003, Wang et al., 2004). FurtKHUPRUHĮ-nAChR 
agonists were shown to suppress inflammatory pathways in patients with 
rheumatoid arthritis (van Maanen et al., 2009). 
 
1.5.2 Other regulatory roOHVIRUĮ-nAChRs: 
,WZDVZHOOGRFXPHQWHGWKDWĮ-nAChRs have a major role on respiratory cell 
growth and subsequent development of lung cancer. This effect is thought to be 
PHGLDWHG YLD WKH SURORQJHG H[SRVXUH RI Į-nAChRs to nicotine, a condition 
that is similar to chronic smoking. Prolonged exposure of human cell lines to 
nicotine can lead to Į-nAChR upregulation (Peng et al., 1999). It is now 
clearly evident that Į-nAChR controls the regeneration and proliferation of 
the airway epithelial cells (Maouche et al., 2009). This role of the receptor 
helps the respiratory epithelial cells to regenerate following wear and tear 
process or after wound healing. The chronic exposure of Į-nAChRs to 
nicotine, as the case for COPD patients, was suggested to inactivate these 
receptors and thus alter the epithelial remodeling. It is worth considering that 
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nicotine exposure can first cause receptor upregulation but also can cause a 
reciprocal inactivation due to desensitization effect (Maouche et al., 2009). It 
was postulated that this effect of nicotine can extend to more than Į-nAChR 
upregulation and subsequently leads to lung cancer in animal models (Carlisle 
et al., 2007, Lam et al., 2007, Paleari et al., 2008). It is worth noting that 
among the mechanisms postulated to explain this upregulation is the repressive 
HIIHFWRIQLFRWLQHRQWUDQVFULSWLRQRIIDFWRUVWKDWVXSSUHVVĮ-nAChRs. Such a 
repressive effect prRYHG HQRXJK WR HQKDQFH Į-nAChR transcription and 
subsequent receptor expression (Finlay-Schultz et al., 2011). It is known that 
nicotine in cigarette smoke is a contributing factor to develop COPD. This 
effect was explored in GWAS studies to find a possible link between smoking 
and lung function and COPD. 
Many GWAS studies were conducted to explore possible susceptibility loci for 
COPD development. Among the loci tested, only one locus (CHRNA3/5) on 
chromosome 15 (15p25) showed correlation with the disease (Zhang et al., 
2011). It is important to know that CHRNA7 locus on chromosome 15 (15q13) 
was not included in any of these studies probably due to the relatively large 
distance from the CHRNA3/5 locus (more than 40 Mb distance) (Pillai et al., 
2009, Wilk et al., 2009, Repapi et al., 2010).  
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1.6 Conclusion: 
Inflammation is considered as a control mechanism that helps the body to 
overcome infections and injuries. This mechanism requires a limiting counter 
regulatory system that helps to localize the body response and prevent 
inflammation from changing to a chronic condition. When such a regulatory 
mechanism (such as the cholinergic anti-inflammatory pathway) is defective, 
inflammation is e[SHFWHGWREHFKURQLFDQGKDUPIXO7KHUROHRIĮ-nAChR is 
crucial in the anti-inflammatory pathway to limit the effect of inflammation in 
certain tissues. The fact that chronic obstructive pulmonary disease is among 
the examples of chronic diseases might KHOSVXJJHVWLQJDUROHIRUĮ-nAChR in 
the disease development or progression. Furthermore, in addition to CHRNA7 
coding for this receptor, the expression of the latter is under further control by 
another gene, the CHRFAM7A (the fusion gene). The fusion gene is down 
regulated once inflammation starts (via inflammatory mediators) allowing for 
&+51$ XS UHJXODWLRQ DQG VXEVHTXHQW Į-nAChR expression. For this 
purpose I proposed to study the expression of these two genes and their splice 
variants in airway epithelial cells to help understand possible mechanisms of 
control between the two genes. 
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2 7KHFKDUDFWHULVDWLRQRI&+51$DQGLWVGXSOLFDWH
JHQHWUDQVFULSWVLQDUDQJHRIKXPDQFHOOOLQHV 
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This chapter will discuss the processes of RNA splicing and alternative 
splicing and the possible effects of splicing elements (enhancers and silencers) 
on these processes. In addition, the role of alternative transcripts of the two 
genes controlling the expression of Į-nAChRs (CHRNA7 & CHRFAM7A) is 
discussed. I present my results on alternative splicing of these two genes in 
several human cell lines. 
 
2.1 NORMAL RNA SPLICING: 
Proteins constitute the essential components of living cells and their synthesis 
involves a multi-step process. For protein synthesis, an intermediate step is 
required involving passing the genetic code from the gene in the nucleus 
(DNA) coding for that specific protein via a message (messenger RNA-
mRNA). )LUVW WKH '1$ LV WUDQVFULEHG LQWR µSUH-P51$¶ which includes a 
replicate of the DNA template with all its exons and introns. The introns are 
WKHQH[FLVHGWRIRUPWKHPDWXUHµP51$¶OHDYLQJRQO\WKHexonic sequence to 
be transferred to the cytoplasm for subsequent translation into the required 
protein7KLVSURFHVVUHIHUUHGWRDVµ51$VSOLFLQJ¶WDNHVSODFHLQWKHQXFOHXV
(Pierce, 2006, Strachan, 2010). This process requires first the recognition of 
exons and introns to help a group of proteins (known as the splicing complex 
or splicing machinery) to assemble on an intron, forming the spliceosome. The 
next step would be removing that intron and joining its flanking exons 
(Robberson et al., 1990) (a detailed discussion about splicing will follow 
shortly). 
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2.1.1 Transcription and splicing: 
For protein formation, the translation of mRNA is a fundamental step. 
However, in addition to transcription there are other essential steps to form 
mRNA in the nucleus include adding a 5` cap, removing intervening introns 
and adding the 3`poly (A) tail. These three major steps help to produce a 
mature and stable mRNA that can ultimately pass to the cytoplasm and be 
recognized by the ribosomes for subsequent decoding (translation) to form the 
required protein.  
It has been established that RNA transcription and splicing are two different 
processes but proceed simultaneously. This feature allows for shortening of the 
time required for splicing the pre-mRNA, thus allowing for only consensus 
splice sites to be recognized (Dujardin et al., 2012, Kosti et al., 2012).  First the 
production of pre-mRNA from the template DNA starts, followed by RNA 
capping which includes adding a 7-methylguanosine monophosphate base to 
the 5` end. This modification enables pre-mRNA recognition for subsequent 
splicing (Izaurralde et al., 1994) followed by its export to the cytoplasm for 
translation. The RNA cap is thought to protect the mRNA from exonuclease 
activity, thus stabilising the mRNA and helping in initiating translation. As 
transcription proceeds, RNA splicing starts via recognised intron/exon 
boundaries for subsequent intron removal. 
 
2.1.2 Intron/exon definition: 
For a successful splicing to proceed, exons require definition for the splicing 
machinery to recognise their boundaries so enhancing their inclusion in the 
mRNA. On the other hand, introns require differentiation from exons to be 
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excluded from mRNA. It is still controversial which part is defined first, exons 
or introns, but after defining both, splicing starts (Dewey et al., 2006, Hertel, 
2008). 
There are important parts that constitute an intron, which include the 5` splice 
site (5`SS) which is formed of GU bases (GT bases in corresponding DNA), 
the A branch point (18-40 nucleotides upstream of 3`end of the intron), the 
polypyrimidine tract (PPT) and the 3` splice site (3`SS) (formed of AG bases), 
(Pierce, 2006, Caporale, 2006 ) (Figure 2-1). 
 
 
 
Figure 2-1: The intron composition (in corresponding DNA sequence). 
The 5` SS (GT) and 3` SS (AG) mark the start and end points of an intron. The 
Adenine branch point (A) is 18-40 nucleotide bases upstream of the 3` splice site, 
followed by the polypyrimidine tract (PPT). 
 
The 5`SS and 3` SS sites (with their adjacent sequences) defining an exon are 
highly conserved and most introns follow the GT-AG rule that defines the start 
and end points (Smith, 2000 , Strachan, 2010). In addition, the adenine branch 
point is highly conserved and is required for defining the 3` SS (Kohtz, 1994). 
Once the splicing machinery identifies these intronic parts, they start to 
assemble onto an intron. First, the U1 small nuclear ribonuclear protein 
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(snRNP) binds to the 5`SS. This will be followed by binding of the branch 
point protein (BBP) (or splicing factor 1 (SF1)) with the branch point. Another 
spliceosome factor termed the U2 auxiliary factor (U2AF) binds to the PPT and 
3`SS via its two major parts: 65 and 35 parts, respectively (Matlin et al., 2005, 
Strachan, 2010) (Figure 2-2). 
 
 
 
 
 
Figure 2-2: The spliceosome assembly. 
The spliceosome is started by the binding of the spliceosome factors U1, SF1, 
U2AF (-65 and -35 parts) to the 5`SS, branch point, PPT and 3`SS, 
respectively. Adapted from (Hertel, 2008). 
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After the spliceosome parts are assembled, the spliceosome machinery starts 
scanning the sequences downstream of a 3` SS until a consensus 5` SS is 
identified. This will define an exon in between these two sites, usually within 
300 nucleotide bases in length, and the splicing complex removes the identified 
intron and joins the newly defined exon with the exon upstream of it (Reed and 
Maniatis, 1986, Robberson et al., 1990). 
 
2.1.3 The spliceosome assembly and intron removal: 
One of the major factors required for a successful splicing process to take place 
is the presence of a group of small nuclear ribonuclear RNAs (snRNAs) and 
proteins (snRNPs), collectively reIHUUHGWRDVWKHµVSOLFHRVRPH¶ 
The main functions of spliceosome are first defining exons and introns, and 
then removing introns to form the mature mRNA (Faustino and Cooper, 2003).  
The RNA splicing process starts by binding of the first and second snRNPs 
with the 5`GU and branch point sequences, respectively. The other snRNPs 
constituting the spliceosome join the reaction, bringing the 5`and 3` splice site 
together with the branch point close to each other. The complex formed is then 
cleaved from the exon boundary (at 5` end of the intron) and attaches to the A 
EUDQFKSRLQWVLWHIRUPLQJDµ/DULDW¶7KHQH[WFOHDYDJHZLOOWDNHSODFHDWWKH3` 
end of the intron, releasing the intron from the mRNA and allowing the two 
successive exons to be joined. The process is repeated until all introns are 
removed and the mature mRNA is formed (Pierce, 2006, Strachan, 2010, 
Caporale, 2006 ) (Figure 2-3).  
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Figure 2-3: RNA splicing steps. 
1: Start of splicing: The Adenine branch point attacks the 5`SS, separating the intronic 
5` end from 5` flanking exon. 2: Lariat formation of the intron. This step starts by 
joining of the 5`SS to the Adenine branch point to form the intronic lariat. This will be 
followed by attack of the XSVWUHDPH[RQZLWKWKH¶HQGRIthe intron. 3: Exon joining 
and release of the lariat (for subsequent degradation). The spliceosome factors U1, 
SF1, U2AF (-65 and -35 parts) binding to the 5`SS, branch point, PPT and 3`SS, 
respectively,are illustrated.  
Exons: dark grey boxes, introns: light grey boxes. Adapted from (Caporale, 
2006 , Strachan, 2010). 
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The splicing process requires several factors for successful splicing to be 
completed, including the spliceosome complex, the splice donor and acceptor 
sites of the intron, branch point site, Exon Splicing Enhancers (ESEs) and 
suppressors (ESS), Intron Splicing Enhancers (ISEs) and suppressors (ISS), in 
addition to ATP (Caporale, 2006 ). 
 
2.1.4 Exon sequence motifs controlling splicing: 
In addition to the splice sites sequences in the intron, there are a number of 
exonic sequence motifs that helps control splicing. Different tissues might 
differ in the use of these sequences, which can alter the results of splicing, 
giving rise to physiological alternative splicing. 
These sequence motifs could be enhancers (ESEs) or suppressors (ESSs). Exon 
splice enhancers (ESE) are purine-rich conserved sequence motifs that are 
present in constitutive exons (Black, 2003, Cote J, 2001). They help in exon 
definition by binding to serine and arginine-rich proteins (SR) that interact with 
spliceosome parts. The SR proteins are thought to enhance and stabilise the 
spliceosome complex assembly on the splice sites flanking a specific exon in 
addition to enhancing propagation on the pre-mRNA. However, changes in 
ESE sequences might affect exon definition and cause exon skipping. The type 
of exons affects their inclusion in the subsequent mRNA. Authentic 
(constitutive) exons are exons that should be included in all mRNA transcripts. 
These are flanked by constitutive splice acceptor and donor sites, and marked 
by large number of ESE sequences included within. However, ESE could be 
found in other exon types, such as pseudo exons. These exons are sequences 
within the introns and are flanked by weak and/or non-functioning 5` & 3` SS 
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and branch point (Cote J, 2001). Furthermore, pseudo exons are enriched with 
silencers (ESS) that interact with suppressor part of the spliceosome and favour 
their skipping (Black, 2003, Wang, 2004, Zhang, 2004). These ESS act via 
activating silencer elements (through binding to SR proteins that binds to these 
silencers), leading to suppressing of the recognition of the flanking splice sites 
(Wang et al., 2006). Another type of exon is the cassette exons which are not 
included in all RNA transcripts for a specific gene (Caporale, 2006 ). These 
might cluster in a close proximity in such a way that only one might be 
included per each RNA transcript (Smith, 1989, Schmucker, 2000).  
 
Once exon definition starts (by identifying the 3` splice site immediately 
upstream of the exon) the splicing machinery scans the downstream  sequence 
for a constitutive 5` splice site. This process is usually active within 300 
nucleotide bases (the average exon length), otherwise the search for an 
alternative (cryptic) 5` splice site starts. If neither 5` splice site was detected, 
the splicing machinery would skip the 3`splice site-recognised exon and starts 
scanning downstream sequence for the next constitutive 3` splice site with its 
immediate downstream exon (Cote J, 2001).  
 
2.1.5 Intron sequence motifs controlling splicing: 
Intron splice enhancers (ISE) work in a similar pattern to ESE by interacting 
with SR proteins to enhance the definition of downstream exons (Black, 2003). 
Similarly, intron splice silencers (ISS) can help in exon skipping. However, the 
same sequence motif can act as ISE or ISS in different tissues depending on SR 
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protein recognition of such a motif as an enhancer or suppressor, thus 
contributing to either exon definition or skipping. 
In general, enhancers are thought to enhance exon recognition or oppose a 
silencer effect allowing constitutive exons to be included in mature mRNA. A 
change in part or all of enhancers and/or suppressors might affect the selection 
of flanking exons (Fairbrother and Chasin, 2000) and change the mRNA 
constitution. 
 
2.1.6 RNA polyadenylation: 
Following transcription, the RNA polymerase II enzyme scans the pre-mRNA 
for the polyadenylation signal (usually within less than 30 nucleotides 
downstream of the stop codon (Strachan, 2010). Once detected, RNA 
polymerase II starts to cut the pre-mRNA and another enzyme (poly (A) 
polymerase) starts adding a long sequence of adenines to the 3` end (poly (A) 
tail). This modification helps in mRNA transport to the cytoplasm and 
assembly of the ribosome for translation initiation (Pierce, 2006, Strachan, 
2010, Jung et al., 2006).  
In summary, for most genes the expression in human tissues passes through 
transcription, 5` capping, splicing, polyadenylation, export to the cytoplasm, 
and then either into translation or degradation depending on the correct 
sequence carried in the mRNA.  
 
2.1.7 Nonsense-mediated mRNA Decay (NMD): 
The accurate translation of mRNA to protein is important for synthesising the 
correct protein required for a specific function. However, if different transcripts 
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of mRNA of one gene were all allowed to be translated, different proteins 
could be produced with different or antagonising functions (Chang, 2007). 
Normally, there are a group of mechanisms termHG µP51$ VXUYHLOODQFH¶
These mechanisms function to prevent, or at least lessen, the effect of 
alternative mRNA transcripts (splice variants) that might interfere with proper 
protein translation. One of these mechanisms is Nonsense-mediated mRNA 
Decay (NMD). This mechanism involves the detection of mRNA with 
premature stop codons, and subsequent degradation before translation. This is 
thought to prevent the formation of different (short or truncated) proteins that 
might possess a different function from the original protein (Chang, 2007). The 
NMD process depends on detecting the Exon Junction Complex (EJC) (formed 
of a group of proteins working together) downstream of a detected premature 
stop codon. Once activated, the NMD activate enzymes that degrade mRNA. 
The premature stop codon is often found in an exon upstream of the terminal 
exon that harbours the original stop codon.  
In a normal transcript, there are no exon-exon junctions detected downstream 
of the stop codon, and NMD is not stimulated. Instead, the EJC will enhance 
translation (Nott et al., 2004). However, in transcripts with premature stop 
codon, at least one exon-exon junction is detected by the EJC. This leads to 
stimulation of NMD and subsequent degradation of mRNA (Figure 2-4). 
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Figure 2-4: Nonsense-Mediated Decay (NMD). 
The nonsense-mediated mRNA decay (NMD) occurs because of premature stop codon 
(PTC) recognition during the first round of translation. Left panel: When exon 
junction complex (EJC) represented by (2 & 3b) is detected downstream of PTC, 
NMD is allowed to degrade RNA. In contrast, a normal transcript (right panels) 
avoids NMD because the last EJC is upstream of the stop codon. CBC: cap-binding 
protein, eRF: eukaryote release factors.  
Taken from (Chang, 2007).   
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The process of alternative splicing might end up with mRNA that codes for a 
protein with different structure and physiological function (or sometimes 
without a specific function).  
 
2.1.8 Tissue-Specific Splicing: 
Many genes express different mRNA transcripts in different tissues. 
Alternative splicing was reported to affect more than two thirds of all human 
genes (Black, 2003) and of these up to 30% was shown to be tissue specific 
splicing (Xu et al., 2002). House-keeping genes are expressed in all tissues due 
to an essential requirement for their function. However, other genes might be 
expressed variably in different tissues, depending on the splicing factors 
specificities or the particular stage of differentiation of these cells (Strachan, 
2010, Grosso, 2008). For a particular gene, this might cause more transcripts in 
one tissue than other tissues due to alternative splicing. In a recent study, it was 
shown that alternative promoters can cause recognition of alternative 
transcription initiation sites, and thus contribute to more than half of the 
alternative splicing in the human genome (Kimura et al., 2006). In this study, 
the most common tissues affected by alternative promoters were testis and 
brain tissue. 
 
2.2 Alternative RNA Splicing: 
More than three decades ago, it was estimated that alternative splicing of 
mRNA affected only 5% of the whole human genome. Now with the advances 
achieved in bioinformatics and genome-wide analysis it has been shown that 
alternative splicing may be as high as up to 90% in the human genome 
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(Dujardin et al., 2012, Matlin et al., 2005). This question was first brought into 
light by the fact that the reported transcripts from the human genome 
outnumbered the reported human genes by almost five times (Modrek and Lee, 
2002, Piva et al., 2012), highlighting that there might be more than one 
transcript for each gene. The process of alternative splicing was investigated 
throughout the human genome to uncover the mechanisms and pathways of 
some diseases. However, alternative splicing can be a part of a regulatory 
pathway (Pierce, 2006, Caporale, 2006 ). This is best explained in Drosophila 
melanogaster (fruit flies), where alternative splicing plays a major role in sex 
differentiation (Black, 2003). Female flies have the sex lethal protein (Sxl) 
which affects the splicing of two genes: transformer (Tra) and Male-specific 
lethal 2 (Msl2) genes. On the Tra gene, Sxl in female flies binds to a 3`SS 
downstream of exon 3, enhancing splicing of exon 3 and subsequent protein 
translation (the reverse is true for male flies, where Sxl is absent causing an 
inactive form of the protein to be translated). The opposite effect was noticed 
in the Msl2 gene, where the presence of Sxl protein in female flies causes 
intron 1 retention and a subsequent inactive form of the protein to be translated, 
while the male flies that lack Sxl will have an active form of the protein. 
There are many types of alternative splicing, including exon skipping, mutually 
exclusive cassette exons, use of alternative 5` or 3` splice sites, use of 
alternative promoter or poly (A) tail or intron retention (Caporale, 2006 , 
Black, 2003) (Figure 2-5). 
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Figure 2-5: Alternative RNA splicing forms. 
A: Exon skipping of cassette exon (C1), B: inclusion of mutually exclusive cassette-exons (C1 or 2), C: alternative 5` splice site, D: alternative 3` splice site, 
E: alternative promoter (P1 or P2) region, F: alternative poly (A) tail, G: intron inclusion. Blue boxes: exons, blue lines: introns, black lines: normal splicing 
pathway, red lines: alternative splicing pathway.       
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The high percentage of alternative splicing could be justified by the fact that 
the spliceosome assembly is dependent on three short sequence motifs at the 
splice sites (5` and 3`) and the adenine branch point. Although these three sites 
are highly conserved (Strachan, 2010) they still represent a dot in a sea of 
nucleotides that constitute introns, and can easily be mixed with similar or even 
sometimes identical sequences at cryptic (decoy) splice sites (Cote J, 2001) that 
might be contained in cassette exons or pseudo exons. Alternative splicing 
could affect human genes in stress, but sometimes they could lead to diseases 
(pathological alternative splicing) (Kelemen et al., 2012). Many examples for 
pathological alternative splicing exist in human diseases, several of which were 
based on finding the inhibitory effects of alternative transcripts and their 
translated truncated proteins on the normal transcripts and their proteins 
(Faustino and Cooper, 2003). Other factors might play a role in alternative 
splicing of some genes, such as the presence of some SR proteins in abundance 
in some tissues and not in other tissues. This might affect the ESE that 
specifically binds to such (target) SR protein, and thus enhancing the inclusion 
of exons containing such a specific ESE in tissues with abundant (target) SR 
protein than other tissues (Caporale, 2006 ). 
 
2.3 Alternative splice variants of CHRNA7 in human and 
animal tissues: 
Like many other genes, several splice variants for CHRNA7 have been 
reported in human and animal neuronal tissues. Garcia-Guzman et al showed 
for the first time an alternative splicing of CHRNA7 in chromaffin cells of 
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bovine adrenal medulla (García-Guzmán et al., 1995). The mRNA and protein 
for the full-length JHQH ZHUH GHWHFWHG DQG WKH DVVHPEO\ RI Į VXEXQLWV LQWR
functional receptors was demonstrated. The splice variant included a transcript 
missing the 87 bp of exon 8 (Figure 2-6, E). This will cause the second 
transmembrane domain to be omitted, but still maintains the reading frame. 
When this transcript was injected in Xenopus oocytes, no functional ion 
channels were detected. +RZHYHU ZKHQ WHVWHG IRU WKH HIIHFW RQ Į VXEXQLW
assembly, this variant proved to have an inhibitory effect when co-expressed 
together with the full-length copy of the gene. It was thought that the exon 
skipping was related to the short length of the exon and weak flanking splice 
sites. This splice variant was suggested to be under the control of species-
specific splicing factors, as it could not be detected in rat brain and adrenal 
medulla tissues WLVVXHVWKDWFRQWDLQĮ-nAChR). A few years later, Gault et al 
showed for the first time the sequence of the full length (CHRNA7) gene for 
the humDQĮ-7 nAChR subunit (Gault et al., 1998). They showed in this study 
that, in addition to the full-length transcript, there are five splice variants for 
the gene (from human brain tissue) that ranged between deletions of exons 3, 4, 
3 & 4, 4 & 5 and 3-5. Of these variants, only one (missing exon 3) maintained 
WKHRSHQUHDGLQJIUDPHRIWKHĮ-7 coding sequence while the other transcripts 
contained premature stop codons (Figure 2-7, A-C, E-G). Later, Saragoza and 
colleagues showed that a novel exon exists in intron 9 of CHRNA7 of mouse 
brain tissue and termed it exon 9b (Figure 2-6, G) (Saragoza et al., 2003). This 
exon included 218 bp inserted from intron 9 sequence, harbouring three in-
frame termination codons leading to NMD. Interestingly, this exon was found 
to lie within a 520 bp region, which is conserved in the corresponding part of 
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the human gene. Similar to transcripts missing exon 8, transcripts with exon 9b 
insertion were shown to have an inhibitory effect when co-expressed with the 
full-length copy of the gene. However, this variant was shown to be influenced 
by tissue-specific splicing factors in mice, where it was detected in mouse 
brain and dorsal root ganglion but not in retinal tissues. Following that, the first 
discovery of exon 4a in rat neuronal tissue was made by Severance et al 
(Severance et al., 2004). This included a novel exon of 87 bp that would 
preserve the reading frame of the transcript in rat tissue. Several other splice 
variants for CHRNA7 were also detected in this study. These variants included 
deletions of exons 3-6 (completely or partially), all of which contained 
premature stop codons that affected the reading frame and resulted in a protein 
PLVVLQJSDUWV WKDWHQFRGH IRUDJRQLVWELQGLQJVLWHVRI WKHĮ UHFHSWRU Figure 
2-6, B-D, F). When compared to full-length transcripts, the exon 4a variants 
showed more sensitivity to bind Ach, and a higher affinity to bind Į%7;; 
however, their desensitisation rate was slower (Severance et al., 2004).  
Following their work in rat tissue, Severance and co-workers detected a novel 
exon between exons 4 and 5 (termed exon 4a) of the human gene (Severance 
and Yolken, 2008). This was larger than the corresponding exon in rat neuronal 
tissue detected previously (124-127 bp size). Another six splice variants were 
detected in this study, two of which were reported earlier by Gault et al (Gault 
et al., 1998) (missing exon 4 or exons 4 & 5). However, the rest were new 
variants including, in addition to inserted exon 4a, partially deleted exon 4, 
exon 5 deletion or a CAG (singlet/doublet) polymorphism at the exon 4-
inserted sequence splice junction (Figure 2-7, C-D, F, H-K). The new variant 
(with the added exon 4a) resulted in addition of 41-42 amino acids that 
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maintained the open reading frame. Surprisingly, the studies on human 
CHRNA7 lacked the functional characterisation of the resulting variant, and its 
effect on translation, assembly, DQGIROGLQJRIĮSURWHLQ is still unknown.  
 
Figure 2-6: Alternative splicing detected for CHRNA7 in experimental animal 
neuronal tissues.  
Top panel: exon numbers, A: full length CHRNA7 mRNA, B: missing exons 3&4, C: 
missing exons 3,4&5, D: missing exons 3&4 and splice junction of exons 5-6, E: 
missing exon 8, F: exon 4a, G: exon 9b. Blue boxes: constitutive exons, red boxes: 
cassette exons. 
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Figure 2-7: Alternative splicing for CHRNA7 in human brain tissue. 
Top panel: exon numbers, A: full length CHRNA7 mRNA, B: missing exon 3, C: 
missing exon 4, D: missing exon 5, E: missing exons 3&4, F: missing exons 4&5. G: 
missing exons 3-5, H-K: Exon 4a transcripts (I: with partial exon 4 deletion, J: with 
exon 5 deletion, K: with CAG polymorphism at exon 4 inserted sequence splice 
junction). Blue boxes: constitutive exons, red boxes: cassette exons. 
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2.4 Alternative splice variants of CHRFAM7A: 
Generally, fewer alternative transcripts for CHRFAM7A were reported. These 
include exon E (between exons A & B) H[RQ '¶ or missing exon B (Riley, 
2002, Gault et al., 2003). However, none of these studies explored the 
expression of the CHRFAM7A protein or its function (Gault et al., 1998, Riley, 
2002) (Figure 2-8). 
 
Figure 2-8: CHRFAMA alternative transcripts. 
Top panel: exon numbers, I: full length CHRFAM7A mRNA, II: including exon E 
between exons B & A, III: LQFOXGLQJH[RQ'¶upstream of exon D, IV: missing exon  
B. Blue boxes: constitutive exons, red boxes: cassette exons. 
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2.5 Aims: 
This chapter had two aims. The first was to characterise the CHRNA7 and 
CHRFAM7A transcripts in an immortalised airway epithelial cell line (A549) 
and other cell lines (BEAS2B, PBMC and BE (2)-c). The second aim was to 
quantify the main transcripts and to predict the protein structure. 
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2.6 Methods: 
2.6.1 Cell culture: 
The A549 cell line (human lung adenocarcinoma epithelial cells) was used as 
an in vitro model for type II pulmonary epithelial cells. Other cell lines were 
also used for testing alternative transcripts of CHRNA7 and CHRFAM7A 
(Table 2-1). 
Table 2-1: Human cell lines used for alternative transcript test. 
Cell line Description  
A549 Alveolar adenocarcinoma cell line 
BEAS2B Bronchial epithelial cell line 
PBMC Peripheral blood mononuclear cells 
BE(2)-c Neuroblastoma cell line ±derived from bone marrow metastasis 
 
The culture medium used for maintaining A549 cells was composed of 
'XOEHFFR¶V 0RGLILHG (DJOH¶V 0HGLXP (DMEM) (SIGMA-ALDRICH, UK), 
10% FBS (foetal bovine serum) (SIGMA-ALDRICH, UK), 2mM L-glutamine 
(SIGMA-ALDRICH, UK), 100U/ml penicillin, 100µg/ml streptomycin 
(Invitrogen, UK) and 2.5µg/ml amphotericin B (SIGMA-ALDRICH, UK) in 
75cm2 flasks. Regarding BE (2)-c cells, thHFXOWXUHPHGLXPXVHGZDV(DJOH¶V
minimum essential medium (EMEM) (SIGMA-ALDRICH, UK), with 15% 
FBS (foetal bovine serum) (SIGMA-ALDRICH, UK), 2mM L-glutamine 
(SIGMA-ALDRICH, UK), 100U/ml penicillin, and 100µg/ml streptomycin 
(Invitrogen, UK) and 2.5µg/ml amphotericin B (SIGMA-ALDRICH, UK) and 
5% NEAA (non-essential amino acids) in 75cm2 flasks. However, RNA for 
BEAS2B and PBMC was kindly provided from other PhD students. 
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For maintenance of A549 or BE (2)-c FHOOVWKH\ZHUHLQFXEDWHGDWÛDQG
CO2 humidity for 24 hrs. For cell splitting, the cell cultures were first examined 
under the light microscope and were subcultured once they reached ~80% 
confluency (about 3x106 cells). The medium was removed, followed by 
washing with PBS (phosphate buffered saline) (Oxoid, England), and cells 
were dissociated from the flasks using trypsin-EDTA (SIGMA-ALDRICH, 
8. IROORZHG E\ LQFXEDWLRQ DW Û IRU  PLQXWHV 2QFH WKH FHOOV ZHUH
successfully detached, DMEM was added and mixture split into two different 
75 cm2 IODVNVDQGLQFXEDWHGDWÛIRUKUV 
 
2.6.2 RNA Extraction: 
Total RNA was isolated from human cell lines of interest (Table 2-1). When 
cell cultures were > 80 % confluent, they were used for RNA extraction. First, 
the cells were harvested by washing the cultures with PBS (5 ml) prior to cell 
dissociation using trypsin-EDTA. The cell suspension was centrifuged for 5 
minutes at 1000 rpm (300g) to pellet the cells. For RNA preparation, RNeasy 
Mini kit (QIAGEN) was used DFFRUGLQJ WR WKH PDQXIDFWXUHU¶V JXLGHOLQHV. In 
addition, RNase-free DNase set (QIAGEN) was used according to 
PDQXIDFWXUHU¶V JXLGHOLQHV 7KLV VWHS ZDV XVHG IRU UHPRYLQJ UHPQDQWV RI
genomic DNA that may interfere with downstream steps. The DNA yield was 
then measured using a Nanodrop spectrophotometer.  
 
2.6.3 cDNA Generation: 
The cDNA was generated from 2 µg of RNA using 500 ng of Oligomer dT 
(Stratagene, Germany) in a final reaction volume of 15.7 µl. The mixture was 
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WKHQ LQFXEDWHG IRU  PLQXWHV DW Û DQG WKHQ Ior 10 minutes at room 
temperature. The following reagents from the Affinity Script kit (Stratagene, 
Germany) were then added to each tube:  1x buffer, 4 mM dNTP, 1 µl of the 
reverse-transcriptase multi-temperature enzyme and 1 U/ µl of RNase Block. 
The reaFWLRQV ZHUH LQFXEDWHG IRU  PLQXWHV DW Û  PLQXWHV DW Û 
PLQXWHV DW Û DQG DW Û KROG ,Q DGGLWLRQ 57-negative samples were used 
(using 1.5 µl of RNase-free water instead of reverse transcriptase enzyme and 
RNase block) to enable the detection of products derived from contaminating 
genomic or plasmid DNA rather than from generated cDNA. 
 
2.6.4 PCR: 
CHRNA7 is located on chromosome 15, proximal to CHRFAM7A (partially 
duplicated CHRNA7) gene. To detect possible expression of splice variants for 
CHRNA7 by A549 cells, several primers were designed to amplify different 
parts of the mRNA. Most of these were designed in a way to avoid detecting 
the common exons 5-10 expressed by both genes. Table 2-2 shows the primer 
sets used to detect CHRNA7 variants. However, for CHRFAM7A, the primers 
were designed to detect for two main parts of the gene mRNA: FAM7A exons 
(D to A) and the duplicated CHRNA7 exons (5-10). Table 2-3 shows the 
primer sets used to detect the main splice variants of CHRFAM7A. 
 
 
 
 
 
The characterisation of CHRNA7 transcripts                                       Chapter 2 
 89 
Table 2-2: Nucleotide sequences of the primers used for CHRNA7 variants 
detection. 
Primer ID Primer sequence CĺC Position  
A7E1_S GACTCAACATGCGCTGCTC Exon 1 
A7E2_S GCCAATGACTCGCAACCACTC Exon 2 
A7E4_S AGATGGCCAGATTTGGAAAC Exon 4 
A7E4a_S TTATGACCAACAGCAGGAAGTG Exon 4a 
A7E4a_AS CACAACAGGGAACATAGACGA Exon 4a 
A7E6_AS CCAGCGTACATCGATGTAGCA Exon 6 
A7E7_S CAGATTCCGGGGAGAAGATT Exon 7 
A7E10_AS AGCCGATGTACAGCAGGTTC Exon 10 
All primers are from Eurogentec, Belgium 
 
 
 
 
 
 
Table 2-3: Nucleotide sequences of the primers used for CHRFAM7A variants 
detection. 
 
Primer ID PULPHUVHTXHQFHCĺC Position 
A7EA_S CCAGCATTTGTGGATAGCTG Exon A 
A7ED_S TCAAGGCCAAACCGAAGTTA Exon D 
A7EC_AS GATTCCAGGTCCTGCTGACT Exon C 
A7E10_AS AGCCGATGTACAGCAGGTTC Exon 10 
All primers are from Eurogentec, Belgium 
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The RT-PCR was performed using a 30 µl reaction, using 1 µl of cDNA, in 
addition to the following reagents in a final concentration/reaction: 1x Taq 
buffer with (NH4)2SO4, 1.5 mM MgCl2, 0.2 mM dNTPs mix (Fermentas Life 
Sciences, UK), 0.3 µM of each primer, and 1 U Taq polymerase (Roche, USA). 
The thermal cycler was used for the PCR amplification (Applied Biosystems) 
using the conditions shown in Table 2-4.  
Table 2-4: RT-PCR conditions used. 
 
Stage1 Stage 2 Stage3 Hold 
 
Initial 
denaturation 
Denaturation Annealing extension 
Final 
extension 
- 
Cycles 1 ĸĺ 1 - 
Temperature 94° 94° 60° 72° 72° 10° 
Time*  2:0 00:30 00:45 1:00 7:00  
*: (minutes : seconds) 
 
A summary for CHRNA7 and CHRFAM7A transcripts targeted in A549 cells 
and their predicted sizes is shown in (Figure 2-9) and (Figure 2-10), 
respectively. 
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Figure 2-9: CHRNA7 amplified parts. 
Diagram showing location of primers used to amplify different transcripts of   
CHRNA7 in A549 RNA. Blue boxes: exons, Green arrow: forward primer, Red 
arrow: reverse primer. The products are A: (exons1-10), B: (exons 2-6), C: (exons 2-
4a), D: (exons 4a-6), E: (exons 4-6), F: (exons 2-10), G: (exons 4-10), H: (exons 7-
10). Only exons included in the PCR amplification were included in the diagram. The 
expected product size (in bp) is shown on the right. 
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Figure 2-10: CHRFAM7A amplified parts. 
Diagram showing location of primers used to amplify different transcripts of 
CHRFAM7A in A549 RNA. Blue boxes: exons, Green arrow: forward primer, Red 
arrow: reverse primer. The products are 1: (exons A-10), 2: (exons A-6), 3: (exons 7-
10), 4: (exons D-C). Only amplified exons were included in the diagram. The 
expected product size (in bp) is shown on the right 
 
2.6.5 Agarose gel electrophoresis: 
PCR products were subjected to agarose gel electrophoresis  using 1% agarose 
gel (Invitrogen, Paisley, UK), with 1 x Tris-acetic acid-EDTA (TAE) running 
buffer  and 5  ng ethidium bromide (SIGMA-ALDRICH, UK) staining/25 ml 
of the gel. 5µl of 100bp DNA Step Ladder (Fermentas life Sciences, UK) was 
used as a size marker and the results visualised using UV light reader 
(Anachem, Luton, UK).   
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2.6.6 TA cloning: 
This included PCR purification, insert ligation, transformation and restriction 
digestion. The purpose of the method is to clone PCR products with multiple 
amplicons. The method is based on hybridization of the Adenine nucleotide 
base (added by Taq polymerase enzyme to PCR products) with the Thymine 
base of a linearized vector with the aid of ligase enzyme. This hybrid DNA 
fragment is then transformed into Escherichia coli bacteria for subsequent 
amplification. Such a method would help separate multiple amplicons 
amplified using one primer set to detect different transcripts of the same gene 
(Holton and Graham, 1991). 
 
2.6.6.1 PCR purification: 
To improve the ligation efficiency, a clean-up step was performed prior to 
ligation to remove primer dimers. For this, QIAquick PCR purification kit was 
used (QIAGEN) DFFRUGLQJ WRPDQXIDFWXUHU¶VJXLGHOLQHV. The DNA yield was 
measured using a Nanodrop spectrophotometer.  
 
2.6.6.2 Insert ligation: 
The PCR product was cloned into the pSC-A-amp/kan StrataClone vector mix 
(Stratagene, Germany) (Figure 2-11). 
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Figure 2-11: pSC-A-amp/kan PCR cloning vector. 
Top: vector map, showing all included sites and features (illustrated). Most important of these is the multiple cloning sites (MCS) that is going to harbour the 
PCR product insert site (illustrated). Bottom: PCR-insertion site. This site shows the recognition sites for the restriction enzyme and the primer sequence.  
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For ligation, a 6 µl reaction, the following reagents were added: 3 µl of 
StrataClone buffer, 2 µl of purified PCR product (about 25ng) and 1 µl of 
StrataClone vector mix amp/kan. This mix contains the two vector DNA arms 
with uridine overhangs that base pair with the adenosine overhangs of the Taq 
polymerase-amplified PCR products.  
The reaction was then incubated at room temperature for 5 minutes. 
 
2.6.6.3 Transformation to competent cells: 
For transformation, StrataClone SoloPack competent cells (Stratagene, 
Germany) were used. These cells contain Cre-recombinase enzyme that 
enhances the recombination of the lox P sites on the two vector arms, thus 
helping the formation of circular plasmid-insert DNA molecule. Such a DNA 
can replicate in host cells growing on ampicillin or kanamycin-containing 
media. The cells were removed from storage at -ÛDQGOHIWRQLFHIRUWKDZLQJ
for 5 minutes. Then 1µl of ligation reaction mixture was added into the 
competent cells, and the reaction mixture was mixed gently (by repeated 
pipetting) and then incubated on ice for 20 minutes. The reaction was then 
heat-VKRFNHGDW Û IRU  VHFRQGV DQG WKHQSXWRQ LFH IRUPLQXWHV 7KHQ
250µl of room temperature SOC solution (super optimal broth medium with 
glucose used to enhance the plasmid transformation efficiency) was added to 
each reaction tube. 7KH UHDFWLRQ PL[WXUH ZDV WKHQ LQFXEDWHG DW Û ZLWK
horizontal shaking for 60 minutes. Finally, 100 µl of reaction mixture was 
spread on plates containing pre-warmed CG agar (Circle Grow rich bacterial 
growth media, Anachem, Luton, UK) (containing 4 g/100 ml CG, 1.5 g/100 ml 
DJDUDQGȝJPODPSLFLOOLQ and 20% X-gal) and incubated overnight at 37°. 
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Single colonies were inoculated into 5 ml CG bacterial growth media 
LQFOXGLQJ  ȝJPO DPSLFLOOLQ DQG incubated for 16-18 hours at 37° in a 
shaking incubator.   
 
2.6.6.4  Insert-specific PCR: 
A screening insert-specific PCR was carried out (using the original amplimers) 
to show which cultures contained the plasmid and insert. All other reagents 
were the same used for PCR mentioned in section 2.6.4 while 1 µl of liquid 
growth was used as the PCR template. The same PCR program shown in table 
(2-4) was used, except for a difference in the initial denaturation time (4 
minutes rather than 2 minutes). The PCR products were subjected to gel 
electrophoresis for analysis (as mentioned in section 2.6.5). 
 
2.6.6.5 Plasmid-insert extraction: 
Using Pureyield Plasmid Miniprep System (Promega, USA), plasmid was 
extracted from bacterial cultures DFFRUGLQJ WRPDQXIDFWXUHU¶V JXLGHOLQHV. The 
DNA yield was then measured using a Nanodrop spectrophotometer. This 
extraction method depends on the use of silica membrane columns that helps in 
nucleic acid extraction. The method includes precipitation of the cell debris 
using centrifugation and lysis buffer. The obtained supernatant (containing the 
plasmid DNA) can then be added on the silica membrane for subsequent 
purification using several buffers (such as the endotoxin removal buffer). 
These purification steps help preparing a plasmid DNA free of proteins, RNA, 
and endotoxin contaminants. 
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2.6.6.6 Restriction digestion: 
In order to identify plasmids containing the insert of interest, plasmid DNA 
was screened using restriction digestion with EcoRI. This enzyme will 
recognise the sequence G: AATTC and then generates fragments that contain 
5`-cohesive termini. The following was added into 10µl reaction: 600 ng of 
plasmid DNA, 1µl of 10x cut buffer-H (Roche), 5U of EcoRI restriction 
enzyme (Roche) and the reaction volume completed by adding nuclease-free 
ZDWHU7KHUHDFWLRQPL[WXUHZDVWKHQLQFXEDWHGIRUKUDWÛ. For detection of 
the size of predicted inserts, the digested DNA was run on 1% agarose gel 
(Invitrogen, Paisley, UK), with 1 x TAE running buffer and 5ng of ethidium 
bromide (SIGMA-ALDRICH). 5µl of 100bp DNA stepladder (Fermentas life 
sciences, UK) was used as a size marker, and the results visualised using UV 
light reader (Anachem, Luton, UK). Equivalent samples from the undigested 
DNA were run on the same gel to compare results. 
 
2.6.7 Gel extraction:  
The QIaquick gel extraction kit (QIAGEN) was used for extraction of PCR 
products from the agarose gel. The PCR products with multiple and relatively 
separable bands were chosen for gel extraction. First, the PCR product of 
interest was run on a range of 1-3.5% agarose gel (as mentioned in section 
2.6.5) to visualise the bands of interest. The gels obtained were put in new 
1.5ml micro centrifuge tubes, and weighed. An empty 1.5ml micro centrifuge 
tube weight was subtracted from the gel-containing tubes weights. The yielded 
weight (in mg) was considered as an equivalent one volume in µl. Three gel 
volumes of QG buffer was added to the gel and the reaction was incubated for 
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 PLQXWHV DW Û ZLWK UHSHDWHG YRUWH[LQJ WR HQVXUH WKH JHO ZDV FRPSOHWHO\
dissolved. One gel volume of isopropanol (Fisher Scientifics, UK) was added 
and mixed with the dissolved gel mixture. To bind DNA, the mixture was then 
applied to a new QIAquick column and centrifuged for 1 minute at 13000 rpm. 
The flow-through was discarded. Then 0.5 ml of QG buffer was added to the 
column and centrifuged for 1 minute at 13000 rpm (10000 g). The flow-
through was discarded. To wash the DNA, 0.75 ml of PE buffer was then 
added to the column and centrifuged for 1 minute at 13000rpm and the flow-
through was discarded. The centrifugation was repeated for 1 minute at 13000 
rpm to ensure complete removal of the buffer. To elute the DNA, the column 
was then put in a new 1.5ml micro centrifuge tube, and 30 µl of BE buffer was 
applied on column, centrifuged for 1 minute at 13000 rpm. The DNA yield was 
measured using a Nanodrop spectrophotometer.  
 
2.6.8 DNA Sequencing: 
For PCR products with single band, a clean-up step was applied prior to DNA 
sequencing, while TA cloning or gel extraction products were sequenced 
directly without this step. The sequence clean-up reaction included adding 2U 
of EXOSAP-IT enzyme (USB, USA) to treat 5 µl of the PCR products (to 
remove the residual primers and dNTPs from the PCR products to be 
sequenced). The samples were then incubated in thermal cycler (Applied 
Biosystems) using the following proJUDPPHF\FOHPLQXWHVDWÛC and 
WKHQPLQDWÛ 
Sequencing of PCR products was carried out using one of the primers used for 
the initial PCR amplification (Table 2-2, Table 2-3, & Error! Reference 
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source not found.). The samples were prepared on ice using the following: 1 
µl of sequencing primer (5µM), 2 µl of Big Dye v3.1 Terminator Ready 
reaction mix (Applied Biosystem)  and 1x sequencing buffer (Big Dye 
terminator, v3.1) (Applied Biosystem) in addition to the DNA template. 
Quantities of DNA template used ranged from 3µl of the enzyme-treated PCR 
product (~20ng), 5-20 ng of gel-extracted product, or 150-500ng of TA cloned 
DNA. The mixture was incubated in a thermal cycler (Applied Biosystems) 
XVLQJ WKH IROORZLQJSURJUDPPHF\FOHV  VHFRQGVDWÛ VHFRQGVDW
Û  PLQXWHV DW Û DQG WKH VDPSOHV WKHQ NHSW DW Û IRU KROG )RU SRVW-
reaction clean up, the sequence column purification tubes (Edge Biosystems 
Performa DTR Gel Filtration Cartridges) were used to remove dye terminators, 
dNTPs, and other low molecular weight materials from the sequencing 
reaction. First, the columns were centrifuged for 3 minutes at 4000 rpm (850 g) 
to remove excess buffer from tubes. The columns were then transferred to a 
new tube, and the sequencing products were then added on the column 
membrane, and centrifuged for 3 minutes at 4000 rpm (850 g). The eluates 
were transferred into new 0.POWXEHVWREHHYDSRUDWHGWRGU\QHVVDWÛ To 
confirm the correct sequence for each of the transcripts detected from PCR 
products, gel extractions, or bacterial clones, DNA sequencing was applied 
using forward and reverse primers for each transcript. All samples were 
separated by capillary electrophoresis for sequencing. 
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The sequences for primers M13 forward and reverse are shown in Error! 
Reference source not found.. 
Table 2-5: Nucleotide sequence for pSC-A-amp/kan vector primers. 
 
Primer ID Primer sequence 
M13 F GGAAACAGCTATGACCATG 
M13 R GTAAAACGACGGCCAGT 
F: Forward primer, R: Reverse primer, M13 primers (100 ng/µl, Invitrogen) 
 
 
2.6.9 Quantitative Real-time PCR (QRT-PCR): 
To estimate the expression of the two major transcripts of CHRNA7 by A549 
cells, QRT-PCR was used. In order to avoid detection of the CHRFAM7A 
transcripts, the sense primer was located outside of the duplicated region, in 
exon 4 (Table 2-2). The antisense primers were designed to bridge the exon-
exon boundaries between exons 8 and 9 (for full-length CHRNA7 transcript) 
and between exons 8 and 10 (for missing exon 9 CHRNA7 transcript) (Table 
2-6) (Figure 2-12).   
Table 2-6: Reverse primers used for QRT-PCR amplification of CHRNA7 two 
major transcripts in A549 cells. 
Primer ID Primer sequence Position 
A7E8/9_AS CGAAGTACTGGGCTATCAATGG Exons 8-9 junction 
A7E8/10_AS GACTCTGGTCTATCAATGGTACC Exons 8-10 junction 
All primers are from Eurogentec, Belgium 
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Figure 2-12: CHRNA7 amplified parts for QRT-PCR. 
Diagram showing location of primers used to amplify two major transcripts of   
CHRNA7 in A549 using QRT-PCR. Blue boxes: exons, Green arrow: forward primer, 
Red arrow: reverse primer. The products are A: (exons 4-8/9), B: (exons 4-8/10). The 
expected product size (in bp) is shown on the right. 
 
SYBR GREEN BRILLIANT III master mix (Agilent technologies) was used 
for the QRT-PCR. The QRT-PCR master mix was prepared into a final volume 
of 20 µl by adding 10 µl/reaction of SYBR green brilliant III master mix, 0.3 
µl/reaction of the diluted reference dye (1/50), 0.3 µM primer concentration 
and 5 µl/reaction of the diluted A549 cDNA and the reaction volume was 
completed using RNase-free water. The cDNA: RNase-free water dilutions 
used were 1:4 (1/5) and 1:19 (1/20) in duplicates for each primer set. Then 
PCR products were subjected to real time PCR machine analysis in addition to 
agarose gel electrophoresis (as mentioned in section 2.6.5).  
For primer specificity check of each primer set used, the cDNA templates used 
for QRT-PCR were used for RT-PCR using the same primer sets. These were 
then used for TA cloning to separate the resulted products (as mentioned in 
section 2.6.6). This was followed by using the prepared clones as templates 
representing full-length or missing exon 9 (according to the primer set used) 
for another RT-PCR by using both primer sets in two separate reactions. This 
test was aimed at showing whether the primer sets designed were specific or 
not (that is full-length primers were supposed to amplify full-length clones, and 
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the same for missing exon 9 part). Previously prepared clones (representing 
full-length exons 1-10 and missing exon 4) were used as control templates. 
 
2.6.10 RT-PCR semi-quantitative assay: 
This assay used same RT-PCR described in section 2.6.4. The primer sets used 
to amplify exons 1-10 of CHRNA7 (Table 2-2; Figure 2-9) and exons A-10 of 
CHRFAM7A (Table 2-3; Figure 2-10). PCR samples were prepared in 
duplicates for cycles 27-35, and cycle-specific samples were removed from the 
thermocycler after each specified cycle and kept on ice (e.g. 27 cycle-specific 
samples were removed after cycle 27, and so on). After completing second 
stage of RT-PCR, the samples were re-introduced into the thermocycler for the 
elongation step till the end of the program. Then PCR products were subjected 
to gel electrophoresis (as mentioned in section 2.6.5). The procedure was 
repeated at least three times to achieve reproducible results. 
 
2.6.11 AlphaDigiDoc software and statistical analysis: 
To evaluate the relative percentage of mRNA expression for the major 
transcripts of CHRNA7 and CHRFAM7A, the gel electrophoresis pictures 
were analysed using AlphaDigiDoc1201 software. The parameter used for 
comparisons was the band intensity for each transcript, which was evaluated 
across duplicated samples for different PCR cycles (27-35) to determine the 
exponential phase and the plateau phase (relative start and end points), and to 
determine the relative percentage of expression of each transcript by A549 
cells (for each gene transcripts).  
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2.6.12 Bioinformatics used for analysis of transcripts: 
First, for the extraction of the reference sequence for CHRNA7 and 
CHRFAM7A, database websites for corresponding human reference sequences 
were used from NCBI, UCSC, and Ensembl. Then for sequence alignment of 
the common parts of the two genes, ClustalW software program was used 
((Larkin et al., 2007). For prediction of the possible restriction enzyme 
recognition sites within exon 9b and flanking introns, Web Cutter and Neb 
Cutter software programs were used. For primer design, primer3 (v.0.4.0) 
software was used for designing the primers, Primer-Blast/NCBI software was 
used to check for the primer specificity. To look for the consensus sequences of 
ESE and ESS, the predicted ESE (PESE) and predicted ESS (PESS), RESCUE-
ESE and Human splicing finder software programs were used (Fairbrother et 
al., 2002). Using ORF finder software programme, the mRNA of resultant 
splice variants was translated into corresponding protein code. Then for 
determining the KOZAK consensus sequence, weakAUG software program 
(Tikole and Sankararamakrishnan, 2008) was used. This was followed by using 
the SOSUI signal software program (Masahiro, 2005) for the prediction of a 
possible signal peptide. Then using PSIPRED software (Jones, 2007), the 
secondary protein structure was predicted for each transcript. A summary for 
the software programs using for bio-informatics analysis and their 
corresponding URLs are listed in (Table 2-7). 
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Table 2-7: Summary for the bio-informatics software programs and tools used 
for analysis of CHRNA7 and CHRFAM7A transcripts. 
Software program URL 
ClustalW (sequence 
alignment) 
http://www.ebi.ac.uk/Tools/msa/clustalw2/  
Web cutter (searching for 
restriction recognition sites) 
http://users.unimi.it/~camelot/tools/cut2.html  
Neb cutter (as above) http://tools.neb.com/NEBcutter2/  
Primer 3 (v.0.4.0) (PCR 
primer design) 
http://frodo.wi.mit.edu/ 
Primer blast/NCBI (check 
primer potential target) 
http://www.ncbi.nlm.nih.gov/tools/primer-
blast/  
RESCUE-ESE (look for 
potential ESE sequences) 
http://genes.mit.edu/burgelab/rescue-ese/  
   
Human Splicing Finder 
(look for splicing sequences) 
http://www.umd.be/HSF/  
ORF finder (look for ORF 
with a start and stop codons) 
http://www.ncbi.nlm.nih.gov/gorf/gorf.html  
WeakAUG (detect possible 
weak start codons) 
http://bioinfo.iitk.ac.in/AUGPred/index.php  
SOSUI (detect signal 
peptides) 
http://bp.nuap.nagoya-u.ac.jp/sosui/  
PSIPRED (test for possible 
protein secondary structure) 
http://bioinf.cs.ucl.ac.uk/psipred/  
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2.6.13 Western blotting: 
2.6.13.1 Cell lysate preparation:  
For cell lysate preparation, all reagents were kept on ice throughout the 
procedure. RIPA buffer (20 mM Tris pH7.5, 150 mM NaCl, 1% triton x-100, 
0.5% sodium deoxycholate, 1 mM EDTA and 0.1% SDS) was prepared and 
mixed with 5x protease inhibitor mixture (Complete Mini protease inhibitor 
cocktail tablets, Roche). First, the cells were cleaned from the old medium and 
dead cells, and then washed with ice-cold PBS. Then 600 µl of the prepared 
buffer mixture was added into the cells for 5 minutes, and then cells were 
detached and transferred into 1.5ml micro centrifuge tubes. The mixture was 
then rotated in a cold room for 30 minutes to allow solubilisation of the 
proteins, before separating the lysate from the cell remnants using a precooled 
FHQWULIXJH DW ÛC for 20 minutes at 12000 rpm (4000 g). After that, the 
supernatant was collected and transferred into a new tube and stored at -8ÛC. 
Then the lysate protein contents were quantified using BCA protein 
quantitative assay kit (Thermo Fisher Scientific, USA), according to 
PDQXIDFWXUHU¶VJXLGHOLQHV. The protein samples were quantified after that using 
FluoSTAROPTIMA spectrometer at 550 nm wavelength (BMGs LABTECH, 
Germany).  
 
2.6.13.2 SDS-PAGE:  
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) 
was used to separate the proteins according to their sizes. This constituted 
discontinuous 5-10% gel. The constituents of gel used are included in (Table 
2-8). 
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Table 2-8: SDS-PAGE reagents. 
Substance Stacking gel  Separating gel  
Gel percentage 5% 10% 
Polyacrylamide mix 40% 625 µl 5 ml 
Tris base 625 µl  (pH 6.8), 1M 5 ml (pH 8.8), 1.5 M 
Ammonium Persulfate (APS) 10% 50 µl  200 µl 
Sodium Dodicyl Sulfate (SDS) 10% 50 µl 200 µl 
Tetramethylethyl diamine (TMED) 5 µl 8 µl 
Distilled water 3.65 ml 9.6 ml 
Total volume 5 ml 20 ml 
 
The samples were prepared by adding aliquots of A549 cell lysate mixed with 
4x loading buffer (240 mM Tris-HCL/Tris base pH 6.8, 8% SDS, 0.04% 
bURPRSKHQROEOXHȕ-mercaptoethanol and 40% glycerol). The mixture was 
WKHQLQFXEDWHGDWÛC for 10 minutes, put on ice before loading on the gel. To 
monitor the protein migration during SDS-PAGE, a protein ladder was used to 
identify the protein size between 10-260 kDa (Fermentas life sciences, UK). 
The power supply was set to 150 volts, 50 mA, for 1:30 hr.  
 
2.6.13.3 Semi-dry Transfer: 
The transfer was carried out using PVDF (polyvinylidene fluoride) membrane. 
The transfer sandwich was prepared as follows (from down upwards): Three 
blotting papers, PVDF, Gel, and three blotting papers on top (with the gel near 
the cathode), all soaked in transfer buffer for 5 minutes prior to arrangement, 
except PVDF which was soaked in absolute methanol then in the transfer 
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buffer. The transfer buffer was composed of the following: 48 mM Tris 
HCL/Tris base, 39 mM glycerin and 20% Methanol. 
 
2.6.13.4 Immunoblotting:  
The membrane was blocked overnight with 5% skimmed milk. This was 
followed by LQFXEDWLRQ ZLWK SULPDU\ UDEELW SRO\FORQDO ,J* DQWLERGLHV IRU Į
protein (ab10096, Abcam, UK) for 1:30 hr., and secondary goat polyclonal to 
rabbit antibodies conjugated to horse radish peroxidise (HRP) (ab6721, 
Abcam, UK) for another 1:30 hr. Each of the blocking and antibody incubation 
steps was followed by washing with PBS-Tween buffer (0.1% Tween-20 and 
phosphate buffered saline) for three times, (10-15 minute duration/each). The 
PHPEUDQHV ZHUH SUREHG ZLWK DQWLERGLHV IRU ȕ-actin as a positive control for 
protein in A549 (primary mouse monoclonal IgG (SIGMA-ALDRICH, UK), 
and secondary goat anti mouse IgG (SIGMA-ALDRICH, UK)). The blocking 
agent and antibodies were all diluted in the 5% milk-PBS-Tween wash buffer. 
The dilutions used for all antibodies are summarized in (Table 2-9). 
Table 2-9:  Sources, dilution and expected protein sizes for antibodies used. 
Antibody Source Dilution 
Expected 
band size 
Primary antibody IRUĮ Abcam, UK 1:400 56 kDa 
 VHFRQGDU\DQWLERG\IRUĮ Abcam, UK 1:3000 
3ULPDU\DQWLERG\IRUȕ-actin SIGMA-ALDRICH, UK 1:4000 46 kDa 
 VHFRQGDU\DQWLERG\IRUȕ-actin SIGMA-ALDRICH, UK 1:10000 
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2.6.13.5 Enhanced chemiluminescence (ECL): 
The expected antibody-protein complexes were detected using ECL reagents 
spray (Calbiochem). The membranes were sprayed twice, and incubated on the 
bench at room temperature for 1 minute. This was followed by using Kodak 
films in a dark room to visualise the protein bands. The exposure duration time 
used was for 15, 30, 45, 60, 90, 120, 300, and 600 seconds.  
 
2.6.13.6 Protein deglycosylation: 
Using deglycosylation kit (New England Biolabs), PNGase F enzyme (peptide: 
N-Glycosidase F) was used for deglycosylation of A549 lysates prior to 
Western blot analysis. For each reaction, 50 µg of A549 lysate protein was 
used.  This was mixed with 1x glycoprotein denaturing buffer, and distilled 
water was used to complete the 20 µl reaction volumes. To denature the 
glycoprotein, the mixture was heaWHG DW Û IRU  PLQXWHV 7KHQ WKH
following reagents were added: G7 reaction buffer (1x), NP-40 (1%) and 1000 
units of PNGase F enzyme. The final reaction volume (of 40 µl) was 
completed using distilled water. RNase B, a positive control, was used for the 
deglycosylation reaction. 
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2.7 Results: 
2.7.1 Characterisation of CHRNA7 transcripts in A549 cells: 
Using primers specific for different parts of CHRNA7 (Table 2-2), RT-PCR 
was used to amplify the target parts as illustrated in Figure 2-9. The PCR 
products detected from A549 cells cDNA using exons 2-6 primer sets are 
shown in (Figure 2-13). 
 
Figure 2-13: Agarose gel electrophoresis for CHRNA7 transcript E2-6. 
Lanes 1-2: duplicate samples of exon 2-6 product from cDNA of A549 (expected size 
is 336 bp=full-length (FL). Two smaller bands of lower intensity than the full length 
were detected, the middle one can be observed (matching to predicted sizes of 
transcripts missing exon 4 (226 bp size=-E4) and the lowermost one that was too faint 
on the gel (matching the predicted size of missing exons 4&5 (146 bp size=-E4&5)), 
respectively. These bands were visible on the gel but were too faint to be captured on 
the image. M: 100 bp DNA ladder, B: blank. 
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The use of other primer sets (spanning different parts of CHRNA7) showed the 
expression of expected band sizes. However, additional novel transcripts were 
also detected (Figure 2-14). 
 
 
Figure 2-14: Agarose gel electrophoresis for all tested CHRNA7 transcripts. 
Different primer sets were used to amplify CHRNA7 exons (E). Lanes 1-6 show A549 
amplified cDNA using CHRNA7 specific primers. 1:E2-4a (expected size is 312 bp), 
2:E4a-6 (expected size=242 bp), 3: E4-6 (expected size=160 bp), 4: E4-10(expected 
size= 857 bp), 5: E2-10 (expected size= 1033bp), 6: E7-10 (expected size= 399 bp). 
Larger size products (lanes 4-6) showed additional products with deletion (lower than 
the expected sizes for the primer pairs used), while only lane 6 (the only product 
amplified from both genes) showed an extra product with insertion (larger than the 
expected size for the primer pair used). M: 100 bp DNA ladder. 
 
For short amplicons (1-3), only a single product was detected. For larger 
amplicons (4-6), two major products were detected. However, PCR product 6 
(amplifying exons 7-10) showed a brighter main band (middle band), a second 
transcript with deletion similar to those noticed with PCR products 4 & 5 
(lower band) and a third transcript with an insertion (top band). 
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Following the RT-PCR results, direct DNA sequencing for products containing 
a single band (E2-4a, 4a-6, and 4-6) and the top band products of (E2-6) was 
gel extracted and showed that these were full-length products, as shown in 
(Table 2-10).  
Table 2-10: Sequencing results for PCR products. 
PCR product Exons included Product size (bp) 
Exons 2-6 2,3,4,5,6 336 
Exons 2-4a 2,3,4,4a 312 
Exons 4a-6 4a,5,6 242 
Exons 4-6 4,5,6 160 
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The full length of CHRNA7 was amplified using specific primers between 
exons 1-10. Similar results were obtained from RT-PCR with two major 
transcripts, the full-length, and a product with around 100bp deletion (Figure 
2-15). 
 
Figure 2-15: Agarose gel electrophoresis for CHRNA7 transcript E1-10. 
Lanes 1-2: duplicate samples of exon 1-10 product from cDNA of A549 (expected 
size is 1173 bp=FL). The FL PCR product (arrowed) was detected in addition to 
another product of smaller size (by about 100 bp) and of almost similar intensity. M: 
100 bp DNA ladder, B: blank. 
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For products with multiple bands, TA cloning or gel extraction or both were 
applied. For products with relatively separable bands after gel electrophoresis, 
gel extraction was used; otherwise, the TA cloning technique was applied for 
products with band closer to each other.  
The use of the gel extraction strategy made it possible for several bands to be 
separated using a high percentage gel electrophoresis, extracted and then 
sequenced. Surprisingly, all large size products showed the expression of a 
novel transcripts missing exon 9. This transcript was not reported in any 
previous study of CHRNA7 transcripts. The results of gel extraction are 
summarised in Table 2-11.  
Table 2-11: Summary for sequencing of gel extraction products. 
PCR 
product 
Product size (bp) Transcripts detected 
E2-6 
366 
226 
146 
E2-6 FL 
missing exon 4 
missing exons 4&5 
E1-10 
1173 
1063 
E1-10 FL 
 missing exon 9* 
E2-10 
1033 
923 
E2-10 FL 
missing exon 9* 
E4-10 
857 
747 
E4-10 FL 
 missing exon 9* 
E7-10 
~ 600 
399 
289 
Inserted product 
E7-10 FL 
missing exon 9* 
E: exon, FL: full length included. *: indicates novel transcripts detected. 
The sequencing results were non-informative for the larger PCR product (with 
insertion) from amplifying exons 7-10. This gel-extracted product was further 
explored using the TA cloning method. 
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Whenever the use of gel extraction was impractical, TA cloning was applied. 
First, the PCR products that were used for TA cloning included products 
amplifying exons 2-6, 1-10, and 7-10 of CHRNA7. For all TA cloning, ligation 
and transformation were applied to insert the PCR product into pSC-A-
amp/kan cloning vector. This was followed by PCR screening to distinguish 
clones with same insert and avoid repeating plasmid-insert extraction of the 
same transcript. Following plasmid-insert DNA extraction, the samples were 
subjected to screening using EcoRI restriction enzyme to distinguish transcripts 
prior to sequencing.  
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2.7.1.1 TA cloning for exons 2-6 PCR product of CHRNA7: 
This PCR product included CHRNA7 transcripts enclosed between exons 2 & 
6. All the clones were sequenced and a summary of the results is detailed in 
(Table 2-15). Then PCR screening (using exons 2-6 primer set) was used prior 
to miniprep plasmid preparation showed products of full-length exons 2-6 and 
missing exon 4 based on expected sizes (Figure 2-16). 
 
Figure 2-16: Agarose gel for PCR screening of exons 2-6 products. 
PCR screening of TA clones from exons 2-6 PCR product of A549 (samples 1-5). The 
clones 4 & 5 match the full-length transcript of exons 2-6. Clones 1-3 match transcript 
missing exon 4. M: 100 bp DNA ladder, B: blank. 
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EcoRI restriction sites on pSC-A-amp/kan vector will cut the vector from the 
insert PCR product. In addition, EcoRI will cut the insert within exon 5 (at base 
45 of exon 5) cutting the insert product of 336 bp into 264bp and 72bp parts in 
addition to the band corresponding to the plasmid backbone (Figure 2-17) 
(Table 2-12). 
 
Figure 2-17: Restriction digestion of plasmid-insert (exons 2-6) DNA using 
EcoRI. 
The figure shows EcoRI recognition sites on pSC-A-amp/kan vector and exons 2-6 
insert (original size=336bp) and possible digested insert parts sizes=264bp and 72bp, 
respectively. F: forward PCR primer, R: reverse PCR primer, 2-6: CHRNA7 exons 
amplified. 
 
Table 2-12: Predicted digestion product sizes for alternative transcript inserts 
from cloning of exons 2-6 PCR products. 
Exons included Product(s) size(s) 
Missing exon 3 219, 72 
Missing exon 4 154, 72 
Missing exon 5 256 (uncut) 
Missing exons 3&4 110, 72 
Missing exons 4&5 146 (uncut) 
Missing exons 3,4&5 101 (uncut) 
With exon 4a 392, 72 
Without exon 4a 264, 72 
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According to the restriction digestion results, samples were sequenced (Figure 
2-18). 
 
Figure 2-18: Agarose gel for restriction digestion using EcoRI for exons 2-6 
clones. 
Lanes 1D/1U: Full-length exons 2-6 product, lanes 2D/2U: missing exon 4 product 
(refer to Table 2-12 for product sizes). D: digested DNA using EcoRI, U: undigested 
DNA. Upper bands (white arrowhead) and lower bands (white arrow) representing the 
two digested parts, with the lower bands were visualised on the gel but were too faint 
to be captured on the image. M: 100bp DNA ladder. 
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2.7.1.2 TA cloning for exons 1-10 PCR product of CHRNA7: 
This PCR product included CHRNA7 transcripts enclosed between exons 1 & 
10. About 25 % of the clones were sequenced and a summary of the results is 
detailed in Table 2-15.Then PCR screening was used prior to miniprep plasmid 
preparation with most of the clones showing products of full-length exons 1-10 
based on expected sizes (Figure 2-19).  
 
Figure 2-19: Agarose gel for PCR screening for exons 1-10 products. 
PCR screening of TA clones from exons 1-10 PCR product of A549 (samples 41-44). 
All the clones shown in this figure match the full-length transcript of exons 1-10 
(size=1173 bp). M: 100 bp DNA ladder. 
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EcoRI restriction sites on pSC-A-amp/kan vector will cut the vector from the 
insert PCR product. In addition, EcoRI will cut the insert within exon 5 
sequence (at base 45 of exon 5) cutting the insert of 1173 bp into 403bp and 
770bp fragments in addition to the band corresponding to the plasmid 
backbone (Figure 2-20) (Table 2-13). 
 
Figure 2-20: Restriction digestion of plasmid-insert (exons 1-10) DNA using 
EcoRI. 
The figure shows EcoRI recognition sites on pSC-A-amp/kan vector and exons 1-10 
insert (original size=1173bp) and possible digested insert parts sizes=403bp and 
770bp, respectively . F: forward PCR primer, R: reverse PCR primer, 1-10: CHRNA7 
exons amplified. 
 
Table 2-13: Predicted digestion product sizes for alternative transcript inserts 
from cloning of exons 1-10 PCR products. 
Exons included Product(s) size(s) 
Missing exon 3 358, 770 
Missing exon 4 293, 770 
Missing exon 5 1093 (uncut) 
Missing exons 3&4 248, 770 
Missing exons 4&5 983 (uncut) 
Missing exons 3,4&5 938 (uncut) 
With exon 4a 530, 770 
Without exon 4a 403, 770 
Missing exon 9 403, 660 
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According to the restriction digestion results, samples were sequenced (Figure 
2-21). 
 
Figure 2-21: Agarose gel for restriction digestion using EcoRI for exons 1-10 
clones. 
Lanes 1D/1U: Full-length exons 110 product, lanes 2D/2U: missing exon 4 product 
(refer to Table 2-13 for product sizes). D: digested DNA using EcoRI, U: undigested. 
Upper bands (white arrowhead) and lower bands (white arrow) representing two the 
two digested parts. M: 100bp DNA ladder. 
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2.7.1.3 TA cloning for exons 7-10 PCR product of CHRNA7: 
This PCR product included CHRNA7 transcripts enclosed between exons 7 & 
10. About 25 % of the clones were sequenced and a summary of the results is 
detailed in Table 2-15. This is the only primer set that was designed to amplify 
the exons found in both genes CHRNA7 and CHRFAM7A. Then PCR 
screening was used prior to miniprep plasmid preparation with most of the 
clones showed products of full-length exons 7-10 based on expected sizes 
(Figure 2-22). 
 
Figure 2-22: Agarose gel for PCR screening for exons 7-10 product. 
PCR screening of TA clones from exons 7-10 PCR product of A549 (samples 7-10). 
All the clones match the full-length transcript of exons 7-10 (size =399 bp). M: 100 bp 
DNA ladder. 
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EcoRI restriction sites on pSC-A-amp/kan vector will cut the vector from the 
insert PCR product. However, EcoRI will not cut the insert leaving one band 
for the insert full length = 399bp in addition to the band corresponding to the 
plasmid backbone (Figure 2-23). 
 
Figure 2-23: Restriction digestion of plasmid-insert (exons 7-10) DNA using 
EcoRI. 
The figure shows EcoRI recognition sites on pSC-A-amp/kan vector and exons 7-10 
insert (original size=399bp) uncut. F: forward PCR primer, R: reverse PCR primer, 7-
10: CHRNA7 exons amplified. 
 
The transcript that was expected to be noticed is missing exon 9 (proved earlier 
by gel extraction) in addition to the transcript with addition with larger size 
than exons 7-10 (Figure 2-14). However, only full-length transcript (exons 7-
10) could be detected. The earlier results of gel extraction and sequencing for 
the isolated three bands detected for exons 7-10 PCR product showed that the 
middle band is full length (exons 7-10) and the lower band is missing exon 9, 
but the upper band was detected as having only full-length transcripts. It was 
assumed that the transcript with insertion (Figure 2-14, lane 6, upper band) 
have less copies than those of the full-length transcripts. As the two PCR 
SURGXFWV¶ LQVHUWLRQ DQG IXOO-length transcripts) bands were so close to each 
other on the gel, the gel extraction might have included a mixture of both 
products during the extraction process for each product. This might explain the 
finding of only full-length copies sequence results for the insertion transcript. 
These results highlighted to the need for a separate TA cloning for the top gel 
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extracted band (insertion transcript) to isolate this transcript from the full-
length transcripts (as discussed below). 
2.7.1.4 TA cloning for top band of exons 7-10 PCR product of CHRNA7: 
For characterising the upper band detected for the exons 7-10 PCR product, TA 
cloning of the gel extracted upper band DNA followed. Then PCR screening 
was used prior to miniprep plasmid preparation with most of the clones 
showing products of transcript with insertion (around 600 bp size) (Figure 
2-24).  
 
 
Figure 2-24: Agarose gel for PCR screening for exon 7-10 top band products. 
After using TA cloning for the upper band products amplified using exons 7-10 primer 
set in A549 cells, PCR screening using the same primer set was carried out (lanes 1-
5). Based on the band sizes from the gel picture,  lanes 1 & 2 showed transcript with 
insertion (around 600 bp size), lane 3 showed transcript slightly larger than the full 
length, lanes 4 & 5 showed clones match the full-length transcript of exons 7-10 (399 
bp size). M: 100 bp DNA ladder. Note: the figure is made from different gel images. 
 
These results showed the presence of full-length transcripts within the gel 
extracted mixture that explains the sequencing results compatible with full-
length transcripts.  
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These samples were sequenced and the results are shown in (Table 2-14). 
 
Table 2-14: Summary for sequencing results of TA clones from exons 7-10 upper 
gel extraction. 
Exons included Product(s) size(s) Sequencing result 
Full length + 
insertion 
399 bp + additional 197  bp 
Exons 7-10 + 197 bp from 
CHRFAM7A*  intron 9 sequence 
(7,8,9,I9,10) 
Missing exon 9 
+ insertion 
289 bp (missing exon9) + 
additional 197 bp 
Exons 7,8,10 + 197 bp from 
CHRFAM7A*  intron 9 sequence 
(7,8,I9,10) 
Full length 
 (exons 7-10) 
399 bp Exons 7-10 
*: The sequencing results were aligned with intron 9 sequences of both genes 
(CHRNA7 and CHRFAM7A). The results showed that the insertion was part of intron 
9 matching that from CHRFAM7A (further details will be discussed for this transcript 
later in this chapter and in chapter 3). 
 
 
From this point onward, this inserted sequence of intron 9 was termed exon 9b 
(E9b).  
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The total number of TA clones with inserts and the results of transcripts 
detected is summarised in Table 2-15. Surprisingly, the novel transcripts 
missing exon 9 could not be detected on TA cloning. 
 
Table 2-15: TA cloning summary for CHRNA7 transcripts. 
PCR 
product 
Clones 
tested 
Transcripts detected Number 
Exons 2-6 11 
full length (exons 2-6) 
missing exon 4 
missing exons 3 & 4 
6 
4 
1 
Exons 1-10 9 
full length (exons1-10) 
missing exon 4 
missing 1st 24 bp of exon 4 
5 
3 
1 
Exons 7-10 15 
full length (exons 7-10) 
with exon 9b 
with exon 9b & missing exon 9 
8 
6 
1 
Note that no transcripts missing exon 9 were detected from all 
amplified sequences. This might highlight the effect of missing exon 
9 on these transcripts when transformed into E.coli, by either causing 
toxic effect on the cell, inhibiting cell growth, reproduction, 
transcription, or other effects.  
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In summary, different methods were employed for the detection of CHRNA7 
transcripts in A549 cells. These included the use of specific PCR primers, gel 
extraction, or TA cloning method. Some of the transcripts should be detected 
using one or more methods depending on that specific method (Table 2-16). 
 
Table 2-16: A summary of CHRNA7 transcripts detected in A549 cells. 
Gene Transcript Detection method 
CHRNA7 
Full length (exons 1-10) RT-PCR, gel extraction, TA cloning 
Missing exon 9 Gel extraction 
Missing exon 4 Gel extraction, TA cloning 
Missing exons 3&4 TA cloning 
Missing exons 4&5 Gel extraction 
Exon 4a (in short 
transcripts) 
RT-PCR 
 
 
 
It is worth noting that full-length transcripts could be detected using all 
methods due to their abundant expression. Missing exon 9 transcripts were 
clearly detected by using PCR primers (shown as a second sequence peak that 
mixed up with the full-length one) or by using gel extraction method. However, 
none was detected using the TA cloning method. For missing exon 4 
transcripts, they were detected both by gel extraction and TA cloning methods, 
but much less than missing exon 9 transcripts when comparing the gel 
extraction method.  
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2.7.2 Characterisation of the main CHRFAM7A transcripts in A549 
cells: 
Using primers specific for different parts of CHRFAM7A (Table 2-3), RT-
PCR was used to amplify the target parts as illustrated in (Figure 2-10). The 
PCR products detected from A549 cells cDNA are shown in (Figure 2-25). 
 
Figure 2-25:Agarose gel electrophoresis for CHRFAM7A transcript. 
A: exons A-10 (expected size is 848 bp=FL) with one band smaller than FL noted, B: 
exons D-C (expected size is 124 bp), C: exons A-6 (expected size is 151 bp). M: 100 
bp DNA ladder, B: blank. 
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Interestingly, the same novel transcript detected for CHRNA7 (missing exon 9) 
was detected in CHRFAM7A transcript.  
In addition, a transcript missing bases 67-68 (TG) of exon 6 that was reported 
before (Gault et al., 1998) was detected from A549 cells (Figure 2-26). 
 
 
Figure 2-26:CHRFAM7A transcript missing TG bases of exon 6. 
TG bases at sequence 67-68 of exon 6 are indicated. From that point, two sequences 
could be detected: a major transcript (with TG bases)-Sequence 1; and a minor 
transcript (without TG bases)-Sequence 2. Base colour reference: A=green, T=red, 
G=black, C=blue.  
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However, regarding the common exons between CHRNA7 and CHRFAM7A genes, 
exons 7-10 part was amplified earlier (results shown in Figure 2-14). These results 
showed the expression of a transcript with an insertion (larger than the size of exons 7-
10 (Figure 2-27). 
 
Figure 2-27: Agarose gel electrophoresis for CHRNA7/CHRFAM7A transcript 
E7-10 in A549 cells. 
Lanes A37 & A6: cDNA samples from A549 (expected size is 399 bp=FL). Two 
additional bands of larger (transcript with insert ~ 600 bp size) and smaller (matching 
to predicted sizes of transcripts with missing exon 9, -E9= 289 bp size) product sizes 
could be observed. M: 100 bp DNA ladder, B: blank. 
 
2.7.2.1 Initial characterization of insert transcripts in A549 cells: 
The larger product (with insertion) was targeted first using gel extraction and 
sequencing. However, the sequencing results came back with a mixed signal of 
full length and an additional sequence (of lower peaks height). We aimed for 
targeting this transcript using TA cloning of the gel extracted largest size band 
(Figure 2-27).  
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2.7.2.1.1 TA cloning of the largest product from RT-PCR for exons 7-10: 
This TA cloning is different from that mentioned in section 2.7.1.3 because it 
was preceded by gel extraction of the exon 7-10 top band prior to cloning.  
PCR screening was used prior to plasmid-insert extraction according to which 
the clones were selected for extraction (Figure 2-28). 
 
Figure 2-28: Agarose gel for PCR screening for exon 9b inserted products. 
PCR screening of TA clones from exons 9b inserts PCR product of A549 (samples 11-
20). The clones12-13, 16-18, & 20 match exons 7-10 transcript with insertion. The 
clones 14 & 19 match the full-length transcript (FL: exons 7-10). The clone 11 
matches transcripts missing exon 9 and with insertion. C: exons 7-10 plasmid insert as 
control for FL. M: 100 bp DNA ladder, B: blank 
 
The TA cloning results showed the presence of an inserted sequence (termed in 
this study as exon 9b) between exons 9 and 10 sequences (Figure 2-29).  
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Figure 2-29: Exon 9b inserted sequence position. 
Exon 9b sequence inserted between exons 9 and 10 sequences. Base colour reference: 
A=green, T=red, G=black, C=blue.  
 
 
Out of 9 clones, 7 were detected to match exon 9b insertion (one of them 
showed combined missing exon 9 with exon 9b insertion) and only two showed 
exons 7-10 matching the expected product from reference sequence of both 
genes (Figure 2-30).  
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Figure 2-30: exon 9b transcripts detected in A549. 
Blue boxes: constitutive exons, grey box: inserted exon 9b. The transcripts are A: 
(exons7-10), B: (exons 7-10, +E9b), C: (exons 7-10, +E9b, -E9). The expected 
product size (in bp) is shown on the right. 
 
2.7.2.1.2 Sequencing the resulting products: 
The inserted sequence showed matched to the part of intron 9 sequence from 
CHRNA7 and CHRFAM7A. However, only two bases were different within 
the exon 9b sequence from the intron 9 part of CHRNA7 but matching that of 
CHRFAM7A when aligned with the reference sequences of both genes 
(CHRNA7 accession number NM_00074 and CHRFAM7A accession number 
NM_139320.1, NCBI) (Figure 2-31). 
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Figure 2-31: Sequence alignment of exon 9b detected. 
The detected exon 9b sequence was aligned with intron 9 of CHRNA7 and CHRFAM7A genes. Two nucleotide bases were different between the two genes at 
positions 77 & 154 of exon 9b (enclosed within black boxes), and these two bases in the exon 9b transcripts (detected in our study) matched that of 
CHRFAM7A. The numbers above indicate the sequence from start of exon 9b (where 1 is start of exon 9b, 77 & 154 represent the two different positions 
between both genes, and 197 is the end of exon 9b). 
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At first, this exon 9b was expected to match that found in mice neuronal tissues 
within a conserved region between human and mice (Saragoza et al., 2003). In 
that study, CHRNA7 transcripts with inserted part of intron 9 (termed in the 
study as exon 9b) were detected. This region corresponds to the nucleotide 
sequences 2028-2574 of the human intron 9, while exon 9b detected in our 
study is located within nucleotide sequences 4025-4222 of human intron 9.  
 
2.7.2.2 Characterization of exon 9b in BE (2)-c cells transcripts: 
After confirming the expression of exon 9b in CHRFAM7A transcripts in 
A549 cells we tried to answer the following question: does this represent a 
tissue specific splicing process? To answer this question, the exons 7-10 were 
amplified from BE (2)-c cDNA using the same primer sets and PCR conditions 
to those used with A549. The results came back supporting those found in 
A549 cells (Figure 2-32).  
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Figure 2-32: Agarose gel electrophoresis for CHRNA7/CHRFAM7A transcript 
exons 7-10 in BE (2)-c cells. 
Lanes 1 & 2: cDNA samples from BE (2)-c (expected size is 399 bp=FL). A: cDNA 
from A549 tested as control for exons 7-10 transcripts. Two additional bands of larger 
(+E9b= 596 bp size) and smaller (-E9= 289 bp size) product sizes can be observed 
(matching to predicted sizes of transcripts with inserted exon 9b and missing exon 9, 
respectively). C: exons 7-10 plasmid-insert as control for FL. M: 100 bp DNA ladder, 
B: blank. 
 
2.7.2.2.1 TA cloning of the largest product from RT-PCR for exons 7-10: 
Similar to results shown early with A549, the results of PCR screening and 
restriction digestion (using EcoRI enzyme) in BE (2)-c cells showed products 
with the predicted sizes expected for exon 9b transcripts (full length (FL), with 
inserted exon 9b (+E9b) and missing exon 9 (-E9)) (Figure 2-33). 
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Figure 2-33: Agarose gel for restriction digestion using EcoRI for exons 7-10 
clones from BE (2)-c cells. 
Lanes 23D/U& 24D/U: inserted exon 9b products (+E9b), lane 27D/U: missing exon 9 
transcript (-E9), lanes 31D/U & 32D/U: full-length exons 7-10 (FL). D: digested DNA 
using EcoRI, U: undigested. These bands were visible on the gel but sometimes were 
too faint to be captured on the image. M: 100bp DNA ladder. 
  
 
Although showing exon 9b inserted transcripts, we could not detect transcripts 
with inserted exon 9b and deleted exon 9 in BE (2)-c cells (Like those found in 
A549 cells).  
 
2.7.2.2.2 Sequencing the resulting products: 
The sequencing results of the detected transcripts were similar to those 
detected in A549 (exon 9b sequence matched the corresponding part in 
CHRFAM7A) (Figure 2-31). 
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2.7.2.3 Exon 9b sequence analysis: 
After detection of exon 9b sequences within CHRFAM7A transcripts in A549 
and BE (2)-c cells, several bioinformatics tools were applied to the sequence to 
check for the splicing driving sequences within exon 9b and the flanking 
introns.  
2.7.2.3.1 Clustal W: 
This software was used for comparing specific sequences for nucleotide base 
differences. The sequencing results for CHRNA7, CHRFAM7A, and exon 9b 
transcripts detected were compared and shown to differ at positions 77 and 154 
of exon 9b sequence. These two bases could differentiate the origin of 
transcripts with exon 9b (CHRNA7 or CHRFAM7A) (Table 2-17) 
  
Table 2-17: Exon 9b sequences detected at positions 77 and 154. 
Sequence Position 77 of exon 9b Position 154 of exon 9b 
CHRNA7 G G 
CHRFAM7A C A 
Exon 9b transcripts in A549 C A 
Exon 9b transcripts in BE (2)-c C A 
The sequence of exon 9b detected in A549 transcripts matched that of corresponding 
intron 9 part of CHRFAM7A. Only two nucleotide bases were different between the two 
genes at positions 77 & 154 of exon 9b. This lead to concluding that exon 9b transcripts 
in A549 cells produced by CHRFAM7A. 
 
2.7.2.3.2 Exon scan: 
This software was used to predict the exonic sequences within a given 
sequence. The software requires the introduction of whole or part of a genomic 
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sequence to predict the presence of exons within a given sequence that should 
be flanked by 20 and 60 nucleotide bases sequences upstream and downstream 
of the exon tested, respectively. To test for exon 9b, sequences from CHRNA7 
(NM_000746) and CHRFAM7A (NM_139320.1) were analysed. The first set 
of data included intron 8, exon 9 and intron 9 while the second set of data 
included only intron 9. The results for both data sets showed that exon 9b was 
not detected as an exon. This means that exon 9b is not a constitutive exon. 
 
2.7.2.3.3 Splice site prediction: 
For predicting the splice sites, BDGP software was used to test for the strength 
of the splice signal (Figure 2-34). 
 
Figure 2-34: Splice site prediction test. 
The strength of the splice sites flanking exon 9b sequence was checked using BDGP 
software program. Start/ end: refers to the start/end of splice site detected within the 
sequence tested. The score represents the strength of splice site. Score cut-off =0.4, the 
exon/intron boundary is shown in big letters. 
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Given that the threshold value used by the software was 0.4 for both splice 
sites, it seems that the splice sites flanking exon 9b are much higher than that 
of the threshold values. When using Human splice finder software, similar 
results were detected. The results of these two software programs for predicting 
potential splice sites are based on testing sequences flanked by AG and GT 
intronic sequences. This is a different analysis method from that used in Exon 
scan software program where it utilises additional ESEs, ESSs and give an 
overall score for a given sequence to predict a defined exon. 
 
In summary, the search for the main transcripts of CHRFAM7A was carried out 
during this study. The main aim was to characterise the main transcripts expressed by 
A549 cells, and only RT-PCR and gel extraction methods were employed for this 
purpose. The results showed that A549 cells express two major transcripts for this 
gene: full-length and missing exon 9 (similar to that expressed by CHRNA7) (Table 
2-18).  
 
Table 2-18: A summary for CHRFAM7A transcripts detected in A549 cells. 
Gene Transcript  Detection method 
CHRFAM7A 
exons A-10 RT-PCR 
Missing exon 9* gel extraction 
Exons D-C RT-PCR 
Missing GT 67-68 of exon 6 Gel extraction 
Exon 9b* Gel extraction & TA cloning 
*: indicates novel transcripts detected. 
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2.7.3 CHRNA7 and CHRFAM7A transcripts detected in other cell lines: 
The main transcripts of CHRNA7 and CHRFAM7A were tested in other cell 
lines (mentioned in section 2.6.1). These transcripts included the full length, as 
well as the two novel transcripts detected in this study (missing exon 9 and 
exon 9b). 
First, the main transcripts of these genes were tested and compared at the same 
time for relative expression in A549 and BEAS2B cells. The expression of 
CHRFAM7A transcripts was higher than the expression of CHRNA7 
transcripts in both cell lines, although much less of the latter transcripts could 
be detected in BEAS2B cells (Figure 2-35). 
 
Figure 2-35: Comparison of the relative expression of CHRNA7 and 
CHRFAM7A by A549 and BEAS2B cells. 
A: CHRNA7 main transcripts. B: CHRFAM7A main transcripts. Cells tested A549 
and BEAS2B. FL: Full-length transcript (referred here for CHRNA7 exons 1-10; or 
for CHRFAM7A exons A-10), -E9=missing exon 9. Product sizes were FL= 1173 bp 
& -E9= 1063bp for CHRNA7, and FL= 848bp & -E9=738bp for CHRFAM7A. These 
bands were visible on the gel but were too faint to be captured on the image.  M: 100 
bp DNA ladder, B: blank. 
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This comparison was also repeated for peripheral blood mononuclear cells 
(PBMC), which again showed a relatively higher expression of CHRFAM7A, 
than CHRNA7 transcripts (Figure 2-36). 
 
 
Figure 2-36: Comparison of the relative expression of CHRNA7 and 
CHRFAM7A by PBMC cells. 
A: CHRNA7 main transcripts. B: CHRFAM7A main transcripts. P1-2: PBMC cDNA 
preps, FL: full-length transcript (referred here for CHRNA7 exons 1-10; or for 
CHRFAM7A exons A-10),   -E9=missing exon 9. Product sizes were FL= 1173 bp & 
-E9= 1063bp for CHRNA7, and FL= 848bp & -E9=738bp for CHRFAM7A.  
P1 PBMC CHRNA7 transcripts were visible on the gel, but were too faint to be 
captured by the image. M: 100 bp DNA ladder, B: blank. 
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Several cDNA preps of PBMC were compared with A549 expression of the 
two genes (Figure 2-37). 
 
Figure 2-37: Comparison of the relative expression of CHRNA7 and 
CHRFAM7A by PBMC and A549 cells. 
A: CHRNA7 main transcripts. B: CHRFAM7A main transcripts. P1-3: PBMC cDNA 
preps, A549: A549 cDNA prep, FL: full-length transcript (referred here for CHRNA7 
exons 1-10; or for CHRFAM7A exons A-10),   -E9=missing exon 9. The CHRNA7 
transcripts were visible on the gel, but were too faint to be captured by the image. M: 
100 bp DNA ladder, B: blank. 
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The same comparison was repeated using BE (2)-c cells cDNA. However, the 
results in these cells were the opposite of that expressed by the other cell lines 
used showing more expression of CHRNA7 than the CHRFAM7A (Figure 
2-38 and Figure 2-39). 
 
Figure 2-38: Comparison of the relative expression of CHRNA7 and 
CHRFAM7A by BE (2)-c and A549 cells. 
A: CHRNA7 main transcripts. B: CHRFAM7A main transcripts. 1-4: BE (2)-c cDNA 
preps, A549: A549 cDNA prep, FL: full-length transcript (CHRNA7=exons 1-10; 
CHRFAM7A=exons A-10),   -E9=missing exon 9. The CHRFAM7A transcripts were 
visible on the gel, but were too faint to be captured by the image. The opposite relation 
between the two genes transcripts is evident on this gel picture, showing more 
CHRFAM7A in A549 cells, while more CHRNA7 in be (2)-c cells.  M: 100 bp DNA 
ladder, B: blank. 
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Figure 2-39: Comparison of the relative expression of short fragment of 
CHRFAM7A between BE (2)-c and A549 cells. 
BE (2)-c and A549 cDNA preps were tested to confirm the expression of exons A-6 
part of CHRFAM7 of 140bp size (arrowed). M: 100 bp DNA ladder, B: blank. 
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For three cell lines (A549, BEAS2B and PBMC), the main transcripts of 
CHRNA7 and CHRFAM7A genes were characterized by RT-PCR and gel 
extraction (Table 2-19). Interestingly, all of the three cells expressed the full 
lengths and missing exon 9 transcripts of both genes. Furthermore, the exon 9b 
transcripts could not be detected in PBMC cells, while -TG transcripts could 
not be detected in BEAS2B cells. 
Table 2-19: A summary for the main transcripts of both genes in three main cells 
tested. 
Gene 
Transcript Cells 
- A549 BEAS2B PBMC 
CHRNA7 
FL 9  9  9  
-E9* 9  9  9  
CHRFAM7A 
E9b* 9  9  X 
FL 9  9  9  
-E9* 9  9  9  
-TG 9  X 9  
Note: FL=full length (for CHRNA7=exons 1-10; for CHRFAM7A=exons A-10),  
-E9=missing exon 9, E9b=with exon 9b, -TG=missing bases 67-68 of exon6. 
9 : detected transcripts, X: non-detected transcripts 
*: indicates novel transcripts detected 
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2.7.4 Quantitative Real-time PCR results: 
For estimating the relative percent expression of full length and missing exon 9 
CHRNA7 transcripts by A549 cells, QRT-PCR was used. For this purpose, the 
primers were designed in a way to avoid amplifying the common sequence 
between CHRNA7 and CHRFAM7A (exons 5-10). Thus, the forward primer 
was used in common for the detection of both transcripts of CHRNA7 (full-
length and missing exon 9) (forward primer on exon4-Table 2-2) while a 
separate reverse primer for each transcript was designed on exon-exon 
junctions (Table 2-6, Figure 2-12). Thus, the two amplified parts of CHRNA7 
would be one representing the full-length transcripts (amplifying exons 4-exon 
junction 8/9 part) and another representing missing exon 9 transcripts 
(amplifying exons 4-exon junction 8/10). 
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2.7.4.1 QRT-PCR optimization: 
First, the primer sets were optimized using RT-PCR. For this purpose, SYBR 
green brilliant III was tested first on a Verity block PCR machine using a 
temperature gradient (Figure 2-40). 
 
Figure 2-40: RT-PCR using QRT-PCR primers and mastermix. 
A549 cDNA preperations were tested using QRT-PCR primers for detection of full 
length (FL, expected product size=584bp) and missing exon 9 (-E9, expected product 
size=581bp) transcripts. It is worth noting that the final temperature used for the QRT-
PCR was 60º. The corresponding products from both primer sets were sequenced and 
the results confirmed the predicted sequences. M: 100 bp DNA ladder, B: blank. 
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The next step included testing these primers on A549 cDNA using QRT-PCR 
(Figure 2-41).  
 
 
 
Figure 2-41: Amplification plots for QRT-PCR. 
Left: Exons 4-8/9 (full length=FL) and Right: exons 4-8/10 (missing exon 9= -E9) 
transcripts of CHRNA7 were detected using QRT-PCR. The amplification plots show 
the delay in amplification Ct values associated with decreasing the amount of template 
starting the reaction (with lower Ct values with 1/5 cDNA dilution and higher Ct 
values with 1/50 cDNA dilution). The dilutions of the cDNA used were 1/5, 1/20 and 
1/50 in duplicates (indicated on top left corner of each plot) and the Ct values for are 
indicated (a box and arrow). These results showed that with increasing the dilution of 
the tested cDNA samples, Ct values were higher, indicating that less template were 
available at the start of the reaction. 
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In addition, the dissociation curves for the above shown QRT-PCR results 
indicated that multiple products could be amplified. This was later confirmed 
when the products were subjected to agarose gel electrophoresis following each 
PCR reaction, and an extra band below the main band of each amplified 
product was noticed just below the main product bands (for all the dilutions 
and all the duplicates) (Figure 2-42). 
 
Figure 2-42: Agarose gel electrophoresis for QRT-PCR products. 
cDNA dilutions (in duplicates) are indicated above each lane. FL: indicates exons 4-
8/9 products, -E9: indicates missing exon 9 products. Lower band is noticed below the 
main band of all products. M: 100 bp DNA ladder, B: blank. 
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RT-PCR was repeated to check for the double banding pattern; however, the 
same results were obtained (Figure 2-43). 
 
 
Figure 2-43: Agarose gel electrophoresis for QRT-PCR products(using 
temperature gradiant). 
Temperature gradient RT-PCR was repeated for QRT-PCR primers and master mix 
using A549 cDNA. Temperatures used indicated above the lanes, FL: indicates exons 
4-8/9 products, -E9: indicates missing exon 9 products. Lower band is noticed below 
the main band of all products. These bands were visible on the gel but were too faint 
to be captured on the image. M: 100 bp DNA ladder, B: blank. 
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Due to the presence of a second band of similar size when using QRT-PCR for 
amplifying both products (exons 4-8/9 (FL) and exons 4-8/10(-E9)), the 
sequence similarities between the reverse primers were checked for matching 
bases. First, both primers have a common sequence (the part of the primer on 
exon 8), this narrowed the comparison area to the 5` end of the primers (the 
parts on exon 9 or 10). However, four more bases were identical between the 
two primers (Figure 2-44). 
 
Figure 2-44: QRT-PCR primers for CHRNA7. 
The primer nucleotides included from exon 8 (in red), exon 9 (in grey) or exon 10 (in 
yellow). The matching nucleotides between the two reverse primers are indicated by 
DUURZVĽ 
 
Due to the presence of 14 nucleotide bases matching between the two reverse 
primers, it was decided to use TA cloning for generating exons 4-8/9 (FL) and 
exons 4-8/10 (-E9) templates test for the primer specificity.  
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2.7.4.2 TA cloning for exons 4-8/9 & 4-8/10 RT-PCR product of CHRNA7: 
Initially, the RT-PCR products amplified using primer sets for exons 4-8/9 and 
exons 4-8/10 were used as the target for TA cloning. The aim was to generate 
full length and missing exon 9 templates. The next step was to use these 
templates to test both primer sets for specificity of each set. Further 
confirmation of the primer specificity was done by using previously prepared 
clones containing exons 1-10 with or missing exon 4, respectively. These 
templates should confirm if the exon 4 specificity is to CHRNA7 and not to 
CHRFAM7A transcripts. As with other TA cloning used before, PCR 
screening was used after TA cloning to limit the extraction of the plasmid-
insert DNA. This was done by using the primers used initially for RT-PCR 
amplification. This means that exons 4-8/9 primers were used for RT-PCR and 
then TA cloning were used for PCR screening and according to the band size 
difference clones were selected for plasmid-extraction and sequencing (the 
same was done for exons 4-8/10 primer sets) (Figure 2-45).  
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Figure 2-45: Agarose gel for PCR screening. 
PCR screening of TA clones from exons 4-8/9 (Top) (with Clone 4 match the full-
length transcript of exons 4-8/9 of 584 bp size) & 4-8/10 (Bottom) (with Clones 11 & 
12 matching transcripts missing exon 9 of 581 bp size) PCR products of A549. M: 100 
bp DNA ladder, C: controls (from gel extraction), B: blank. 
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A further screening step was followed (prior to sending the plasmid inserts for 
sequencing) by using EcoRI for digestion of the plasmid from the insert (with 
no recognition site for EcoRI in exons 4-8/9 or 4-8/10) (Figure 2-46). 
 
Figure 2-46: Agarose gel for restriction digestion using EcoRI for exons 4-8/9 & 
4-8/10 clones. 
Top: exons 4-8/9 clones digestion (with lanes 1, 2 & 4D matching uncut exons 4-8/9 
product size=584 bp), Bottom:  exons 4-8/10 clones digestion (with lanes 3 & 5D 
matching uncut exons 4-8/10 product size=581 bp). D: digested DNA using EcoRI, U: 
undigested, M: 100bp DNA ladder. 
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After extracting the plasmid-insert DNA, the samples were sent for sequencing 
and matched the expected products: with sequence of exons 4-8/9 matched full 
length CHRNA7 transcripts and the inserts of exons 4-8/10 matched missing 
exon 9 CHRNA7 transcripts (Figure 2-47). 
 
Figure 2-47: DNA sequencing of extracted plasmid-insert for QRT-PCR primer 
products. 
Upper panel: exons 4-8/9 (full-length CHRNA7 transcript) sequencing results, Lower 
panel: exons 4-8/10 (missing exon 9 CHRNA7 transcript) sequencing results. For 
each sequencing result, three areas are shown: plasmid, exon 9 or 10 and then exon 8 
of the reverse primer, respectively. Sequencing primer used was exon 4S primer 
(Table 2-2). Base colour reference: A=green, T=red, G=black, C=blue.  
 
 
 
The characterisation of CHRNA7 transcripts                                       Chapter 2 
 157 
2.7.4.3 Testing QRT-PCR primer specificity: 
These DNA extracts were used as templates for further testing. By using QRT-
PCR primer sets, PCR amplification was applied and both templates sets (full 
length and missing exon 9) were tested by both primer sets (full length and 
missing exon 9) to test for the primer specificity (Figure 2-48). 
 
 
Figure 2-48: Agarose gel for PCR of testing QRT-PCR primer specificity. 
PCR using QRT-PCR primers on A549 DNA clones representing full length (FL) and 
missing exon 9 (-E9) templates. Upper panel: FL primers used on both templates, 
Lower panel: -E9 primers used on both templates. Both primer sets amplified both 
template sets, and faint lower bands could be detected for most of the PCR products. 
White arrowheads indicate the products selected for the illustrated DNA sequence in 
the next figure (Figure 2-49). These are representing a missing exon 9 template 
amplified by using exons 4-8/9 (FL) primer set (on the upper panel) and a full-length 
template amplified by using the exons 4-8/10 (-E9) primer set (on the lower panel). M: 
100 bp DNA ladder, B: blank. 
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This result indicates that the primers are non-specific and can bind to both 
templates leading to the non-specific nature of the reaction. The PCR products 
of the above reaction (Figure 2-48) were sent for sequencing, and the results 
showed sequence of all the products matching the expected sequence except 
the last part, represented by the sequence of the 5` end of the reverse primers 
(Figure 2-49). 
 
Figure 2-49: DNA sequencing results for PCR products of QRT-PCR primer 
specificity testing. 
This figure shows the sequence of two of the PCR products shown on Figure 2-48. 
Upper panel: The missing exon 9 template amplified by full-length primers 
(indicating that the 5` end of this primer which represents exon 9 sequence was not 
annealing to anything (in the PCR)). Lower panel:  The full-length template amplified 
by missing exon 9 primers (indicating that the 5` end of this primer which represents 
exon 10 sequence was not annealing to anything (in the PCR)).  
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To prove that the sense primer for QRT-PCR (exon 4S-Table 2-2) was specific 
to CHRNA7 transcripts, another PCR was performed on clones prepared from 
A549 cDNA by using exons 1-10 primer set (Table 2-2) and were proved by 
sequencing to be matching full length and missing exon 4, respectively. These 
template DNA samples were subjected to amplification by PCR using QRT-
PCR primer sets for full length and missing exon 9 transcripts. The results 
showed that exon 4S primer is detecting CHRNA7 with exon 4, and could not 
detect those missing exon 4, indicating that this primer is specific to CHRNA7 
transcripts with exon 4 (Figure 2-50). 
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Figure 2-50: Agarose gel for PCR products testing of exon 4S primer specificity. 
PCR using QRT-PCR primers on A549 DNA clones representing full length (FL) and 
missing exon 4 (-E9) templates. Upper panel: FL primers used on both templates, 
Lower panel: -E9 primers used on both templates. Only CHRNA7 templates with 
exon 4 were amplified using both primer sets. The use of ±E9 QRT-PCR primer set 
(exons 4-8/10 primers) in addition to the FL ones aimed at testing both primer sets for 
annealing when exon 4 was within (FL) or missing from (-E4) the template.  C1: A549 
cDNA, C2: BEAS2B cDNA. M: 100 bp DNA ladder, B: blank. 
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In addition, the sequence of exon 4S primer was aligned with exons 1-10 of 
CHRNA7 and it matched sequence of exon 4. When exon 4S sequence was 
aligned with exons D-A of CHRFAM7A, it did not match to any sequence 
(Figure 2-51). 
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Figure 2-51: Sequence alignment of exon 4S primer and CHRFAM7A exons D-A.  
1: with exon D, 2: with exon C, 3: with exon B, 4: with exon A. No complete 
matching of exon 4S primer was detected on any of these exon sequences (asterisks 
below the sequences indicates the matching between the nucleic acids aligned) . 
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2.7.5 PCR semi-quantitative assays: 
Due to the difficulties encountered while attempting QRT-PCR amplification 
of CHRNA7 main transcripts (full-length and missing exon 9) an alternative 
semi-quantitative RT-PCR assay was used. This method depends on the use of 
primer sets that were used to amplify the main transcripts of both genes (exons 
1-10 primers for CHRNA7 and exons A-10 for CHRFAM7A).  This method 
helped to estimate the relative percent expression of the main transcripts of 
these genes by A549 cells. This step was followed by quantifying the intensity 
of the representative bands present on gel electrophoresis using a densitometry 
method. 
The target templates were amplified using RT-PCR (as described in section 
2.6.4) and the results were then analysed using AlphaDigiDoc 1201 software 
(as described in section 2.6.11). For this purpose, A549 cDNA was used. 
Before the quantitation assay, the cDNA was tested using RT-PCR to check for 
CHRNA7 and CHRFAM7A expression. Once confirmed, this cDNA was used 
IRUDOOVXEVHTXHQWUXQVIRUTXDQWLWDWLRQRIERWKJHQHVWUDQVFULSWV¶ 
 
2.7.5.1 PCR semi-quantitative assays for CHRNA7 transcripts:  
RT-PCR was used for amplifying CHRNA7 in A549 cells using different cycle 
number for amplifications (cycles 21-35). This helped narrow the cycle 
numbers used. For optimization purposes, the first run was performed on single 
samples. The results showed that the amplification starts at cycle 27 and 
reaches a plateau phase after cycle 33 (Figure 2-52). 
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Figure 2-52: Semi-quantitative assay optimisation for CHRNA7 transcripts. 
Upper panel: Agarose gel electrophoresis of RT-PCR applied on A549 cDNA. PCR 
sample tubes were removed from PCR block after cycles 21-35 (cycle number shown 
on top). Lower panel:  AlphaDigiDoc analysis for PCR products that were visually 
detectable on the gel (for cycles 27-35) (using band intensity). M: 100 bp DNA ladder, 
B: blank. 
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From this point onward, the cycles selected were 27-35 (27 cycles which 
showed the first visible CHRNA7 transcripts). The results for CHRNA7 
transcripts semi-quantitative assay is shown in (Figure 2-53). 
 
Figure 2-53: Agarose gel electrophoresis for Semi-quantitative assay of 
CHRNA7. 
RT-PCR applied on A549 cDNA to test for CHRNA7 transcripts. M: 100 bp DNA 
ladder, B: blank. 
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After completing 3 runs for CHRNA7 semi-quantitation, AlphaDigiDoc 
analysis was applied to measure the band intensities for each duplicate of each 
cycle. The mean intensity of the bands at each cycle and the means from three 
runs for each cycle were calculated. These intensities were subsequently used 
to calculate the corrected intensity adjusted for the band size of the two major 
bands (full length and missing exon 9 transcripts). Finally, the percent 
expression of these two transcripts in each cycle was calculated (Figure 2-54). 
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Figure 2-54: AlphaDigiDoc analysis of CHRNA7 semi-quantitative assays. 
A: The intensity curve is showing the correlated increase in intensities of the bands 
with increasing PCR cycles (mean + SEM). This intensity was adjusted for the size of 
the PCR product on the Y-axis while the PCR cycles on the X-axis. B: The percent 
expression of both transcripts at each cycle presented as bar charts. The percentage is 
shown on the Y-axis while the PCR cycles are shown on the X-axis. This figure shows 
the exponential phase starts at cycle 27-33. The relative ratio of full-length: missing 
exon 9 is ~2:1. 
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2.7.5.2 PCR semi-quantitative assays for CHRFAM7A transcripts: 
The same steps were followed for CHRFAM7A transcripts as for CHRNA7. 
The results for CHRFAM7A transcripts semi-quantitative assay is shown in 
(Figure 2-55). 
 
Figure 2-55: Agarose gel electrophoresis for Semi-quantitative assay of 
CHRFAM7A. 
RT-PCR applied on A549 cDNA to test for CHRFAM7A transcripts expression. M: 
100 bp DNA ladder, B: blank. 
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After completing 3 runs for CHRFAM7A semi-quantitation, AlphaDigiDoc 
analysis was applied to measure the band intensities for each duplicate of each 
cycle. The mean intensity of the bands at each cycle and the means from three 
runs for each cycle were calculated. These intensities were subsequently used 
to calculate the corrected intensity adjusted for the size of the two major bands 
(full length and missing exon 9 transcripts). Finally, the percent expression of 
these two transcripts in each cycle was calculated (Figure 2-56). 
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Figure 2-56: Alpha DigiDoc analysis of CHRFAM7A semi-quantitative assays. 
A: The intensity curve is showing the correlated increase in intensities of the bands 
with increasing PCR cycles (mean + SEM). This intensity was corrected for the size of 
the PCR product on the Y-axis while the PCR cycles on the X-axis. B: The percent 
expression of both transcripts at each cycle presented as bar charts. The percentage is 
shown on the Y-axis while the PCR cycles are shown on the X-axis. . This figure 
shows the exponential phase starts at cycle 27-33. The relative ratio of full-length: 
missing exon 9 is ~2:1. 
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2.7.6 Bio-informatics analysis of alternative transcripts and protein 
structure: 
2.7.6.1 Using splicing/alternative splicing tools: 
For detection of ESE sequence motifs within each exon of both genes, and to 
calculate the ratio of predicted ESE (PESE) to predicted ESS (PESS) the 
Human Splice Finder software program was used (Table 2-20 and Table 2-21). 
The default thresholds of the above mentioned software programs were used as 
the reference values. These included the consideration of a constitutive exon 
for each exon with a PESE/PESS ratio value more than 5.5 compared to 
alternatively spliced exons (with a ratio of 3.6) and pseudoexons which have a 
ratio of around 0.63 (Zhang, 2004). Taking these threshold values into 
consideration, it seems that exons 1, 2, 6, 7, and 10 have a constitutive or 
alternatively spliced exon characteristic while the same was not true for exons 
3, 4, 4a, 8 and 9 when CHRNA7 exons were tested (Table 2-20). These results 
were somewhat consistent with the previous results detected for alternative 
splicing affecting CHRNA7 as exons 3, 4, and 4a were found to be frequently 
missing from RNA transcripts solely or in combinations (Gault et al., 1998, 
Severance and Yolken, 2008). While no transcripts missing exon 8 were 
reported before in studies testing human tissues, our study show the existence 
of transcripts missing exon 9 and backing the PESE/PESS ratio results 
predictions.  
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Table 2-20: ESE analysis for CHRNA7 exons.  
Exon ESE PESE/PESS ratio 
1 1 14 
2 15 12 
3 9 0.52 
4 16 0.38 
4a 7 2.25 
5 2 No silencer motif detected 
6 12 3.86 
7 12 3.63 
8 2 0.79 
9 6 1.08 
10 31 6.89 
The PESE/PESS ratio for exons 1,2,6,7 and 10 showed values of 
constitutive or alternatively spliced exons (>3.6), while those of 
exons 3,4,5,8 and 9 showed smaller values. 
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When testing CHRFAM7A exons using PESE/PESS ratios, the results showed 
that exons D, 6, 7, and 10 have a constitutive or alternatively spliced exons 
characteristics, while the same was not true for exons C, B, A, 8, 9, and 9b 
(Table 2-21). Only transcripts missing exon B were detected before (Gault et 
al., 1998) in addition to missing exon 9 transcripts detected in our study that 
back up the PESE/PESS ratio results.   
 
Table 2-21: ESE analysis for CHRFAM7A exons. 
Exon ESE PESE/PESS ratio 
D 10 3.5 
C 17 1.83 
B 8 0.24 
A 2 0.06 
5 2 No silencer motif detected 
6 12 3.86 
7 12 3.63 
8 2 0.79 
9 6 1.08 
9b 15 2.63 
10 31 6.89 
The PESE/PESS ratio for exons D, 6, 7 and 10 showed values of 
constitutive or alternatively spliced exons (>3.6), while those of exons 
C, B, A, 5, 8, 9 and 9b showed smaller values. 
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2.7.6.2 Predicting the ORF and secondary protein structure: 
For the analysis of the results obtained and for further prediction of the impact 
RQ SURWHLQ VWUXFWXUH DQG H[SUHVVLRQ RI WKH Į UHFHSWRU, a number of 
bioinformatics software programs were used. 
 
2.7.6.2.1 ORF finder results: 
For the splice variants detected for both genes in A549 cells, the transcripts 
were subjected to ORF finder software for initial detection of the mRNA open 
reading frame (ORF), possible start and stop codons and by comparing the 
preserved and the lost parts of mRNA and their corresponding translated parts 
of the protein (Table 2-22 & Table 2-23). 
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Table 2-22: Summary for bioinformatics software analysis for CHRNA7 main transcripts detected in A549 cells. 
Transcript 
Predicted protein amino 
acids 
ORF Possible effects on the protein 
Total Conserved New ORF  
Start 
codon 
Exon 
Stop 
codon 
Exon Preserved lost 
FL 502 502 - +1 1 E1 TAA E10 All - 
Missing E9 380 306 13 +1 1 E1 TGA E10 
SP, N-end, all GLY, all BD, 
TMD1-3 
All P, most of IC loop, TMD4, 
C-end 
FL=full length, E=exon, IC=intracellular, GLY=glycosylation site, N-end= aminoterminal, C-end= carboxy terminal, TMD= trans-membrane domain, BD= 
binding domain, P= phosphorylation sites, Start codon: the cDNA sequence of starting Adenine nucleotide of ATG of the predicted ORF, SP: signal peptide. 
Start codon: refers to c.1 of the reference sequence of CHRNA7 accession number NM_000746. 
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Table 2-23: Summary for bioinformatics software analysis for CHRFAM7A main transcripts detected in A549 cells. 
Transcript 
Predicted protein amino 
acids 
ORF Possible effects on the protein 
Total Conserved New ORF 
Start 
codon 
Exon 
Stop 
codon 
Exon Preserved lost 
FL 412 412 - +1 319 EB TAA E10 All (No SP) - 
Missing E9 290 230 13 +1 319 EB TGA E10 N-end, all GLY, all BD, TMD1-3,  C-end All P, IC loop, TMD4,  
Inserted 
E9b 
264 246 4 +1 319 EB TGA E9b N-end, all GLY, all BD, TMD1-3,  C-end 
All P, part of IC loop, 
TMD4 
Missing E9 
& inserted 
E9b 
221 212 1 +1 319 EB TAA E9b N-end, all GLY, all BD, TMD1-3 
All P, IC loop, TMD4, 
C-end 
FL= full length, E= Exon, EB= exon B, IC= intracellular, GLY= glycosylation site, N-end= aminoterminal, C-end= carboxy terminal, TMD= trans-membrane 
domain, BD= binding domain, P= phosphorylation sites, Start codon: the cDNA sequence of starting Adenine nucleotide of ATG of the predicted ORF. 
Start codon: refers to c.1 of the reference sequence of CHRFAM7A accession number NM_139320.1. 
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2.7.6.2.2 Predicting the start codon: 
Several software programs were employed to predict the start codon of 
different transcripts detected earlier (like the ORF finder and the Human 
Splicing Finder). In addition, start codons within weak contexts were predicted 
using the Weak AUG software program. This program used the KOZAK 
consensus sequence to predict the translation initiation site. The presence of 
Adenosine nucleotide base at position -3 or guanosine nucleotide base at 
position +1 of an AUG (or ATG in corresponding DNA sequence) can help 
predict the Kozak consensus sequence for a start codon. The transcripts were 
first subjected to ORF finder and the Human Splicing Finder analysis to help 
predict the start codon, and then the ORF predicted the RNA to be translated. 
Further analysis using WeakAUG was undertaken to test for possible weak 
consensus start codons. Based on the results shown above (Table 2-22 & Table 
2-23), only CHRNA7 transcripts missing exons 4, 3 & 4 or 4 & 5 in addition to 
all CHRFAM7A transcripts were shown to have a weak start codon for 
translation initiation (using weakAUG software program) (Figure 2-57). 
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Figure 2-57: KOZAK consensus sequence prediction. 
Upper panel: CHRNA7 transcripts detected in A549 cells. Lower panel: CHRFAM7A 
transcripts detected in A549 cells. Red box: ATG start codon, blue arrow: A at -3 or G 
at +4 positions required for recognising A at position +1 as the start of start codon. 
Predicted: indicate a Weak or Strong ATG predicted in a given sequence. This test 
showed that CHRFAM7A transcripts had a weak AUG, unlike CHRNA7 transcripts. 
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2.7.6.2.3 SOSUI signal software program: 
The transcripts that were detected in A549 for both genes were tested for the 
presence of a signal peptide within the translated mRNA sequence using 
SOSUI software program. Only CHRNA7 transcripts were detected shown to 
have signal peptide while CHRFAM7A transcripts did not. 
 
2.7.6.2.4 PSIPRED software program: 
For prediction of the secondary structure of the proteins translated from the 
transcripts detected for both genes in A549 cells, the PSIPRED software 
program was used.  After using ORF finder, transcripts with start and stop 
codons were picked up for subsequent bioinformatics testing. The 
corresponding amino acid sequences of the selected ORF sequences were 
subjected to secondary structure prediction using PSIPRED software program. 
The results for CHRNA7 transcripts showed that full length and inserted exon 
4a have the same structure with aminoterminal and carboxyterminal ends both 
were extracellular, 4 transmembrane domains and intracytoplasmic loop 
(between TMD 3 & 4). The results for missing exon 9 transcripts showed that 
the translated protein would lose transmembrane domain 3 and part of the 
intracytoplasmic loop modifying the protein structure with the carboxyterminal 
end converted intracytoplasmic in position (Figure 2-58). 
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Figure 2-58: Secondary protein structure prediction for CHRNA7 transcripts. 
A: protein structure for the full-length CHRNA7 transcripts. B: protein structure for 
the missing exon 9 CHRNA7 transcripts. 
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The results for protein structure of CHRFAM7A transcripts showed that full-
length transcripts have a protein with similar structure to that of CHRNA7 full 
length transcript. The same was true for results of missing exon 9 transcripts, 
inserted exon 9b and combined inserted exon 9b and missing exon 9 transcripts 
were all showed similar protein structure for that of CHRNA7 missing exon 9 
(Figure 2-59). 
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Figure 2-59: Secondary protein structure prediction for CHRFAM7A 
transcripts. 
A: protein structure for the full-length and. B: protein structure for the missing exon 9 
transcript protein. C: protein structure for the inserted exon 9b transcript, D: protein 
structure for the missing exon 9 and inserted exon 9b transcript. Note: -GT (67-68) of 
exon 6 predicted protein is similar to full length transcript protein, except for a shorter 
N-end. This means that missing exon 9, including exon 9b or both could lead to the 
same results of missing TMD 3 and reversing C-terminus intracellularly. 
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2.7.7 Western blotting results: 
Western blot analysis was performed on A549 cell lysates to confirm the 
H[SUHVVLRQRIĮSURWHLQ$IWHU WKH WUDQVIHUSURFHVV WKHJHOZDV VWDLQHG ZLWK
Coomassie brilliant blue stain to check for the efficiency of transfer of proteins 
to the membrane. The preliminary results for detecting Į7 proteins (using the 
antibody against the N-terminus part of CHRNA7±from Abcam-) in A549 cells 
showed many bands detected by Western blotting. However the brightest of 
these were two bands of around 42 and 34 kDa sizes, respectively. The next 
run showed clearer, but still abundant bands (run 2). However after changing 
the blocking into 1 hour rather than overnight, and incubating the PVDF 
PHPEUDQHZLWKSULPDU\DQWLERG\VSHFLILFIRUĮSURWHLQRYHUQLJKWWZRPDMRU
bands were noticed above 55 kDa size. Furthermore, another antibody that can 
detect the LQWUDF\WRSODVPLFORRSSDUWRIWKHSURWHLQH[SUHVVHGE\ERWKĮDQG
GXSĮSroteins- from Santa Cruz-) was used to probe the A549 lysate.  These 
latter antibodies could detect three bands of 55+ kDa sizes (the predicted size 
of the protein is 56 kDa) (Figure 2-60). 
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Figure 2-60: Western blot analysis for A549 cell lysate using Į7 antibodies. 
A549 cell lysates were used for testing the antibodies. Size indicator (in kDa) is shown 
on left of Western blot with arrows, ȕ-actin: indicate control protein (of 46 kDa size) 
(shown at the lower part of this figure)%ODFN WULDQJOH LQGLFDWHH[SHFWHGĮSURWHLQ
band (~57 kDa size). Run 1: Many bands were detected, but the brightest two were 
around 42 and 34 kDa sizes, respectively. Run 2: similar to run 1, but with two main 
large bands around 55+ and 75+ kDa sizes, respectively. Run 3: two major bands at 
55+ kDa size, Run 4: three bands at 55+ kDa size. Note that the antibodies used in 
runs 1- IURP $EFDP GHWHFW WKH DPLQRWHUPLQDO SDUW RI Į SURWHLQ only, while the 
antibodies used in run  4 are (from Santa Cruz ) could detect the intracytoplasmic loop 
in the common region RIERWKSURWHLQVĮDQGGXSĮ 
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7KHSULPDU\DQWLERG\DJDLQVWĮprotein was designed to target the amino acid 
range 22-7RIWKHKXPDQĮSURWHLQ7KHKXPDQĮSURWHLQharbors three N-
Glycosylation sites, one of which is at position 46 (within the range targeted by 
the primary antibody used) which directed us towards the use of a 
deglycosylation enzyme PNGase F (New England Biolabs). After the 
deglycosylation step, the Western blot analysis for A549 cells revealed two 
bands of sizes between 34 and 42 kDa that were different from those reported 
by Plummer et al (Plummer et al., 2005) but similar to those reported by 
Drisdel and Green (Drisdel and Green, 2000) (Figure 2-61). 
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Figure 2-61: Western blot analysis for Į7 nAChR protein. 
A549 lysate was used for Western blot analysis (samples c1, c2, 1-3). left: Coomassie 
blue staining of the gel, Right: Western blot result: PNGase F deglycosylation kit was 
used on A549 lysates (DeGLY) using different incubation times (hr=hours) at 37°. 
Two A549 controls without deglycosylation were used: C1 (not heated) and C2 
(heated at 37° for 3 hr). Size indicator (in kDa) is shown on left of Western blot with 
arrows. 
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This was followed by the use of mouse muscle lysate as a control for Į7 
receptor protein expression according to Abcam antibody website.  In addition, 
PBMC and BE (2)-F FHOO O\VDWHV ZHUH FKHFNHG IRU WKHLU H[SUHVVLRQ RI Į
protein (Figure 2-62) (mouse muscle and BE (2)-c cell lysates were kindly 
gifted by fellow researchers. The results showed that PBMC expressed several 
forms of the protein of different sizes, while mouse muscle and BE (2)-c cells 
expressed four different forms of the protein, three of which were almost 
identical (around 55+ kDa and around 95+ kDa). 
 
Figure 2-62: Western blot analysis for protein lysate of other cells using Į7 
antibodies. 
M1 & M2: mouse muscle lysates, P: PBMC lysate, BE2: BE (2)-c cells lysate, Size 
indicator (in kDa) is shown on left of Western blot with arrows, ȕ-actin: indicate 
control protein (of 46 kDa size), Black triangle: LQGLFDWH H[SHFWHG Į SURWHLQ band 
(~57 kDa size). 
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2.8 Discussion: 
This study involved the characterization of two genes, CHRNA7 and 
CHRFAM7A that were linked with the anti-inflammatory pathway. Our results 
show that both genes express a novel transcript that is described for the first 
time and is missing exon 9. As both genes express exons 5-10 within their 
transcripts of almost exact sequence, it is interesting to detect transcripts 
missing exon 9 from both genes, highlighting the fact that tissue splicing 
factors might influence such a mechanism. The cells tested include A549 and 
BEAS2B cells, which represent airway epithelial cells. 
2.8.1 CHRFAM7A feedback control on CHRNA7: 
CHRNA7 JHQHHQFRGHV IRUĮQ$&K5VXEXQLW WR IRUPDQ LRQJDWHGFKDQQHO
that helps in controlling inflammation. This receptor seems to be the key 
UHJXODWRU IRU WKH µDQWL-LQIODPPDWRU\ SDWKZD\¶ WR FRXQWHUDFW WKH HIIHFWV RI
inflammation once it started and help keeping it localized (Borovikova et al., 
2000, Wang et al., 2003).  
CHRFAM7A is a partial duplication of CHRNA7, including exons 5-10 of the 
latter. The first 4 exons of CHRNA7 are missing from CHRFAM7A and are 
replaced by exons A-C of ULK4 gene in addition to exon D (unknown origin) 
(Gault et al., 1998, Riley, 2002, Araud et al., 2011). The first 4 exons of 
CHRNA7 are responsible for encoding the agonist binding part of the protein, 
representing its main functional part, and by missing these exons, CHRFAM7A 
SURWHLQGXSĮZDVSURSRVHGWRODFNWKHOLJDQGELQGLQJIXQFWLRQRIĮSURWHLQ
Till recently, the GXSĮprotein role and function was unknown. Many studies 
since then have confirmed WKDWWKHGXSĮSURWHLQPDLQWDLQs a feedback control 
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RQ WKH Į SURWHLQ under basal conditions. Once inflammation starts, the 
production of inflammatory mediators is supposed to down regulate the 
CHRFAM7A and thus enhancing CHRNA7 upregulation (Benfante et al., 
2011, de Lucas-Cerrillo AM, 2011) (Figure 1-11). 
This indicated that in the normal condition, the expression of CHRFAM7A is 
higher than that of CHRNA7 (at transcriptional and translational levels).  
This control mechanism may be affected by the alternative transcripts of both 
genes. It was shown before that some transcripts of CHRNA7 (missing exon 8 
RULQFOXGLQJH[RQEUHQGHUHGWKHĮUHFHSWRUOHVVRUQRQ-functional (García-
Guzmán et al., 1995, Saragoza et al., 2003).   
2.8.2 The alternative splicing of CHRNA7 and CHRFAM7A in airway 
epithelial cells: Novel transcripts detected 
The choice of cells tested was based on their role in the anti-inflammatory 
pathway in the human. Airway epithelial cells (A549 and BEAS2B) and 
PBMC cells were targeted for testing CHRNA7 and CHRFAM7A expression. 
Here we show that there are a number of alternative transcripts detected for 
CHRNA7 in A549 cells, ranging from insertion of exon 4a to deletions of 
exons 3, 4, & 5 alone or sometimes in combinations (Table 2-16). Among these 
transcripts is one missing exon 9 that is reported for the first time. This 
transcript was detected in all CHRNA7 transcripts targeting the amplification 
of exon 9 and its flanking coding part (Figure 2-14 & Figure 2-15). 
Surprisingly, missing exon 9 transcripts were not confined to CHRNA7 and 
this was also detected with corresponding CHRFAM7A transcripts (Figure 
2-25). The expression of some of the transcripts detected in our study was 
reported before in human neuronal tissue such as missing exon 4, missing 
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exons 4 & 5 and missing exons 3 & 4 (Gault et al., 1998). Similarly, inserted 
exon 4a was reported previously in human neuronal tissue (Severance 2008). 
Interestingly, not all CHRNA7 transcripts could be detected by all methods 
used. For example, missing exon 9 transcripts could be detected by using RT-
PCR or by using gel extraction methods, while missing exons 4 & 5 could only 
be detected by gel extraction method and missing exons 3 & 4 could only be 
detected by TA cloning. The lowermost band of amplified exons 2-6 
(suggested to be missing exons 3 & 4 on Figure 2-13) was very faint and might 
get lost during the gel extraction. Similarly, low number of colonies were 
purified and sequenced from amplified exons 2-6, giving the chance to only 
some transcripts to be detected, like missing exons 3 & 4 and not missing 
exons 4 & 5. However, the most surprising results is that no single colony 
could detect missing exon 9 transcript, an effect that could be explained by 
causing an inhibitory effect on DNA replication in the host cell, but a definite 
explanation cannot be provided by our results. 
So to check for tissue specific splicing effect, these transcripts (of both genes) 
were tested in other noncancerous cells, such as BEAS2B, PBMC or other 
cancerous cells such as BE (2)-c cells (Figure 2-35 to Figure 2-38). The 
expression of CHFRAM7A (transcript consisting of exons A-10) was higher 
than that of CHRNA7 (transcript consisting of exons 1-10) in A549 cells, 
BEAS2B (immortalized human bronchial epithelial cells) and PBMC (human 
primary peripheral blood mononuclear cells) which is similar to reports by 
other researchers in other cell lines (Villiger et al., 2002, Severance et al., 
2009, de Lucas-Cerrillo AM, 2011).  For PBMC, there were many reports that 
VKRZHG WKDW WKHUH LV QR H[SUHVVLRQ RI &+51$ RU RI DQ\ IXQFWLRQDO Į
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receptors in human leukemia cell lines or PBMC (Villiger et al., 2002, 
Severance et al., 2009, Benfante et al., 2011). However, a recent study showed 
that PBMC actually express CHRNA7 and functioQDO Į UHFHSWRUV DOWKRXJK
&+5)$0$ DQG LWV GXSĮ SURWHLQ ZHUH H[SUHVVHG LQ PXFK higher 
concentrations (de Lucas-Cerrillo AM, 2011). The only cells that showed a 
reverse expression ratio (CHRNA7 > CHRFAM7A) were BE (2)-c cells. This 
was consistent with results from other studies (Araud et al., 2011).  
It was shown that exon skipping could be used as a mechanism in enhancing 
protein function. This effect was shown in Apobec 3 gene, where a protein 
isoform translated from transcripts missing exon 5 helped to protect against 
viral infections better than the full-length protein (Li et al., 2012). This might 
explain the expression of missing exon 9 transcripts of CHRNA7 and 
CHRFAM7A in the cells we examined. This might shed the light on the 
possible control mechanism of CHRFAM7A over CHRNA7 via transcripts 
missing exon 9. 
This transcript was not reported in human or animal tissues which might 
explain a role for species specific splicing (Gromoll et al., 2007). 
In addition, our results show that CHRFAM7A transcripts contained another 
novel transcript including an inserted exon within intron 9 sequence (exon 9b) 
and a transcripts missing two nucleotide bases TG at position 67-68 of exon 6 
(Table 2-19). This seems to be a reported deletion that has been reported in 
dbSNP and Ensembl databases (accession number is rs201490160, showing a 
MAF=0.37). (Gault et al., 1998). This means that the orientation of 
CHRFAM7A in the cells tested (A549, BEAS2B and PBMC) was the same to 
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that of CHRNA7 (tail-to-head orientation) (as mentioned in section 1.3.4.1) 
(Araud et al., 2011).  
Testing for exon 9b showed that it was flanked by a splice site donor and 
acceptor sites (Figure 2-34). This part of intron 9 is included in sequences from 
both genes, CHRNA7 and CHRFAM7A. Thus, sequence alignment was used 
to differentiate the origin of exon 9b transcripts. The results showed that the 
detected exon 9b transcripts sequences matched those within intron 9 of 
CHRFAM7A (Figure 2-31). The main difference between the two genes within 
exon 9b sequence was the two bases at positions 77 and 154 of the exon. These 
bases were both G in CHRNA7 sequence and C & A (respectively) in 
CHRFAM7A sequence (termed from this point as G-G and C-A alleles of exon 
9b, respectively). Several cell lines were selected for testing the expression of 
exon 9b, such as A549, BEAS2B, BE (2)-c and PBMC cells. The primer set 
that amplifies the common part between the two genes (exons 7-10) and RT-
PCR were employed for this purpose. The detection of an additional PCR band 
that was larger than the expected size of exons 7-10 (399 bp) was the initial 
thread of evidence of inserted sequence expression (Figure 2-14). This 
transcript was detected in A549, BEAS2B, BE (2)-c cells, but not in PBMC 
(which could be due to tissue specific factors). All the resulted PCR products 
were subjected to sequencing, and were confirmed to harbour exon 9b 
sequence. For the upper band that was detected, the sequence was mixed in 
some instances that encouraged the use of TA cloning method to isolate the 
transcripts for subsequent sequencing. This was applied for A549 and BE (2)-c 
cells and the results were almost identical. Most transcripts from both cells 
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expressed exons 7-10 with and without exon 9b. The only difference was the 
inclusion of exon 9b and missing exon 9 in one transcript only in A549 cells.  
In-silico analysis was used for assessment of the nature of the detected 
sequence. First, splice site prediction was used that confirmed that exon 9b is 
flanked by a donor and an acceptor splice sites (Figure 2-34). For testing the 
possibility of exon inclusion, Exon scan software was used. However, the 
results showed that exon 9b was not detected as a constitutive exon.  
 
2.8.3 Can the use of PESE/PESS ratio help to predict exon 
inclusion/exclusion? 
The previous report on CHRNA7 transcripts showed some missing exon 3, 4, 5 
in single or combined deletions (Gault et al., 1998, Severance and Yolken, 
2008). The inclusion or exclusion of an exon within a transcript is dependent 
on many factors, including the splice sites, the branch point and the presence of 
enhancer or silencer elements within an exon. Among the factors that help 
defining an exon as `authentic` or `constitutive` is the presence of more ESEs 
and less ESSs within its sequence. This will help differentiate pseudo exons 
which usually have an estimated ESE/ESS ratio of around 0.63 while a 
constitutive exon will have about 8.6 fold this ratio (ratio ~5.5 ) (Zhang, 2004). 
By using bioinformatics to predict this ratio for CHRNA7 exons, exons 3 & 4 
seem to have a ratio close to that of pseudo exons that might cause their 
deletion in many of CHRNA7 transcripts. This is not true for exon 5 as the 
same software could not detect silencer elements within exon 5 and that of 
exon 8 is still less than 3 (Table 2-20). However, that of exon 9 is lower than 3 
(=1.08) and exon 9 is missing from almost half of CHRNA7 transcripts. The 
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same is true for CHRFAM7A, with the ratio of exons C, B, A, 8, 9 & 9b all 
less than 3. However, only transcripts missing exon B were reported before 
(Gault et al., 1998), and only transcripts with missing exon 9, including exon 
9b or both were detected in our study (Table 2-18). This selective exon deletion 
or insertion might be dependent on the ESE and the SR proteins that bind to 
them, directing the splicing machinery towards or away from these exons, 
respectively. This may be in part due to the abundance of a specific SR that 
binds to such ESE. Another factor that affects such alternative splicing 
processes is a long intron length that precedes the exon to be excluded or 
included. This might be true for exons 3, 4 and 5 of CHRNA7 where they are 
preceded by relatively large introns (ranging from 10-70 kb in size) which 
might explain why the splicing machinery could not detect such exons and 
rather skip them from the final transcript. The intron size was proved to 
correlate with splicing, with larger intronic sizes favoring exon skipping. It was 
shown that reducing intronic sequence sizes flanking an alternatively spliced 
exon resulted in exon inclusion (Cote et al., 1997, Hertel, 2008). It was 
proposed that the recognition of an exon requires the interplay of many factors, 
such as splice sites and enhancer elements. However, for some exons, the 
minimal changes that might affect splicing may play a significant role in 
changing the status of that exon in the opposite way (from inclusion to 
exclusion). This may be due to, for instance,  a change of a SR protein 
concentration in a specific tissue (Hertel, 2008).  
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2.8.4 Aiming to quantify the full-length and missing exon 9 transcripts:  
The next step we tried was to quantify the CHRNA7 transcripts percent 
expression by A549 (of full length and missing exon 9) using QRT-PCR. For 
this reason, we designed the primers for detecting these two transcripts within 
CHRNA7 sequence. This seemed to be best achieved by using the forward 
primer on exon 4 and the reverse primers bridging exon junctions (8-9 for full 
length and 8-10 for missing exon 9 transcripts) (Table 2-2 & Table 2-6). These 
primers sets were targeting the minimum possible amplicons of around 580 bp 
size for both products. The first results showed that there was a steady delay in 
amplification with increasing the cDNA dilution used for the reaction (Figure 
2-41). However, when subjecting the reaction products to gel electrophoresis, 
the results showed that there were double products detected for both primer 
sets (Figure 2-42). This highlighted the fact that the primers might be non-
specific and a further difficulty in checking such primers was added by the 
novelty of missing exon 9 transcripts (a novel transcript that is not yet available 
on the NCBI database) by using the primer blast software . When the sequence 
of both reverse primers was checked for sequence similarities between both 
sets, apart from the exon 8 part that was common between both primers, there 
were an additional 4 nucleotide bases common between the 5` ends of exons 9 
& 10 (nucleotide bases 2-5 were exactly matching between the two exons, 
which were part of the reverse primers bridging exon junctions (Figure 2-44)). 
For this reason, the primer specificity was checked using TA cloning of the 
PCR products of both primer sets. Once detected, they were first checked by 
sequencing. The results confirmed that only single products were amplified 
from each primer set, and the sequencing results showed that only one product 
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was amplified by each set. However, this effect could be possibly due to the 
presence of the second product (that is amplified missing exon 9 within full-
length RT-PCR products, and the reverse is true) at lower levels than the main 
amplified product. The next step was using the RT-PCR products for TA 
cloning to isolate the target inserts (full length and missing exon 9). This was 
completed successfully and confirmed by sequencing (Figure 2-47). The next 
step was to use these two prepared templates (full length and missing exon 9) 
for RT-PCR using QRT-PCR primers sets (4-8/9 & 4-8/10).  The results 
showed that both primer sets were non-specific as both sets could amplify both 
templates (full length and missing exon 9) (Figure 2-48). Sequencing was 
carried out for all the RT-PCR products and it was expected to see full length 
template amplified by full length primers (and the same for missing exon 9). 
However, the surprising part was that full length template was amplified by 
missing exon 9 primers and a missing exon 9 template was also amplified 
using full length primers (Figure 2-49). This indicated that the primers were 
less specific than they were thought to be, and the QRT-PCR approach for 
detecting the relative percent expression of the two main transcripts was no 
longer applicable (Figure 2-63). 
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Figure 2-63: schematic representation for possible cause for primers non-
specificity. 
A: the similar nucleotide bases matching between both primer sets, B: possible 
explanation for missing exon 9 reverse primer binding to full length template part, C: 
possible explanation for full length reverse primer binding to missing exon 9 template 
part. Red boxes=exon 8, grey boxes=exon 9, yellow boxes= exon 10.    
 
A further check for the common sense primer on exon 4 for non-specificity 
was carried out. First, TA clone plasmid templates with full length and missing 
exon 4 inserts were used for RT-PCR using both primer sets. This time, the 
forward primer was proved to be specific and could amplify only templates 
with exon 4 (Figure 2-50). In addition, sequence alignment analysis for exon 4 
primer sequence was run against exons D-A of CHRFAM7A. The result again 
showed that exon 4 forward primer is unlikely to hybridise with any sequence 
on these exons, and thus it is specific for CHRNA7 sequences (Figure 2-51). 
This signaled for the presence of many difficulties facing the use of QRT-PCR 
technique for quantifying the two main CHRNA7 transcripts. Surprisingly, 
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during the course of search for other references that used QRT-PCR with 
CHRNA7, a recent paper published results for CHRNA7 (using primers 
designed to amplify the part between exons 9 & 10 of the gene) and compared 
it with CHRFAM7A (using primers designed to amplify exons D & C of the 
gene). A major limitation of this study is that it could not distinguish CHRNA7 
and CHRFAM7A transcripts as they used exons 9-10 relative to exons D-C to 
compare the expression of the two genes (van der Zanden et al., 2012). This is 
due to the fact that exons 9-10 are expressed by both genes and its 
amplification signal is reflecting transcripts from both genes. Furthermore, 
exons D-C might not be the perfect choice for representing CHRFAM7A as 
they have been shown to be replicated on three loci on chromosome 15 
between CHRNA7 and CHRFAM7A, one of these is just upstream of 
CHRNA7 duplicated part (exons 5-10) and forming the CHRFAM7A (see 
Figure 1-9 in section 1.3.3) (Araud et al., 2011). This common part between the 
two genes (exons 5-10) was used in another study which referred this part only 
to CHRNA7 and used QRT-PCR for amplifying part of exon 10 and 
interpreting the results as an effect of CHRNA7 solely (Schedel et al., 2011).  
As an alternative for QRT-PCR, a semi-quantitative RT-PCR method was used 
to analyse the percent expression of the main transcripts (full length and 
missing exon 9) of both genes in A549 cells. This was applied using a similar 
techniques described before for estimating the relative expression of two 
transcripts of CHRNA7 (Saragoza et al., 2003). RT-PCR reactions for 
CHRNA7 (exons 1-10 products) and CHRFAM7A (exons A-10 products) were 
carried out. Duplicate samples were used for the PCR and the samples were 
removed after each (from cycles 27-35) to determine the exponential and 
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plateau phases of PCR amplification and the relative percent expression of the 
two major transcripts for both genes (Figure 2-52 to Figure 2-56). This method 
helped in estimating that A549 expression for CHRNA7 transcripts was 
divided into around two thirds of full length and one third of missing exon 9. A 
similar ratio for CHRFAM7A transcripts was noted. Interestingly, this ratio 
was more than that reported for other CHRNA7 transcripts as missing exon 8 
(García-Guzmán et al., 1995) including exon 9b (Saragoza et al., 2003) or 
including exon 4a (Severance et al., 2004). As missing exon 9 seems to affect 
both genes, and bearing in mind that exon 9 is within the common part of both 
genes, it might be worth considering that exon 9 is considered as a cassette 
exon in such cases and is not included in all transcripts of both genes. The 
results of PESE/PESS ratio for exon 9 might support this theory (=1) as it is 
less than that of constitutive exons (=5.5) and is more than that of pseudo 
exons (=0.63). 
 
2.8.5 Using bio-informatics tools to predict the protein structure: 
Using ORF finder shed the light on the possible start codons for the detected 
transcripts. Interestingly, such analysis showed that missing exon 9 was in-
frame, and that CHRNA7 main transcripts full length and missing exon 9 has 
the same starting codon with missing exon 9 ending shorter than the full length 
one (Table 2-22). For CHRFAM7A transcripts, the ORF seemed to start at 
exon B for all the transcripts detected except missing TG transcript (Araud et 
al., 2011) (Table 2-23). When predicting the secondary protein structure of the 
detected transcripts using a number of bio-informatics software programs 
(section 2.6.12) the full length transcripts of both genes were almost identical, 
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with amine and carboxylic ends located extracellularly, all TMD and 
intracytoplasmic loop were almost identical. The transcripts missing exon 9 
from both genes and all transcripts included exon 9b in CHRFAM7A 
transcripts showed almost similar pattern of losing the third TMD and some of 
intracytoplasmic loop with the inversion of the carboxylic end into intracellular 
localization (Table 2-22 & Table 2-23) (Figure 2-58 & Figure 2-59). It is well 
documented that the agonist binding domains that are located in the large 
DPLQH WHUPLQXV RI WKH Į SURWHLQ DQG WKDW DUH HQFRGHG E\ H[RQV -4 of 
CHRNA7 (CHRFAM7A lacking this part) to be responsiblHIRUWKHĮSURWHLQ
folding and assembly in the endoplasmic reticulum (ER) (Green and Millar, 
1995). The second TMD is responsible for the ion channel pore lining, and the 
other TMD (1, 3 & 4) have a role in fixing the protein to the cell membrane 
(Bertrand D., 1995). The carboxy terminal end was proved to have no effect on 
changing the physical and pharmacological properties of the receptor (Bertrand 
et al., 2008). However, this study only tested for the role of carboxy terminal 
end in its extracellular position. The formaWLRQ RI IXQFWLRQDO Į UHFHSWRUV
UHTXLUHVVHYHUDOVWHSV)LUVWWKHWUDQVODWLRQRIWKHSURSHUP51$LQWRĮSURWHLQ
subunit is required. Then a number of post-translational modification steps take 
place in the ER to configure the ultimate receptor. These steps include folding 
of each subunit in such a way that allow the amine termini of the adjacent 
subunits to form the ACh binding sites and hold the members of the pentamer 
together (Brejc et al., 2001). This was proposed to be followed by assembly of 
RIWKHĮVXEXQLWVWRIRUPWKHĮUHFHSWRUWKDWLVVHWIRUWUDQVSRUWWRWKHFHOO
surface. Then the TMD2 of all the 5 subunits will form the core of the ion 
channel pore (Bertrand D., 1995, Green and Millar, 1995, Bertrand et al., 
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2008). In addition, the formation of three N-JO\FRV\ODWLRQ VLWHV DQG Į-BTX 
binding sites are essential for the assembly of the receptors (Green and Millar, 
1995, Chen et al., 1998).  It is worth noting that the presence of RIC-3 protein 
is essential for proper IROGLQJ DQG DVVHPEO\ RI Į UHFHSWRUV LQ PDQ\ VSHFLHV
including humans (Lansdell et al., 2005, Williams et al., 2005).  Our results 
show that missing exon 9 transcript might cause the translation of truncated 
protein (towards its carboxy terminal end). This protein, if translated, might 
DVVHPEOHZLWKWKHZLOGW\SHĮSURWHLQDQGWKXVPLJKWEHWUDSSHGZLWKLQWKH
ER and not transported to the cell membrane. This is similar to the assumption 
WKDW GXS Į SURWHLQs co-DVVHPEOH ZLWK Į VXEXQLWV LQ the ER and form a 
heteropentamer that might interfere with its transport to the cell membrane or 
HYHQ UHQGHU Į QRQIXQFWLRQDO (Araud et al., 2011, de Lucas-Cerrillo AM, 
2011).  
 
2.8.6 7KHĮSURWHLQGHWHFWLRQ 
Previously published ZRUNRQĮSURWHLQZDVLQFRQVLVWHQWDQGVKRZHGGLIIHUHQW
sizes for the protein in different tissues.  'LIIHUHQW VL]HV RI Į SURWHLQ ZHUe 
correlated with different conformations of the disulfide bonds (Drisdel and 
Green, 2000). However this explanation was only for larger sized bands than 
the original protein. Other researchers showed that different sizes could be 
GHWHFWHGIRUĮSURWHLQEHVLGHVWKHN'DSUHGLFWHGSURWHLQEDQG. These were 
attributed to differential post-translational modification, different modification 
by RIC-3 protein or palmitoylation steps (Rakhilin et al., 1999, Drisdel and 
Green, 2000, Wang et al., 2001, Williams et al., 2005). Other studies explained 
such different protein bands detected to different glycosylation modification of 
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Į SURWHLQ LQ UHVSLUDWRU\ HSLWKHOLDO FHOOV (Carlisle et al., 2004, Carlisle et al., 
2007). $QRWKHU JURXS VKRZHG YHU\ ZHDN H[SUHVVLRQ IRU Į SURWHLQ LQ $
cells using specific antibodies (Plummer et al., 2005). This result may be 
OLQNHG ZLWK WKH UHVXOWV RI RWKHU VWXGLHV VKRZLQJ WKDW WKH H[SUHVVLRQ RI Į
mRNA was more than its protein in respiratory epithelial cells, possibly due to 
the effect of CHRFAM7A (Wang et al., 2001, Carlisle et al., 2004). We tried to 
use these same antibodies (as they were the only available antibodies for 
Western blot analysis specific for CHRNA7). Previous reports with this 
DQWLERG\VKRZHGWKHH[SUHVVLRQRIGRXEOHEDQGVRIN'DVL]HIRUĮSURWHLQ
in respiratory epithelial cells (Plummer et al., 2005). 
The test for this protein in A549 cells proved to be not a straight forward 
process and several adjustments were required in our protocol including 
changing the constituents of the polyacrylamide gel, the buffers used and the 
membrane for transfer. In addition, different signals were obtained with 
different blocking buffers and antibody concentrations. After optimizing the 
Western EORWWKHWHVWIRUĮSURWHLQVKRZHGWKHGHWHFWLRQRIPXOWLSOHEDQGVLQ
A549 and other cell lines (Figure 2-60). This raised the following question: 
Which part of the protein is the antibody targeting? Then it seemed that the 
antibody is targeting the area around the first glycosylation site. This raised the 
need for a deglycosylation step prior to Western blotting step. The results then 
showed that two major bands (smaller than the original protein) were detected 
around 42 and 38 kDa sizes.  Taking into account that the average molecular 
weight of an amino acid is about 110 Daltons, and that exon 9 constitutes 
DURXQGDPLQRDFLGVRIWRWDORIIRUĮSURWHLQWKHQE\PXOWLSO\LQJE\
110 Daltons give exon 9 a molecular weight contribution of around 4 kDa to 
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WKHWRWDOPROHFXODUZHLJKWRIĮSURWHLQSubsequently, it was predicted that the 
two protein products detected of 42 and 38 kDa sizes coincides with the 
detected two major transcripts of full-length and missing exon 9, respectively. 
7KHSURWHLQVL]HVGHWHFWHGZHUHGLIIHUHQWIURPWKDWUHSRUWHGIRUĮSURWHLQ and 
taking into account the different sizes of the reported proteins in different 
tissues and the addition of deglycosylation step to our Western blotting, 
collectively there seems to be fair evidence that the detected bands represent 
the detected mRNA transcripts full length and missing exon 9. However, there 
is a possibility that this effect of different protein size detected was due to the 
effect of proteolysis. 
 It is worth noting that other cell line were tested IRUĮSURWHLQ(mouse muscle 
SURWHLQDVUHFRPPHQGHGE\WKHDQWLERG\PDQXIDFWXUHU¶VZHEVLWH, in addition to 
PBMC and BE (2)-c cells lysates). All these cells showed similar results for the 
Į SURWHLQ ZLWK WZR EDQGV DURXQG  N'D Figure 2-62). Regarding PBMC 
and BE (2)-c cells, their mRNA showed the expression of full length and 
missing exon 9 transcripts similar to A549 (Figure 2-36 and Figure 2-38, 
respectively). This might indicate, at least in these two cell types, that the two 
main bands expressed might be representing the full length and missing exon 9 
proteins, respectively, using the molecular weight of the amino acids for each 
protein as a guide (as explained above). Similar results for expression of 
GRXEOH EDQGV IRU Į SURWHLQ ZHUH UHSRUWHG LQ 6+-SY5Y cells (bone marrow 
with neuroblastoma cells) (Charpantier et al., 2005) and from human 
macrophages and rat phaeochromocytoma cells (Wang et al., 2003). 
It is worth noting that RIC-3 is a well-recognized chaperone that is required for 
ĮSURWHLQDVVHPEO\DQGH[SUHVVLRQ(Lansdell et al., 2005) and that the mRNA 
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transcripts for this protein were detected in A549 cells (that were used in our 
study) an earlier study in our laboratory (Al-masmoum, 2011).    
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2.9 Conclusion: 
In summary, the results of testing alternative splicing on the CHRNA7 and 
CHRFAM7A showed the expression of two novel transcripts that are reported 
for the first time. The first of these is expressed by both genes and is missing 
exon 9. This transcript preserves the reading frame but is lacking the TMD3 
and with an intracellular carboxy-terminus. These changes are predicted to 
DIIHFW WKH IXQFWLRQ RI WKH Į SURWHLQ DQG PLJKW DIIHFW WKH VXEVHTXHQW LRQ
FKDQQHO IRUPHG IURP WKH UHVXOWLQJSURWHLQ ,W LV ZHOO NQRZQ WKDWĮ-nAChRs 
are homopentamers, but it is still possible that such a protein resulting from 
missing exon 9 to co-assemble with the full-length protein, leading again to an 
ion channel with altered conduction. This effect might alter the receptor 
function in the anti-inflammatory pathway, favoring inflammation. 
Regarding the second novel transcript detected, it included an inserted 
sequence within intron 9 (so termed here as exon 9b). This transcript was 
shown to be expressed by CHRFAM7A by sequencing. To test for possible 
expression from both genes, further detailed work was carried out using the 
minigene methods (as will be discussed in detail in the next chapter). 
The cells tested for the transcript expression from CHRNA7 and CHRFAM7A 
were airway epithelial cells and PBMC that are involved in anti-inflammatory 
pathways and could modulate the inflammatory response associated with 
COPD.  
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This chapter will discuss the preparation of exon 9b minigene constructs from 
both genes to test for the possible effects of nucleotide base differences on the 
inclusion of exon 9b from both genes. 
 
3.1 Introduction: 
During the process of RNA splicing, the spliceosome assembly on the exons is 
dependent on the sum effect of enhancer and suppressor factors that either 
drive the spliceosome into or away from such an exon leading to its inclusion 
or exclusion, respectively (Fairbrother and Chasin, 2000). Among the factors 
that help establish the spliceosome on the exon are exon splice enhancers 
(ESEs). These will bind to SR proteins, and oppose the effects of exon splice 
suppressors (ESSs) binding to silencer elements. The balance of the ESEs and 
ESSs within a given exon seem to have a major role on exon inclusion or 
exclusion in the forthcoming mRNA transcript, with the ESEs predominance 
helping to shift towards exon inclusion while ESSs favours the opposite (Sun, 
2000, Dewey et al., 2006, Zhang, 2004).  
 
3.1.1 Exon inclusion: 
The basic elements required for exon definition are the splice sites and the 
adenine branch point (Robberson et al., 1990). The exon is defined when the 
flanking splice sites and adenine branch point are recognised by the complex 
spliceosome machinery. However, failure to define an exon will have an 
impact on subsequent exon skipping, directing the splicing machinery to start 
screening for the next possible exon. The assembly of the spliceosome on a 
µGHILQHGH[RQ¶LVQRWPHUHO\driven by the splice sites and the branch point but 
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rather influenced by additional effects of other auxiliary factors. These include 
exon size (preferably less than 300 nucleotides), intron size (preferably shorter 
than 3 kb), enhancer elements represented by ESEs and ISEs (the more 
abundant, within an exon and its flanking introns, the more an exon is defined), 
ESSs and ISSs (opposite to ESEs and ISEs effects) (Hertel, 2008, Black, 2003, 
Reed and Maniatis, 1986). Sometimes two different SR proteins may act 
competitively to include or exclude an exon.  
 
3.1.1.1 Intron size effect: 
It is now evident that the sizes of flanking introns affect exon inclusion in the 
mRNA transcript. The splicing process starts with either exon or intron 
definition to help recognise the start and end points for the spliceosome 
machinery assembly. It was shown that the spliceosome might first use the 
intron definition approach looking for defining the splice sites and the branch 
point. However, this step is limited by a maximum intron length of 250 
nucleotides. Once this limit is exceeded, which is the case most of the time, the 
spliceosome would switch to the exon definition mode (Hertel, 2008).  For 
alternatively spliced exons, factors like the intron size and ESEs might affect 
splicing (as mentioned in chapter 2). It was shown that larger intron sizes, 
particularly those upstream to an exon, would shift the splicing away from such 
an exon, resulting in exon skipping (Berget, 1995, Hertel, 2008). In another 
study, it was shown that in addition to the intron size, other important factors, 
such as splice sites and ESEs, tend to compensate for enhancing splicing. This 
was illustrated in the form of increased ESEs density in exons flanked by rather 
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short introns (less than 1.5 kb size) while splice site signal strength was 
increased in larger size introns (Dewey et al., 2006). 
 
3.1.2 Exon inclusion: the effect on certain diseases in human 
Alternative splicing was shown to affect the development and progression of 
some diseases in humans. Among the common examples is spinal muscular 
atrophy (SMA). This disease is motor neuron disease that could cause death in 
some patients. There are two genes that encode for survival of motor neuron 
(SMN) protein: SMN1 and SMN2 genes. In SMA disease, most of the patients 
suffer SMN1 deletion, allowing SMN2 gene only to code for the SMN protein. 
This will result in a single nucleotide change from that encoded by SMN1 gene 
&ĺ7FKDQJH WKDW OHDGV to increasing disease severity (Cooper et al., 2009). 
This single nucleotide base change seems to affect a known ESE sequence 
causing exon 7 skipping, thus lowering the SMN protein concentrations. 
Another study suggested that the base change leads to suppression of SR 
protein binding rather than changing the ESE function into an ESS (Kashima 
and Manley, 2003). Whatever the real change is, it will affect the spliceosome 
assembly on exon 7 of SMN2 mRNA causing its skipping (Figure 3-1, A). 
Another example is the alternative splicing of Dystrophin gene causing mild 
form of Duchenne muscular dystrophy (DMD). The Dystrophin gene is liable 
to a wide range of effects from alternative splicing events due to the large size 
of the gene. Among these effects is a single nucleotide substitution within exon 
31 that can create an ESS site near an ESE one. Such an effect is enough to 
cause skipping of exon 31 and aid in the production of partially functioning 
protein that cause the development of this disease form (Figure 3-1, B) (Disset 
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et al., 2006). Another common effect of alternative splicing on human disease 
development is the effect of alternative splicing on the tau gene. This gene 
codes for the tau protein, which is responsible for the assembly and 
morphogenesis of microtubules in the neurons. This protein has four 
microtubule binding domains encoded by exons 9-12. However, for a better 
function of the protein and to prevent neuronal degeneration, domain 2 
encoded by exon 10 is omitted by alternative splicing of exon 10, thus keeping 
the ratio of exon 10 excluded/included transcripts almost equal. This effect is 
achieved via several nucleotide base changes that can affect an existing ESE 
site within exon 10 (Cooper et al., 2009). Some of these changes can increase 
the ESE strength and its binding to SR proteins, causing increased exon 10 
inclusion. Such an effect will change the exon 10 excluded/included ratio, 
leading to FrontoTemporal Dementia with Parkinsonism on chromosome 17 
(FTDP-17) (Figure 3-1, C) (Liu and Gong, 2008) .  
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Figure 3-1: Examples of ESE changes on human diseases. 
(A) The spinal muscular atrophy could result from single nucleotide base changes 
affecting the SMN protein production. The initial step includes deletion of the SMN1 
gene, allowing for SMN2 (which has a CĺT substitution in exon 7) to dominate the 
source of protein-producing mRNA. This will causes ESS to substitute an existing 
ESE leading to exon 7 skipping. (B) The Duchenne muscular Dystrophy (DMD): a 
mild form of the disease is precipitated by a single nucleotide substitution in exon 31 
of the dystrophin gene 7ĺ$ 7KLV FKDQJH ZLOO LQWURGXFH D SUHPDWXUH VWRS FRGRQ
(Stop) and an ESS, leading to exon 31 skipping. (C) Frontotemporal dementia: a 
single nucleotide base change can cause a change in the ratio of transcripts expressing 
or not exon 10 of the MAPT gene. This change can cause enhanced ESE site, which 
functions to increase exon 10 inclusion, thus changing the ratio of exon 10 transcripts. 
Taken from (Cooper et al., 2009) 
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The alternative splicing can affect the mode of the protein function. Such an 
effect was shown in the Apobec3 gene in mice, where transcripts missing exon 
5 of the gene (due to polymorphisms) lead to the production of the APOBEC3 
protein isoform. This protein isoform was shown to act more efficiently, 
helping in resisting viral infections better than the full-length protein (Li et al., 
2012).  
 
3.1.3 Exon 9b: a novel exon  
In our earlier results, we showed that there was a transcript with a novel exon 
(exon 9b) from A549 cells in PCR products amplifying the common sequence 
from CHRNA7 and CHRFAM7A genes (exons 7-10 transcripts). However, 
DNA sequencing results later confirmed that these transcripts originated only 
from CHRFAM7A according to the reference sequence of both genes. When 
testing CHRFAM7A transcripts in A549 and BEAS2B cells, similar transcripts 
which included exon 9b were detected. These findings raised the following 
question: do exon 9b transcripts originate only or mainly from CHRFAM7A? 
And if this was true, do these two base differences have a possible role in this 
exon inclusion? To answer this question we decided to design minigene vectors 
that carry exon 9b sequences from both genes with only two nucleotide bases 
different between the two constructs. 
 
3.1.4 Using the minigene technique: 
The use of the minigene method was a key for exploring many ambiguous 
RNA splicing mechanisms. This method includes the generation of plasmid 
constructs that can harbor parts of or entire genes to study the process of 
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splicing and the related control mechanisms. The minigene construct 
preparation includes the use of vectors with a restriction enzyme recognition 
region that is flanked by multiple restriction sites. The latter sites can enhance 
the use of restriction enzymes that can recognize sequences on the vector and 
on the template amplified (Cooper, 2005). These sites are usually selected 
based on the sticky end method, and thus allowing for ligation of the insert 
with the plasmid or vector. This helps constructing a hybrid gene that can be 
introduced into different cell types for studying the splicing mechanism. Using 
the minigene method can help testing for cell, tissue, or species-specific 
splicing effects (Gromoll et al., 2007).  Furthermore, minigene methods could 
test as small as ten nucleotides and up to several kb sequences. The use of the 
minigene method was employed for testing the splicing effect of nucleotide 
changes on exon inclusion/ exclusion (Smith, 1989, Cote et al., 1997, Kosaki et 
al., 1998, Gromoll et al., 2007, Vezain et al., 2010), splice site alterations 
(Reed and Maniatis, 1986, Cote J, 2001), ESEs/ESSs sites (Jumaa and Nielsen, 
1997, Ibrahim et al., 2005) or even in treatment trials (Phelps et al., 1995).  
Exon trap (also called pET01) is a cloning vector that allows the insertion of 
exons within the multiple cloning site of the vector. This vector represents a 
shuttle system that contains the necessary genetic factors for replication within 
the host cells. It can help positioning the exon (with its flanking intronic 
sequences) flanked by exon trap introns. In this way, any sequences within this 
site that are defineGE\WKHVSOLFLQJPDFKLQHU\DVµH[RQV¶ZRXOGEHUHFRJQLVHG
once they are introduced into mammalian cells, and would be included within 
the mRNA of the vector, flanked by the exon trap 5` and 3` exons, respectively 
(Figure 3-2). 
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Figure 3-2: Exon trap vector. 
Schematic representation of exon trap vector, Bottom: showing exon trap multiple 
cloning site enclosed between its 5` & 3` exons, Top: multiple cloning site showing 
restriction enzymes recognition sites, SalI and XbaI (within red boxes) were selected 
as target sites. 
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In summary, minigene experiments included preparing the two alleles of exon 
9b from CHRNA7 and CHRFAM7A (G-G and C-A alleles) in genomic DNA 
samples by using TA cloning. This was followed by inserting these alleles into 
the exon trap vector for minigene construct preparations. These constructs were 
used as templates for preparing another two constructs using site-directed 
mutagenesis (G-A and C-G alleles). All the constructs were transfected into 
A549 and Cos7 cells, and the RNA was extracted from these cells for RT-PCR 
testing of exon 9b inclusion. The RT-PCR results were analysed on gel 
electrophoresis and then using AlphaDigiDoc software (Figure 3-3). 
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Figure 3-3: Minigene experiments summary. 
SD: site-directed, alphaDigiDoc: software for densitometric analysis tool. Short: refers to short exon 9b fragment minigene constructs. 
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3.2 Aim: 
The work of this chapter aimed at testing the effect of the two nucleotide bases 
(different between both genes within exon 9b sequence) on exon recognition, 
and which bases have the most influential effect on exon 9b inclusion.  
To achieve this aim, minigene plasmid vectors carrying exon 9b sequences 
from CHRNA7 and CHRFAM7A genes were designed and prepared. Then 
these minigene constructs were transfected into A549 and Cos7 cells to test for 
the effect of the two nucleotide bases on exon 9b recognition. 
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3.3 Methods:   
3.3.1 Bio-informatics analysis: 
First, for confirming the sequence detected for exon 9b and the flanking 
introns, similar methods were used (as mentioned in section 2.6.12). This was 
true for extracting the reference sequence for intron 9 from both genes using 
NCBI, UCSC and Ensembl databases, and for using ClustalW  sequence 
alignment to compare the resulting transcripts sequences. For testing exon 
inclusion within a transcript, Exon Scan software was used. This software uses 
the GT-AG base and RESCUE-ESE software for exon inclusion within a given 
sequence. For prediction of the possible restriction enzyme recognition sites 
within exon 9b and flanking introns, Web Cutter and Neb Cutter software 
programs were used. For primer design, primer3(v.0.4.0) software was used for 
designing the primers, Primer-Blast/NCBI software was used to check for the 
primer specificity and SNPCheck software was used to avoid including SNPs 
within the designed primers.  For exon definition, splice site prediction 
software (BDGP) was used (Reese et al., 1997). However, for predicting the 
ESE sequences within the detected exon 9b sequences, ESE finder (release 3.0) 
(Cartegni et al., 2003, Smith et al., 2006) and Splicing rainbow software 
programs were used in addition to other methods mentioned in section 2.6.12 
(RESCUE-ESE and Human splicing finder). Further analysis for detecting 
possible SNPs within exon 9b were carried out using Ensembl and dbSNP 
software programs. The default thresholds of the above mentioned software 
programs were used as the reference values (Table 3-1). 
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Table 3-1: Summary for the bio-informatic software programs and tools used for analysis of exon 9b transcripts. 
Software program URL 
Clustal W (sequence alignment) http://www.ebi.ac.uk/Tools/msa/clustalw2/  
Exon Scan (exon definition) http://genes.mit.edu/exonscan/  
Web cutter (restriction enzyme recognition sites) http://users.unimi.it/~camelot/tools/cut2.html  
Neb cutter (same as above) http://tools.neb.com/NEBcutter2/  
Primer 3 (v.0.4.0) (PCR primer design) http://frodo.wi.mit.edu/ 
Primer blast/NCBI (sequence  http://www.ncbi.nlm.nih.gov/tools/primer-blast/  
SNP check (check presence of SNP within a 
designed primer sequence) 
https://ngrl.manchester.ac.uk/SNPCheckV3/snpcheck.htm;jsessionid=4228B00C8535DA
EE9062415214505CC7 
BDGP (splice site detection) http://www.fruitfly.org/seq_tools/splice.html  
ESE finder (release 3.0) (detect potential ESEs) http://rulai.cshl.edu/cgi-bin/tools/ESE3/esefinder.cgi?process=home  
Splicing rainbow (predict  SR protein binding) Currently not available 
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3.3.2 Preparation of the minigene constructs: 
For preparing minigene constructs, exons 9b alleles (G-G & C-A) from short 
and long exon 9b fragments were amplified (using PCR) from genomic DNA 
samples of heterozygous subjects (details about these fragments will be 
discussed shortly after this summary). After preparing the amplified exon 9b 
(PCR products), these were introduced into the exontrap vector sequence 
(MoBiTec GmbH 2010). 
 
3.3.2.1 Isolation of exon 9b alleles:  
Prior to preparation of minigene constructs, exon 9b alleles were isolated from 
CHRNA7 and CHRFAM7A sequences. For this purpose, two exon 9b 
fragments were designed (short and long) using primer sets that amplify short 
(around 100 bp) or long (around 900 bp) intronic sequence upstream of exon 
9b. Furthermore, as exon 9b and surrounding intronic sequences are almost 
exactly identical between CHRNA7 and CHRFAM7A genes, using the 
designed primers from either segment would amplify exon 9b from both genes. 
According to the NCBI reference database, there are only two bases within 
exon 9b sequence that are different between the two genes and these are at 
positions 77 and 154 of exon 9b sequence, respectively. These two bases are 
G-G in CHRNA7 allele (termed here as the G-G allele) and C-A in 
CHRFAM7A allele (termed here as the C-A allele). For this purpose, the term 
G77 during the text would refer to G nucleotide base at position 77 (in the G-G 
allele) while the term A154 would refer to A nucleotide at position 154 (in the 
C-A allele).  
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3.3.2.1.1 Exon 9b primers design: 
For amplifying exon 9b from both genes, the reference sequence alignment of 
intron 9 parts of both genes was used as a target for designing the primers. 
While one reverse primer was designed (starting 122 nucleotide bases 
downstream of the exon 9b 3` end), two sets of forward primers were designed 
with the first primer (starting 133 nucleotide bases upstream of the exon 9b 5` 
HQGJHQHUDWLQJ³VKRUWH[RQEIUDJPHQW´DQGWKHVHFRQGSULPHUstarting 994 
QXFOHRWLGH EDVHV XSVWUHDP RI H[RQ E C HQG JHQHUDWLQJ ³ORQJ H[RQ E
IUDJPHQW´ (Figure 3-4). The reason for using two different segments 
surrounding exon 9b is to test for the regions of sequence differences between 
CHRNA7 and CHRFAM7A that are present within the long fragment 
according to the databases used. However, it could also prove to be useful 
when thinking of possible enhancer or suppressor elements within the intronic 
sequences upstream of exon 9b for possible stimulatory or inhibitory effect on 
inclusion in the transcripts (Cote et al., 1997).  
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Figure 3-4: Diagram showing location of primers used to amplify short and long 
exon 9b fragments. 
A: exon 9b short fragment, B: exon 9b long fragment. Blue boxes: exons, Green 
arrow: forward primer (including sequence for SalI restriction enzyme), Red arrow: 
reverse primer (including sequence for XbaI restriction enzyme), flanking gene 
(CHRNA7 or CHRFAM7A) introns (black lines) sizes are indicated below the introns; 
the expected size of the construct is shown in the boxes on the right. Exon 9b size= 
197 bp.  
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For optimal results using the minigene method, the primers sets for generating 
the two allelic constructs were designed to amplify exon 9b with its flanking 
introns (at least ~ 0.1 kb of introns on either side) (Cooper, 2005). For all the 
primers, a restriction recognition site was added on 5` end (SalI site for forward 
primers and XbaI site for reverse primer) (Table 3-2).  
 
Table 3-2: Nucleotide sequences of the primers used for exon 9b transcripts 
detection. 
Primer ID 3ULPHUVHTXHQFHCĺC Position  
E9b-shortS AATAAGGTCGACTGCCTTAACAATGTAGCACCT I 9 
E9b-longS TCCAAGGTCGACAGACCCAACCTTTCCAGGAC I 9 
E9bAS ACAGCTTCTAGAAAGGGGAAGGCTATCTGAGC I 9b 
All primers are from Eurogentec, Belgium. 
I= intron, S: Forward primer, AS: reverse primer.  E9b-short: upstream of exon 9b by 
~ 0.1 kb, E9b-long: upstream of exon 9b by > 0.9 kb, E9bAS: downstream of exon 9b 
by ~ 0.1 kb. Restriction enzyme recognition sites for SalI (on E9b-shortS & E9b-
longS) and XbaI (on E9bAS) are underlined. 
 
 
3.3.2.1.2 Genomic DNA preparation:  
Genomic DNA was extracted from A549 and BE (2)-c cells for PCR 
amplification applications. QIAamp DNA blood mini kit (QIAGEN) was used 
IRUWKLVSXUSRVHDFFRUGLQJWRWKHPDQXIDFWXUHU¶VJXLGHOLQHV 
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3.3.2.1.3 TA cloning of exon 9b PCR products: 
The PCR products of exon 9b (from both short and long fragments and for both 
alleles (G-G & C-A)) were inserted into the pSC-A-Amp/kan vector using the 
TA cloning method (as mentioned in section 2.6.6).  
 
3.3.2.1.4 Restriction digestion using Eco57I: 
For initial screening of the allele constitution of the initially prepared TA 
clones, the restriction enzyme Eco57I (AcuI) (Fermentas Life Sciences) was 
used. The recognition site of this enzyme is located around the G77 of exon 9b. 
This means that this enzyme can cut the G-allele of exon 9b (from CHRNA7) 
but not the C-allele (from CHRFAM7A). The enzyme would cut at specific 
positions on the insert-plasmid construct and will show different product sizes 
on electrophoresis according to the allele digested (Figure 3-5) (Table 3-3). 
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Figure 3-5: Schematic representation of Eco57I enzyme recognition sites. 
Eco57I recognition sites (Black arrows) on pSC-A-Amp/Kan vector (orange boxed 
line) and inserts of exon 9b (blue boxed line): A) short fragments, B) long fragments. 
Red arrow: recognition site only for G at position 77 of exon 9b (indicated by inverted 
red triangle). The plasmid numbering starts at 1 (in circle) while the insert numbering 
starts at 2 (in square). 
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Table 3-3: The product sizes resulting from restriction using Eco57I enzyme. 
Fragment used 
G-G allele-specific 
product sizes (bp) 
C-A allele-specific 
product size (bp) 
Allele non-specific 
product sizes (bp) 
Exon 9b short 
fragment 
150 , 328  478  
432, 538, 866, 1022, 
1384 
Exon 9b long 
fragment 
150 , 663  813  
432, 531, 538, 863, 
1022, 1384 
 
For restriction digestion using Eco57I, up to 1 µg of the target DNA was added 
with G and SAM buffers (final concentration 1x for both) and finally adding 
2.5 units of Eco57I into a total reaction volume of 20 µl. The reaction mixture 
was then mixed gently and incubated for 60 minutes at 37°. This was followed 
by a heat inactivation step for the enzyme at 65° for 5 minutes. The digested 
DNA samples were subjected to gel electrophoresis (as mentioned in section 
2.6.5 using 2% agarose gel). 
The restriction using Eco57I helped to differentiate the G-G and C-A clones 
within each group of exon 9b fragments (short and long). This was followed by 
sequencing of six plasmid-inserts from each of the four different clones that 
were prepared (confirmed by sequencing using M13 forward and reverse 
primers). The plasmid-inserts picked up for subsequent preparation of 
minigene constructs were mainly four alleles: the G-G alleles (short and long) 
from CHRNA7 and the C-A alleles (short and long) from CHRFAM7A. 
 
3.3.2.2 Preparation of minigene constructs: 
First, each of the isolated exon 9b clones (mentioned above) were cut using 
restriction enzymes SalI and XbaI (as illustrated in Table 3-2). The restriction 
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of exontrap vector was applied in a separate step. This was followed by 
running the digested DNA fragments on gel electrophoresis (as mentioned in 
section 2.6.5). Using dark reader, the bands of expected size for each exon 9b 
allele (or the vector)-digested fragment were gel extracted and purified (as 
mentioned in section 2.6.7). This step was followed by ligation of each of the 
exon 9b alleles isolated with exontrap vector and the different plasmid-inserts 
prepared were used for subsequent cloning. 
 
3.3.2.2.1 Restriction digestion using SalI and XbaI: 
For the minigene constructs preparation, FastDigest SalI and XbaI enzymes 
were used (Fermentas Life Sciences). The clones that harbored exon 9b 
(inserted with pSC-A-Amp/kan) were subjected to restriction digestion using 
SalI and XbaI (Figure 3-6). 
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Figure 3-6: Restriction using SalI & XbaI for minigene constructs. 
Exon trap-exon 9b (or pSC-A-Amp/kan-exon 9b) inserts are shown as grey circle 
(exon trap or pSC-A-Amp/kan vector) and blue box (exon 9b). The junctions between 
the two parts are SalI and XbaI recognition sites (orange triangles 1 & 2, respectively). 
SalI (boxed 1) and XbaI (boxed 2) enzymes function to cut (interrupted red arrow) at 
the specific sites, resulting in separating the two parts. Exon trap containing exon 9b 
inserts were digested to check that only exon 9b inserts are included. 
 
For the restriction reaction, the DNA targets (up to 1 µg) were added to the 
reaction mixture in addition to the enzymes and green buffer (Fermentas Life 
SciencesDFFRUGLQJWRWKHPDQXIDFWXUHU¶VJXLGHOLQHV)RUWKHH[RQWUDSYHFWRU
ligation, 2 units of alkaline phosphatase enzyme (Fast AP, Roche, GmbH, 
Germany) was added to dephosphorylate the vector ends and prevent self-
religation of the vector. The resulting products were subjected to gel 
electrophoresis (as mentioned in section 2.6.5) and according to the expected 
product size (452 bp size for short exon 9b fragments, 1313 bp size for long 
exon 9b fragments, and 4016 bp size for exon trap vector) were subjected to 
gel extraction (as mentioned in section 2.6.7). After minigene construct 
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preparation, SalI and XbaI enzyme restriction was used as a screening test prior 
to sequencing.  
 
3.3.2.2.2 Ligating the inserts with exon trap: 
Following DNA quantification, one of exon 9b alleles (G-G or C-A) and exon 
trap vector were both added in a ligation reaction to insert the alleles within the 
vector sequence for subsequent steps. For this purpose, the vector: insert ratio 
used was 1:3 and was calculated using the following equation: ௩௘௖௧௢௥ሺ௡௚ሻൈ௜௡௦௘௥௧௦௜௭௘ሺ௕௣ሻ௧௢௧௔௟௩௘௖௧௢௥௦௜௭௘ሺ௕௣ሻ  ൈ 3ൌ ng of the insert required for the ligation 
reaction.  
This equation was used to calculate the insert from both exon 9b fragments 
required for the ligation, and the results are shown as follows: ௩௘௖௧௢௥ሺଵ଴଴௡௚ሻൈ௜௡௦௘௥௧௦௜௭௘ሺସହଶ௕௣ሻ௧௢௧௔௟௩௘௖௧௢௥௦௜௭௘ሺସସ଺ଵ௕௣ሻ   ൈ 3ൌ 30.39 ng (for exon 9b short 
fragment). 
 ௩௘௖௧௢௥ሺଵ଴଴௡௚ሻൈ௜௡௦௘௥௧௦௜௭௘ሺଵଷଵଷ௕௣ሻ௧௢௧௔௟௩௘௖௧௢௥௦௜௭௘ሺସସ଺ଵ௕௣ሻ   × 3= 88.29 ng (for exon 9b long 
fragment). 
For monitoring purposes, a vector-only ligation reaction was run in parallel to 
check for the levels of background ligation (due to undigested and/or re-ligated 
vector molecules). The ligation reaction mixture included 100 ng of the 
exontrap vector, 1 unit of T4 DNA ligase and 1x ligation buffer (Roche, 
GmbH, Germany) and the total volume of 20 µl reaction was completed using 
RNase-free water. The reaction mixture was then incubated at 4° overnight.  
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3.3.2.2.3 Transformation into supercompetent cells: 
Following ligation, about 50 ng of ligated DNA product was added into XL1-
EOXHVXSHUFRPSHWHQWFHOOV $JLOHQW WHFKQRORJLHV DFFRUGLQJ WRPDQXIDFWXUHU¶V
guidelines. This included adding 100 µl of XL1-blue cells on pre-chilled 1.5 ml 
microcentrifuge tubes. Then about 10 ng of the vector-insert DNA was added 
to the cells. The mixture was incubated on ice for 30 minutes and then 
subjected to heat shock at 42° for 45 seconds. The mixture was incubated on 
ice for another 2 minutes before adding pre-heated SOC (super optimal broth 
medium with glucose used to enhance the plasmid transformation efficiency) to 
a final volume of 1 ml. The mixture was then incubated at 37° with horizontal 
shaking for 60 minutes. Finally, 100 µl of reaction mixture was spread on 
plates containing pre-warmed CG agar (Circle Grow rich bacterial growth 
media, Anachem, Luton, UK) (containing 4 g/100 ml CG, 1.5 g/100 ml agar 
DQGȝJPODPSLFLOOLQDQG;-gal) and incubated overnight at 37°. Single 
colonies were inoculated into 5 ml CG bacterial growth media (including 50 
ȝJPODPSLFLOOLQDQGLncubated for 16-18 hours at 37° in a shaking incubator. 
On the next day, colonies were selected for purification and sequencing.  
The vector-only ligation product was used as a control for monitoring the level 
of background ligation.  
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3.3.2.2.4 Plasmid-insert extraction: 
Using endotoxin-free QIAprep Spin Miniprep kit (QIAGEN), plasmid was 
extracted from bacterial cultures according WRPDQXIDFWXUHU¶V JXLGHOLQHV 7KH
DNA yield was then measured using a Nanodrop spectrophotometer. 
 
3.3.2.2.5 Screening for insert-specific products: 
To check for inclusion of the insert within the vector, SalI and XbaI (supposed 
to be located between the inserts and the vector sequences) were used for 
digesting the extraction products and to screen for the possible samples to send 
for DNA sequencing (using primers E9b-shortS, E9b-longS, & E9bAS primers, 
from Table 3-2) (as mentioned in section 2.6.8). The results of the sequencing 
were compared with the reference sequence of the corresponding exon 9b 
alleles. 
 
3.3.2.2.6 Endotoxin-free midiprep preparation: 
After confirming the insert DNA sequence is the correct sequence and is in the 
correct orientation, the minipreps DNA was further extracted by using 
QIAfilter Plasmid Midi kit 4,$*(1DFFRUGLQJWRPDQXIDFWXUHU¶VJXLGHOLQHV 
 
3.3.2.3 Site-directed mutagenesis: 
Using the Quick Change II Site-Directed Mutagenesis kit (Agilent 
technologies, USA) exon 9b generated alleles (G-G & C-A) were used as 
templates to generate another two alleles (G-A & C-G). First, two primer sets 
were designed using Agilent software recommended by the manufacturer.  
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The primer design aimed at targeting a single base within exon 9b, which was 
either G154 (on G-G allele) or the A154 (on C-A allele). Using this technique, 
the nucleotide base at position 154 of exon 9b in G-G and C-A minigene 
constructs (from exon 9b short fragment) were targeted for substitution. This 
included the generation of two more constructs to cover all four possible alleles 
of exon 9b (Table 3-4). 
 
Table 3-4: Site-directed mutagenesis summary for exon 9b minigene constructs. 
Exon 9b allele Base at position 154 Substituted base Resulting allele 
G-G G A G-A 
C-A A G C-G 
 
The characteristics and sequences of the primers are summarized in (Table 
3-5). 
Table 3-5: primer design recommended guidelines-Agilent technologies. 
Primer length (bp) 25-45  
Base to be 
substituted-position 
In the middle part of the primer 
Primer last base G or C 
Primer GC contents > 40% 
Primers overlap 
Both forward and reverse primer should overlap the region 
of substitution 
AG-S* TGTACAACCTCCCCCAGACACTCTTTGCGAATTTG 
AG-AS* CAAATTCGCAAAGAGTGTCTGGGGGAGGTTGTACA 
CG-6Á TGTACAACCTCCCCCAGGCACTCTTTGCGAATTTG 
CG-$6Á CAAATTCGCAAAGAGTGCCTGGGGGAGGTTGTACA 
*: sequences of primers for generating the AG allele of exon 9b. 
ÁVHTXHQFHVRISULPHUVIRUJHQHUDWLQJWKH&*DOOHOHRIH[RQE 
S: forward primer, AS: reverse primer. 
The mutation base is highlighted in bold letter. 
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The method was used according to the manufactuUHU¶VJXLGHOLQHV This method 
involves the use of the designed primers in a PCR reaction. The templates used 
for the PCR included the exontrap vector with exon 9b insert (either G-G or C-
A allele). Following amplification of the new (mutated) allele, the used of Dpn-
I restriction enzyme aimed at degrading the old template and keeping the new 
template. This was followed by sequencing the mutated-insert and once the 
mutagenesis was proved successful, the same steps used for preparing the 
minigene constructs were followed (as mentioned in sections 3.3.2.2.6). 
 
3.3.3 Ex vivo splicing testing: 
3.3.3.1 Transfection: 
Transient transfection experiments were applied for the generated constructs in 
two cell lines: A549 and Cos7 cells (fibroblast-like cells derived from monkey 
kidney tissue). The latter was used as a comparative cell line (due to its high 
transfection efficiency) (Cooper, 2005). Interestingly, the Cos7 cells were 
VKRZQ WR EH DPRQJ WKH FHOOV WKDW GR QRW H[SUHVV Į-nAChRs (Cooper and 
Millar, 1997). Three independent experiments were run for each construct in 
both cell lines. Empty exon trap vector was used in the transfection mixture 
compared to transfection with plasmid-inserts constructs. This step was 
included to confirm that  the origin of the expressed transcripts with exon 9b 
are due to an exon sequence inserted within the exontrap vector sequence and 
do not originate from the transfection per se.    
 
 
The effect of single nucleotide base                                                     Chapter 3                                                   
 234 
3.3.3.2 Cell culture: 
For A549 and Cos7 cells, the same media and conditions for growing the cells 
were used (as described in section 2.6.1). 24 hr prior to transfection, the target 
cells were seeded into 60 mm2 dishes (7.5 ൈ 105 of A549 cells/dish and 3.75 × 
105 of Cos7 cells/dish). The cells were tested using a light microscope for 
viability and confluency before and after each step, and only confluent cells 
(50-80%) were used for transfection.  For each transfection experiment, 1 µg of 
the construct DNA was mixed with 9 µl of TRANS-FAST transfection reagent 
(Promega) and 2 ml of serum-free DMEM. After vortexing the mixture, it was 
incubated for 15 minutes at room temperature to be ready for use with the 
target cells. Then the old medium was removed from the cells and PBS cell 
washing was applied before adding the prepared transfection mixture. The 
latter was added slowly to the cells (to avoid excessive detachments, couple of 
cells detached were considered acceptable) and this was followed by 
examining the cells under the microscope for possible detachments. Once 
checked, the cells were incubated with the transfection mixture for 1 hr at 37°. 
After incubation, cells were examined before and after adding 4 ml of DMEM 
slowly. This was followed by incubating the cells for further 24 hr. On the next 
day, the RNA of transfected cells was prepared to allow for subsequent 
transcript testing. 
 
3.3.3.3 RNA extraction and cDNA generation: 
Following 24 hr of transfection, RNA was extracted from A549 and Cos7 cells 
(as mentioned in section 2.6.2). The extracted RNA was used for generation of 
cDNA as a template for RT-PCR (as mentioned in section 2.6.3). 
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3.3.3.4 RT-PCR: 
Similar protocol and methods were used for RT-PCR mentioned in section 
2.6.4, except for the primer sets used (Table 3-6). 
 
Table 3-6: Nucleotide sequences of the primers used for exon 9b minigene 
construct sequencing. 
Primer ID 3ULPHUVHTXHQFHCĺC Position  
PET01S GATCGATCCGCTTCCTG 5` ET exon 
PET01AS CGGGCCACCTCCAGTG 3` ET exon 
All primers are from Eurogentec, Belgium. 
ET: exon trap vector, S: Forward primer, AS: reverse primer. PET01S & PET01AS 
are exontrap primers that anneal to the  5` and 3` exons of the vectors, respectively. 
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3.3.3.5 Confirming the sequence of the amplified transcripts:  
Following RT-PCR amplification, the detected products were gel extracted (as 
mentioned in section 2.6.7) and then sequenced (as mentioned in section 2.6.8) 
(Figure 3-7). 
 
Figure 3-7: Diagram showing the location of primers used for sequencing exon 9b 
minigene constructs. 
A: exon 9b short fragment. B: exon 9b long fragment. Blue boxes: exons (ET: 
exontrap exons: 5` and 3`), green arrows: forward primers, red arrows: reverse 
primers, black lines: flanking exontrap intron sequences, the expected sizes of 
the minigene constructs is shown on the right (boxed). Exon 9b size= 197 bp. 
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3.3.3.6 AlphaDigiDoc software and statistical analysis: 
To evaluate the relative percentage of mRNA expression for the exon 9b 
transcripts, the gel electrophoresis pictures were analysed using 
AlphaDigiDoc1201 software (similarly to the method mentioned on section 
2.6.11). The parameter used for comparisons was the band intensity for each 
transcript. To determine the relative percentage of expression of each transcript 
by A549 and Cos7 cells (for each gene transcripts), the ratio of band intensities 
of exon 9b-included/excluded transcripts was calculated and the correction for 
the size of products was applied. This was applied by dividing the intensity 
values of each band by the corresponding product size values (in bp).  
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3.4 Results: 
Following the detection of exon 9b transcripts (as mentioned in chapter 2), the 
sequences of exon 9b within intron 9 of both genes (CHRNA7 and 
CHRFAM7A) were analysed for detecting exon defining elements (such as the 
GT-AG splice sites flanking the exon, ESEs and ESSs). This was followed by 
amplifying exon 9b alleles from a heterozygous control subject (that expresses 
both alleles) to prepare exon 9b alleles that represent both genes, CHRNA7 and 
CHRFAM7A. The isolated alleles of exon 9b were then used as template for 
preparing exon 9b minigene constructs. 
 
3.4.1 Bioinformatics analysis: 
The detected exon 9b sequence was tested using several bioinformatics 
software programs. First, using Exon scan software, exon 9b sequence (from 
both genes) could not define exon 9b as a constitutive exon. Similar results 
were obtained using Gene scan software program (Burge and Karlin, 1997). 
The next step included testing exon 9b sequences from both genes for potential 
ESE and ESS using Human splicing finder, RESCUE-ESE, ESE finder and 
splicing rainbow software programs. The reason for using different software 
programs is that to test for recognition of the two bases in exon 9b (at positions 
77 and 154) to lie within ESEs or ESSs by one or more programs. A SNP 
check was applied using dbSNP and Ensembl databases. Finally, ClustalW 
software program was used for alignment of sequences from CHRNA7 and 
CHRFAM7A genes with those detected from transcripts of exon 9b. 
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3.4.1.1 Human splicing finder results: 
Using Human splicing finder program, the potential splice sites, branching 
point, predicted ESEs (PESE), predicted ESSs (PESS), PESE/PESS ratio, 
enhancer and silencer elements within the tested sequence were predicted. The 
splice donor, splice acceptor and the branch point sites where detected at 
exactly the same positions in relation to exon 9b (Table 3-7 & Table 3-8). 
 
Table 3-7: Summary for Human splicing finder results of exon 9b. 
 G-G allele C-A allele 
splice donor site position* -12 
-12 
splice acceptor site position* +2 
+2 
Branch point position* -31 -31 
PESE/PESS1 2.75 2.63 
PESE/PESS2 1 0.98 
*: position in relation to exon 9b (-: refer to upstream sequences,+: refer to exon 9b 
sequences), PESE1: using exon 9b short fragment, PESE2: using exon 9b long 
fragment. 
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Table 3-8: Collective results of Human splicing finder results (experimental and other In-Silico analysis web-based) for analysis of exon 9b alleles 
with their flanking 100 bp inronic sequences (representing short exon 9b fragments). 
In-Silico analysis E9b G-G allele E9b C-A allele 
- Position 77 Position 154 Position 77 Position 154 
RESCUE-ESE (Fairbrother et al., 2002) ctgaaG, tgaaGt - gaaCtg - 
PESE (Zhang, 2004) cctgaaGt - ctgaaCtg - 
EIE (Zhang et al., 2008) ctgaaG, gaaGtg - ctgaaC cccagA, ccagAc, cagAca 
ESE motif from HSF- (SR 9G8) gaaGtg - - ccagAc 
Silencer motif (Sironi et al., 2004)-motif2 tgaaGtgc - - - 
IIE (Zhang et al., 2008) tgaaGt, Gtgctt - - - 
ESR elements (Goren et al., 2006) ctgaaG, aGtgct cccagG - - 
PESE=predicted ESE, EIE=exonic identity elements, IIE=inronic identity elements, ESR: exonic splicing regulating. 
Underlined= Silencing sequences, upper case letters: represents corresponding exon 9b base (77 or 154), lower case letters: flanking exon 9b sequence  
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These results showed that the splice sites and branch points were identical for 
both exon 9b alleles. However, the predicted ESE/ESS ratio was higher for G-
G allele in both short and long exon 9b fragments.  
 
3.4.1.2 RESCUE-ESE results: 
RESCUE-ESE results showed that exon 9b sequence from CHRNA7 (G-G 
allele) would harbour 16 ESEs while the presence of C allele at position 77 (C-
A allele from CHRFAM7A) would predict one less ESE at this position 
making the total of 15 ESEs within exon 9b C-A allele (Figure 3-8). 
 
Figure 3-8: RESCUE-ESE test for exon 9b sequences. 
Exon 9b sequences from CHRNA7 (G-G allele) and CHRFAM7A (C-A allele) were 
subjected to RESCUE-ESE analysis. At position 77 (arrowed) two potential ESEs 
for G-G allele were compared to single different ESE for C-A allele (within red 
boxes). The rest of the predicted ESEs were the same in both sequences (data 
not shown). 
 
 
The effect of single nucleotide base                                                     Chapter 3                                                   
 242 
3.4.1.3 ESE-finder results: 
For further test of ESE effects, ESE finder program was used. The results 
expressed possible potential binding of five SR proteins to ESE sequences 
within exon 9b (Table 3-9) (Figure 3-9). 
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Table 3-9: ESE finder results for exon 9b alleles. 
SR proteins 
(threshold value) 
Exon 9b G-G allele Exon 9b C-A allele 
position77 Position 154 position77 Position 154 
SF2/ASF (1.956) ctgaaGt (2.3) cccagGc (2.05) - - 
IgM BRCA1 
(1.867) 
ctgaaGt (2.44) cccagGc (3.0) - ccccagA (2.4) 
Sc35 (2.383) - - - - 
SRp40 (2.67) - ccccagG (3.5) - - 
SRp55 (1.676) - - - - 
Sequence motifs for potential binding with SR proteins (shown on the left) are indicated for sequences at positions 77 & 154 of 
exon 9b from the two alleles (indicated). The threshold values (between brackets) are indicated for each motif detected and are 
FRQVLGHUHGµKLJK¶ZKHQWKH\DUHJUHDWHUWKDQWKHWKUHVKROGYDOXH 
Upper case letters: represents corresponding exon 9b base (77 or 154), lower case letters: flanking exon 9b sequence 
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Figure 3-9: ESE finder results for exon 9b alleles. 
Exon 9b alleles are shown on the left, and the two bases at positions 77 & 154 are 
indicated above (and arrowed). Potential SR protein binding (colour indicator is 
shown on left lower corner) to the alleles (exon 9b position) are: 1) G allele (77): for 
SF2/ASF & IgM BRCA1, 2) G allele (154) for SF2/ASF, IgM BRCA1 & SRp40, 3) C 
allele (77): for none; and 4) A allele (154) for IgM BRCA1. The nucleotide sequence 
tested is shown on the X-axis. The height of the bars indicate score values 
(represented on the Y-axis) while the width of the bars represent their nucleotide 
length and position within a given sequence (Cartegni et al., 2003). 
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3.4.1.4 Splicing rainbow results: 
Similarly, Splicing rainbow program was used to test for the SR proteins and 
the splicing inhibitors (hnRNPs) potential binding sites within exon 9b allele 
sequences (Figure 3-10 & Figure 3-11). 
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Figure 3-10: Splicing rainbow results for exon 9b G-G allele. 
Bases at positions 77 & 154 of exon 9b are indicated on top and arrowed on bottom. 
Potential SR protein binding sites for 1) G allele (77): SRp40, SRp55 & ASF/SF2, 2) 
G allele (154): SRp40 & SRp55, Potential splicing inhibitor factors (hnRNP) binding 
for 2) G allele (154): E1E2. 
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Figure 3-11: Splicing rainbow results for exon 9b C-A allele. 
Bases at positions 77 & 154 of exon 9b are indicated on top and arrowed on bottom. 
Potential SR protein binding sites for 1) C allele (77): SRp40, SRp55 & ASF/SF2, 2) 
A allele (154): SRp55 & 9GB. Potential splicing inhibitor factors (hnRNP) binding for 
2) A allele (154): E1E2. 
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A summary of the sequence motifs potential binding sites for enhancer and 
silencer elements at positions 77 and 154 of exon 9b from all used In-Silico 
analysis tools is represented in (Figure 3-12).  
 
 
Figure 3-12: Summary for enhancer and silencer potential sites at positions 77 
and 154 of exon 9b. 
Exon 9b alleles are indicated above (G-G & C-A). Potential enhancer motif sites are 
shown in green shapes, while potential silencing sites are shown in red shapes. Human 
splicing finder web-based multi-software analysis tool included results for predicted 
enhancer motifs (RESCUE-ESE, PESE, EIE, and ESE from HSF & ESE-finder) and 
predicted silencer motifs (motif-2 silencer, IIE, PESS & ESR elements). In addition, 
splicing rainbow results for potential enhancer motifs are shown. The results are 
shown in table form to show enhancer or silencer sequence motifs that included each 
allele of exon 9b (at position 77 and 154).  
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3.4.1.5 Screening for SNPs: 
To screen for possible SNPs located within exon 9b, Ensembl, dbSNP and 
Hapmap project databases were used. The two nucleotide base difference 
between the two genes exon 9b sequences were found to correspond to 
predicted positions for SNPs but with no genotype reported (rs286097 G/C and  
rs286098 G/A, for exon 9b bases at positions 77 & 154, respectively). 
However, very little is known about these two positions from the databases. 
These data indicates that each of the two positions was detected in few 
European individuals (Table 3-10). 
Table 3-10: dbSNP data for the two-nucleotide bases on exon 9b (at positions 77 
& 154, respectively). 
SNP detected Genotype detected Individuals tested 
rs286097 CG/CC/CC 3 
rs286098 AA/AG 2 
 
 
From the mentioned data above, it is evident that little is known about these 
two nucleotide bases and their ancestral origin is unknown. According to these 
results and as was shown previously (Makoff and Flomen, 2007, Flomen et al., 
2008, Araud et al., 2011) that an individual might have a single or rarely 
double deletion of CHRFAM7A or rarely a single deletion of CHRNA7 (as 
mentioned in section 1.3.4.1), we concluded the following genotypes for exon 
9b in a given population: 
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A) Individuals without SNPs affecting the two-nucleotide bases of exon 9b 
(at positions 77 & 154) would have double heterozygous alleles for 
exon 9b. This means (according to the reference sequence databases 
from NCBI) that individuals without SNPs affecting exon 9b bases at 
the above mentioned positions would have the G/C and G/A 
phenotypes at positions 77 and 154, respectively.  
B) Individuals with a SNP affecting one of the two-nucleotide bases of 
exon 9b would have a single heterozygous genotype. 
C) & D) Individuals missing both copies of CHRFAM7A or CHRNA7 
would have single heterozygous genotype, respectively (Table 3-11). 
 
Table 3-11: Possible exon 9b allele genotypes in individuals:   
Gene Allele sequence (in exon 9b) 
CHRNA7 copies CHRFAM7A copies At position 77 At position 154 
2 (or rarely 1) 2 (or 1) G/C G/A 
2 (or rarely 1) 0 (rarely) G G 
0 (rarely) 2 (or 1) C A 
This indicated that when an individual have the two genes, both exon 9b alleles could 
be detected (G-G and C-A). However, for individuals with only one of the gene, the 
corresponding exon 9b allele would be detected on genotyping exon 9b. 
 
This indicates that, when both genes are present on chromosome 15, 
sequencing of exon 9b will show a double heterozygous peaks at positions 77 
and 154 (G/C and G/A respectively).  
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3.4.1.6 Differences between intronic sequences flanking exon 9b:  
 
This was tested using ClustalW software program. The sequences of intron 9 
part upstream of exon 9b that were included in exon 9b fragments (short and 
long) were used for this purpose. The analysis detected three sites of 
differences in the sequence of intron 9 between the two genes and was given 
the sign (-) to indicate their upstream position in relation to exon 9b. These 
differences included single base at position -900, five bases at position -837 to 
-833, and at position -122 (Table 3-12) (Figure 3-13). However, when control 
subjects were tested for recognition of these differences (by using RT-PCR and 
sequencing) it showed that they actually do not exist and that there were no 
differences within intronic sequences from both genes at these positions (will 
be shown later). 
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Table 3-12: The sequence differences between exon 9b and flanking intronic parts of long/short exon 9b fragments. 
Gene/position Exon 9b allele Intron upstream of exon 9b 
Position1 77-Á -900* -837 to -833* -122* 
CHRNA7 G-G A TAAGA A 
CHRFAM7A C-A G - G 
1: position of nucleotide base related to exon 9b, *: nucleotide bases within intron 9 sequence (- : refers to upstream of exon 
9b) Á QXFOHRWLGH EDVHV ZLWKLQ H[RQ E VHTXHQFH (CHRNA7 accession number NM_00074 and CHRFAM7A accession 
number NM_139320.1, NCBI). 
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Figure 3-13: Sequence alignment of long exon 9b fragment from both genes. 
Long exon 9b fragment corresponding sequence from intron 9 of CHRNA7 and CHRFAM7A was subjected to sequence alignment using Clustal W software. 
Three differences were detected upstream of exon 9b: 1: at position -900, 2: at positions -837 to -833, 3: at position -122. 
Numbers on the right side indicate the sequence within intron 9.
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3.4.2 Preparation of minigene constructs: 
3.4.2.1 Screening genomic DNA for heterozygous exon 9b: 
)RUWKLVSXUSRVH³VKRUWH[RQE´SULPHUVZHUHXVHGXVLQJ3&56FUHHQLQJof 
11 control subjects, in addition to the genomic DNA of A549 and BE (2)-c 
cells, showed the detection of exon 9b in all of the subjects (Figure 3-14). 
 
Figure 3-14: Agarose gel electrophoresis for short exon 9b fragment 
amplification using RT-PCR. 
Testing genomic DNA samples for short exon 9b fragment (expected size =452 bp); 
Lanes 3-115: DNA of control subjects, A: DNA of A549 cells, BE: DNA of BE (2)-c 
cells. M: 100 bp DNA ladder, B: blank. 
 
 
The PCR products were sequenced and the results showed that control subjects 
48 & 50, in addition to A549, were of double heterozygous genotype (for exon 
9b bases at position 77 and 154), while all the other samples tested showed a 
single homozygous genotype (at position 77) and with only BE (2)-c cells 
showing double homozygous genotype (at both positions) (Table 3-13). 
Table 3-13: sequencing results for exon 9b genotype of the tested samples.  
Exon 9b allele genotype (G/C)* & (G/A)Á C* & (G/A)Á C*/AÁ 
Samples 48, 50, A549 3, 11, 37, 39, 45, 49, 69, 115  BE (2)-c 
Nucleotide base of exon 9b at position: * (77) and Á (154).  
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These results showed that BE (2)-c cells showing only exon 9b of C-A 
genotype that is matching that of CHRFAM7A. This is different from our 
earlier results where we could detect CHRNA7 more than CHRFAM7A in 
these cells (as mentioned in section 2.7.3). Thus, the detection of the C-A allele 
in BE (2)-c cells might suggest possible nucleotide polymorphisms within the 
WZR EDVHV RI H[RQ E IURP &+51$ *ĺ& DW SRVLWLRQ  DQG *ĺ$ DW
position 154).  
Control subject 48 was selected for subsequent analysis to generate the two 
alleles of exon 9b: G-G and C-A.  
6LPLODUO\³ORQJH[RQEIUDJPHQW´was tested in controls 48, 49, A549 and BE 
(2)-c cells (Figure 3-15). 
 
Figure 3-15: Agarose gel electrophoresis for long exon 9b fragment amplification 
using RT-PCR. 
Testing genomic DNA samples for long exon 9b fragment (expected size =1313 bp); 
Lanes 48-49: DNA of control subjects, A: DNA of A549 cells, BE: DNA of BE (2)-c 
cells. M: 100 bp DNA ladder, B: blank. 
 
 
These products were sequenced using exon 9b long primer set and the results 
are summarized in (Table 3-14), (Figure 3-16) and (Figure 3-17). 
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Table 3-14: Sequencing summary for the DNA samples tested. 
DNA tested Intron upstream of exon 9b Exon 9b genotype Expected gene of origin 
Position1 -900* -837 to -833* -122* 77 & 154Á - 
Subject 48 A TAAGA A G/C & G/A CHRNA7 & CHRFAM7A 
Subject 49 A TAAGA A C & G/A CHRNA7 & CHRFAM7A 
A549 A TAAGA NA G/C & G/A CHRNA7 & CHRFAM7A 
BE (2)-c A TAAGA NA C &     A CHRNA7 & CHRFAM7A 
1: position of nucleotide base related to exon 9b, *: nucleotide bases at intron 9 sequence (-: refer to upstream of exon 9b), Á: nucleotide bases 
within exon 9b sequence. (CHRNA7 accession number NM_00074 and CHRFAM7A accession number NM_139320.1, NCBI). No differences 
were found between the two alleles of exon 9b, mentioned in the reference sequence databases mentioned above, at positions -900, -837 to -833 
and -122 of intron 9 upstream of exon 9b.  
NA: non-applicable comparison, as the sequences at this position were not amplified or sequenced. 
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Figure 3-16: Sequencing result for intronic sequences upstream exon 9b. 
Sequencing for intronic sequences upstream of exon 9b (Black arrow: nucleotide base 
at position -900, grey arrow: nucleotide bases at positions -837 to -833). Genomic 
DNA tested from: (1) A549 cells, (2) BE (2)-c cells and (3) control subjects 48 & 49. 
The sequences at these positions were A (at -900) and TAAGA (at positions -837 to -
833) which match the CHRNA7 database reference sequence. Base colour reference: 
A=green, T=red, G=black, C=blue. Note that an apparent A peak in parts 2) and 3) is 
due to the flanking high peaks of A surrounding the G peak in the middle 
 
Surprisingly, these results were different from what was expected based on the 
reference sequences used while designing the primers (Figure 3-13). This 
meant that both genes, CHRNA7 & CHRFAM7A, had no differences at 
positions suggested by the reference sequence. 
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Figure 3-17: sequencing results for exon 9b sequences. 
Sequencing for exonic sequences of exon 9b (Black arrow: nucleotide base at position 
77, grey arrow: nucleotide base at position 154). Genomic DNA tested from: (1) A549 
cells, (2) subject 48, (3) BE (2)-c cells and (4) other subjects (including subject 49). 
A549 and subject 48 showed double heterozygous expression at positions 77 & 154 of 
exon 9b, single heterozygous expression (at position 154 of exon 9b) could be 
detected in other subjects, while homozygous genotype was detected from BE (2)-c 
cells. Base colour reference: A=green, T=red, G=black, C=blue.  
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The sequencing results could not detect the sequence difference between the 
two genes (in the intron upstream of exon 9b) at positions -900 and -837 to -
833 (upstream of exon 9) as shown in the reference sequence (Table 3-12) 
(Figure 3-13). Meanwhile, regarding exon 9b sequence, A549 cells and subject 
48 showed double heterozygous genotype (with no possible polymorphic 
changes at either exon 9b bases) while BE (2)-c cells showed homozygous 
genotype (possibly due to polymorphisms at both exon 9b bases) and other 
subjects showed only single heterozygous genotype (at position 154) (possibly 
due to single polymorphism at position 77) (Figure 3-17).  
 
3.4.2.2  TA cloning for exon 9b PCR products: 
Exon 9b fragments (long and short) from control subject 48 (that were 
amplified using PCR (Figure 3-14 & Figure 3-15)) were inserted into the pSC-
A-Amp/Kan vector using TA cloning technique. This was followed by 
screening for G-G & C-A alleles constitution prior to extraction using the 
restriction enzyme Eco57I. The most striking digested fragment for G-G allele 
(helped to differentiate it from C-A allele) was of 150 bp size. 
This screening test was followed by sequencing several G-G and C-A alleles of 
exon 9b fragments (short and long) throughout the whole fragment sequence to 
ensure the compatibility of the fragments with the reference sequences and that 
the only difference between the two constructs was the two bases at positions 
77 and 154. The sequence of the clones matched exactly the reference 
sequence that were used for minigene construct subsequent preparation. 
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3.4.2.3 SalI and XbaI restriction: 
The restriction digestion using SalI and XbaI showed expected band size of 
corresponding exon 9b fragment (short=452 bp, long =1313bp) (Figure 3-18). 
 
 
 
Figure 3-18: Agarose gel for restriction digestion using SalI & XbaI for exon 9b 
short & long fragments. 
Upper panel: exon 9b short fragment (452 bp size product-arrowed), Lower panel: 
exon 9b long fragment (1313 bp size product-arrowed). D: digested DNA, U: 
undigested DNA. Similar results were detected for both exon 9b alleles. M: Upper 
panel= 100 bp DNA ladder, lower panel=1kb DNA ladder. 
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Once the sequence was confirmed, each allele was subjected to further DNA 
extraction step using midiprep system to generate minigene constructs in 
amounts required for the transfection step. 
 
3.4.2.4 Site directed mutagenesis: 
Once prepared, these constructs were first confirmed to match the reference 
sequence target (except for the substituted base) by sequencing, and then they 
were subjected to midiprep system for generating extra amounts for 
transfection experiments (Figure 3-19). 
 
Figure 3-19: sequencing results for minigene constructs generated by site-
directed mutagenesis. 
Sequencing at positions 77 & 154 of exon 9b (Black arrow& grey arrow, 
respectively). 1) G-A allele, 2) C-G allele. Base colour reference: A=green, T=red, 
G=black, C=blue.  
 
 
3.4.3 Transfection: 
Following preparation of all four minigene constructs of exon 9b, they were 
used for transfection experiments (Figure 3-20). 
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Figure 3-20: Summary for transfection of minigene constructs of exon 9b. 
A549 and Cos7 cells were transfected using the four minigene constructs prepared (G-
G, C-A, G-A & C-G), in addition empty vector (V) and non-transfected cells as a 
control (C). 
 
3.4.3.1 Testing for transfection results: 
For this purpose, RNA was extracted from the transfected cells 24 hr following 
transfection start. This was followed by cDNA preparation to use as a template 
for RT-PCR with exon trap primers (Table 3-6). 
 
3.4.3.2 RT-PCR results: 
During the initial runs, it was noticed that the results prediction was affected by 
the position of the PCR product applied in the electrophoresis tank as more 
ethidium bromide seemed to be concentrated in the upper half of the tank 
affecting the brightness of the products bands compared to the lower half with 
less ethidium bromide and hence less brightness of all bands that affected the 
AlphaDigiDoc analysis results (Figure 3-21). 
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Figure 3-21: Agarose gel electrophoresis for optimising RT-PCRs using exon trap primers. 
Two alleles were compared (G-G and C-A) from two exon 9b fragments minigene constructs short. These constructs were transfected into A549 cells. Product 
size (arrowed): exon 9b-included transcripts (+E9b) =439 bp and exon 9b-excluded transcripts (-E9b) =242 bp.  10 replicates of each allele were tested using 
exon trap primers in RT-PCR. A) Testing G-G allele (in the upper half of electrophoresis tank using the upper sample row) & B) Testing C-A allele (using the 
lower half and row). M: 100 bp DNA ladder, B: blank. 
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It is clear from these results that the upper half of the gel picture seems more 
bright and thus might affect the AlphaDigiDoc analysis as the lower row 
showed only very intensely stained bands (exon 9b including transcripts) 
compared to the bottom bands (missing exon 9b). This led to the preference of 
using only the upper row of samples for gel electrophoresis for all the 
subsequent analysis to help maintain the consistency of the results.  
First, exon 9b long and short fragments minigene constructs (G-G & C-A) 
were tested for exon 9b inclusion in A549 and Cos7 cells in three independent 
experiments (Figure 3-22). 
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Figure 3-22: Agarose gel electrophoresis for first RT-PCRs using exon trap primers. 
Two alleles were compared (G-G (GG) and C-A (CA)) from two exon 9b fragments minigene constructs: long (L) and short (S). These constructs were 
transfected into two cell lines: A549 (1) and Cos7 (2). Product size (arrowed): exon 9b-included transcripts (+E9b) =439 bp and exon 9b-excluded transcripts 
(-E9b) =242 bp. ET: exontrap exons 5` & 3`. M: 100 bp DNA ladder, B: blank. 
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Exon 9b was included in all PCR products but the C-A allele constructs in both 
cell lines showed more remarkable expression of exon 9b transcripts than the 
G-G allele constructs. It is worth noting that there was no noticeable difference 
that could affect the expression of exon 9b between the exon 9b short and long 
fragments.  
The next step included testing exon 9b short minigene constructs (G-G, C-A, 
G-A & C-G) to test the effect on these nucleotide base changes on exon 9b 
inclusion. These minigene constructs were tested in two cell lines (A549 and 
Cos7 cells) in three independent experiments (Figure 3-23). 
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Figure 3-23: Agarose gel electrophoresis for second RT-PCRs using exon trap primers. 
Four alleles were compared (G-G (GG), C-A (CA), G-A  (GA) & C-G (CG)) from exon 9b short fragment minigene constructs. These constructs were 
transfected into two cell lines: A549 (1) and Cos7 (2). Product size (arrowed): exon 9b-included transcripts (+E9b) =439 bp and exon 9b-excluded transcripts 
(-E9b) =242 bp. ET: exontrap exons 5` & 3`. M: 100 bp DNA ladder, B: blank. 
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Again, exon 9b was included in all PCR products but the C-A and C-G allele 
constructs showed more remarkable expression of exon 9b transcripts than the 
other two alleles (G-G and G-A). 
All the products from the RT-PCR were first gel extracted and then were 
sequenced and all the results came back matching the reference sequences 
expected. 
Following transfection of the four exon 9b short fragment constructs, the same 
cDNA extracted from A549 cells was tested for CHRNA7 and CHRFAM7A 
main transcripts. This test aimed at testing a possible effect of transfection on 
expression of the two main transcripts for both genes (full length and missing 
exon 9). The results matched the previous results obtained for A549 cells, 
showing a relatively similar ratio of expression of full length: missing exon 9 
for both genes, and a much more CHRFAM7A compared to those of CHRNA7 
under the same conditions (Figure 3-24). 
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Figure 3-24: Comparison of the relative expression of CHRNA7 and 
CHRFAM7A main transcripts in exon 9b-transfected A549 cells. 
A) CHRNA7 main transcripts. B) CHRFAM7A main transcripts. RT-PCR was run 
using cDNA from exon 9b-transfected A549 cells as template. Four alleles were 
compared (G-G (GG), C-A (CA), G-A  (GA) & C-G (CG)) from exon 9b short 
fragment minigene constructs using specific primers (CHRNA7=exons 1-10; 
CHRFAM7A=exons A-10). Two major transcripts were detected, full length (FL) and 
missing exon 9 (-E9) (arrowed). M: 100 bp DNA ladder, B: blank. 
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3.4.3.3 AlphaDigiDoc analysis: 
This software analysis is a type of densitometric analysis for semi quantitative 
measurement of the band intensities on agarose gel electrophoresis. Following 
each RT-PCR run, the products were subjected to agarose gel electrophoresis 
and the visualized bands were subjected later to AlphaDigiDoc software 
analysis. The band intensity was the main parameter used and the exon 9b-
excluded transcripts (lower bands on gel electrophoresis) were used as an 
internal control for each minigene construct. The analysis included calculation 
of the ratio of transcripts with/without exon 9b inclusion adjusted for the size 
of the bands used (as the upper band, with exon 9b-included, is of 439bp size 
while the lower one, without exon 9b, is of 242 bp size) (Figure 3-25).  
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Figure 3-25: AlphaDigiDoc analysis for the exon 9b inclusion/exclusion transcript 
ratios of minigene transfection experiments. 
The ratio of band intensity for exon 9b-included/excluded (E9b (+/-)) transcripts 
resulted from transfection of minigene constructs into A549 and Cos7 cells. The 
minigene constructs used were G-G (GG), C-A (CA), G-A (GA) & C-G (CG) from 
exon 9b long (L) or short (S) fragments with number of replicates indicated (between 
brackets). The ratio corrected for size is shown. For all the data presented, the average 
of three independent experiments was used and the standard deviation and standard 
error of the mean were calculated (the latter is shown on the bars). 
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The results showed that position 77 seem to be the key element in transcript 
determination and that the presence of C allele at this position enhanced the 
inclusion of exon 9b compared to the correspondent G allele. This can be 
shown as follows: for A549 cells, the band intensity ratio was increasing from 
0.45 for G-G allele (GGL) to nearly double up to 0.83 for the corresponding C-
A allele (CAL). Similarly, the G-G allele (GGS) and G-A allele (GA) showed a 
0.6 ratio that increased up to 1.5-1.25 fold (up to 0.9 and 0.8) when the 
corresponding C-A allele (CAS) and C-G allele (CG) were compared. Similar 
results were shown for Cos7 cells, with more consistent results showing almost 
double- fold increase in the band intensity ratio from 0.4 for all G-G alleles 
tested to 0.7 for all C-A alleles tested (Table 3-15). 
Table 3-15: Summary of AlphaDigiDoc results for minigene constructs of exon 
9b. 
 Minigene constructs  
Cells tested 
A549 Cos7 
GGL 0.45 0.4 
CAL 0.83 0.7 
GGS 0.6 0.42 
CAS 0.9 0.74 
GA 0.6 0.43 
CG 0.8 0.7 
The values shown represent the band intensity as tested by using AlphaDigiDoc 
software analysis adjusted for size of the RT-PCR product (intensity of exon 9b-
inserted RT-PCR products/intensity of exon trap exons RT-PCR products. 
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3.5 Discussion:  
The work in this chapter focused on testing the effect of the two nucleotide 
bases (at positions 77 and 154) on CHRNA7 and CHRFAM7A transcripts. Our 
results suggested that the G77 allele harboured more silencing elements than 
the C77 allele. This was followed by preparing exon 9b minigene constructs 
and both exon 9b alleles (G-G from CHRNA7 and C-A allele from 
CHRFAM7A) were expressed in A549 and Cos7 cells. However, the 
expression of C-A allele was more than that of the G-G allele. We next aimed 
at testing single nucleotide effects. The results again were similar with all exon 
9b alleles expressed in the same cells, but with C-containing alleles being 
expressed more than G-containing comparatives at position 77. These results 
explains why exon 9b transcripts were detected after amplifying CHRFAM7A 
but not CHRNA7A transcripts in cells tested (A549, BEAS2B, and BE (2)-c). 
 
3.5.1 Earlier results on exon 9b transcripts: 
In the current study, I tested for the possible effect of a single nucleotide base 
change on exon inclusion in transcripts of CHRNA7 and its duplicated gene, 
CHRFAM7A. Earlier results showed that transcripts with inserted sequence 
between exons 9 and 10 could be detected when amplifying exons 7-10 (Figure 
2-27, section 2.7.2). As this part is common between CHRNA7 and 
CHRFAM7A, it was possible to originate from either gene. However, after 
using sequence alignment and comparing the detected sequence with intron 9 
parts from both genes, the inserted sequence was confirmed to match the 
reference sequence of intron 9 of CHRFAM7A using NCBI and UCSC 
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genome browser databases (Figure 2-31, section 2.7.2.1.2). CHRFAM7A is a 
partial duplication of CHRNA7 that has exons 5-10 almost completely 
identical (Gault et al., 1998). However, there are still some differences within 
the introns connecting these exons when aligning such sequences from both 
genes. The main difference between the two genes within exon 9b sequence 
was the two bases at positions 77 and 154 of the exon. These bases were both 
G in CHRNA7 sequence and C & A (respectively) in CHRFAM7A sequence. 
This fact led to the following question: Do these two bases affect exon 9b 
inclusion?  
3.5.2 The effects of exonic sequences on exon inclusion: 
A proper RNA splicing will include all constitutive exons and remove all 
introns and pseudo exons (Robberson et al., 1990). However, sometimes 
splicing might include cassette (alternatively spliced) exons that are not present 
in all the mRNA transcripts, and that might be included during specific cellular 
requirements (as a part of a control mechanism) (Wang et al., 2006). 
There are a group of factors that might help to direct the spliceosome towards 
(or away from) a specific exon. These factors are known collectively as the 
exonic splicing regulatory elements (ESRs) and are grouped into two parts, 
based on their influencing effect, into enhancers or silencers (Zhang et al., 
2008). During RNA splicing, the splicing factors start screening the pre-mRNA 
sequence for sequence motifs that can bind to enhancers and silencer elements. 
This is supposed to be followed by the binding of corresponding enhancer and 
silencer proteins and the net effect are directed towards the more prevalent 
group (enhancer or silencer) (Sironi et al., 2004). This might explain the reason 
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behind including constitutive exons rather than pseudo exons in spite of the 
latter overwhelming the former in more than 10- fold.  
From a splicing point of view, exons were supposed to be classified into 
constitutive, alternatively spliced and pseudo exons (Zhang, 2004). By 
comparing ESE and ESS within each type of these exons, it was evident that 
when the ratio of ESE to ESS (PESE/PESS) is higher, the chances of exon 
inclusion are increased (Table 3-16). 
 
Table 3-16: Results for PESE/PESS among different exon types. 
Exon type PESE/PESS 
Constitutive 5.5 
Alternatively spliced 3.6 
Pseudo exon 0.64 
Summarised from (Zhang, 2004) 
 
In addition to enhancer and silencer elements, other factors play an important 
role in defining exons such as splice sites, intron sizes and SR proteins (Dewey 
et al., 2006) and the overall interaction of these factors with the dominant 
effector (enhancer or silencer) interact together. 
There is a growing body of evidence that enhancers and silencers compete for 
settling in or getting rid of the spliceosome, respectively. This seems clearer on 
changing a single nucleotide base within ESE or ESS sequences, an effect that 
can change the entire function of such a sequence in the opposite direction 
(Sironi et al., 2004, Wang, 2004, Zhang, 2004). These minor changes can have 
a huge impact on changing exon status in either way from inclusion to 
exclusion or vice versa (Kashima and Manley, 2003, Buratti et al., 2004, 
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Cooper et al., 2009, Vezain et al., 2010). It was supposed that enhancer 
elements act by recruiting spliceosome and antagonising effects of silencer 
elements, influencing exon inclusion (for constitutive exons), whereas the 
silencers predominate the overall effects when pseudo exons are enrolled for 
spliceosome scanning (Fairbrother and Chasin, 2000).  
3.5.3 Using bio-informatics tools to test for the effects of exon 9b bases: 
Exon Scan software was used which could not predict exon 9b as possible 
transcripts of both genes. This result confirms the other results tested this 
sequence and could not detect a constitutive exon sequence using PESE/PESS 
ratio (Table 3-7). The next step included checking for a possible SNP site 
within the two base sites. The results came back with scarce information (with 
no ancestral origin and the fact that the results included test in few individuals) 
rendering the information less important and could not name these two 
positions as SNPs (Table 3-10).  
Other differences within intron 9 (upstream of exon 9b) were detected using 
NCBI and UCSC genome browser databases (Table 3-12).  
The next step was using In-Silico analysis using multiple software analysis 
tools for exploring enhancer and silencer motifs surrounding exon 9b positions 
77 and 154. The two main sequences compared were exon 9b short fragments 
of G-G and C-A alleles. First, the Human Splicing Finder tool was used, which 
comprises more than eight based-in software analysis tools that apply multiple 
functions. The first parameters compared between the two alleles were the 
splice sites and branch points and these were exactly matching between both 
alleles. The next part included analysis for enhancer and silencer elements 
within exon 9b and their flanking 100 bp intronic sequences. This analysis 
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showed that the G77 allele was more enriched with ESE sequences than C77 
allele based on analysis from RESCUE-ESE, ESE-finder and other Human 
splicing finder-based experimental tools (Table 3-8). Similar results were 
obtained when using RESCUE-ESE, ESE-finder software program 
independently via their specific website. In addition, splicing rainbow software 
analysis tool was used and it showed similar results for both alleles in terms of 
enhancers and silencers around the two bases compared. However, Human 
splicing finder is wealthier with analysis tools, and the silencer testing showed 
that more silencer elements were clustered around G77 site (Table 3-8 and 
Figure 3-12). Taking into account all these results, it seems that G77 site is 
attracting more silencer elements than C77 site within exon 9b, although G77 
seem to have more potential binding preferences to enhancer elements than 
C77. The In-Silico analysis tools were confirmed of high accuracy in predicting 
ESE sequence motifs but were also suggested not to include all potential ESE 
sites. The same can be true for silencer elements, increasing the challenge for 
predicting exactly enhancer and silencer elements for a given sequence prior to 
experimental testing for the effect of a specific sequence on splicing (Goren et 
al., 2006). It is worth mentioning that the ratio of predicted ESE/ESS 
(PESE/PESS) was higher for G-G allele than for C-A allele in the short exon 
9b fragments (Table 3-7). However, this ratio was almost equal when long 
exon 9b fragment sequences of the two alleles were compared, indicating that 
more silencer elements for G-G allele or more enhancer elements for C-A 
allele were included. Our results showed that there was no single difference 
within the intron 9 part included in exon 9b long fragment apart from bases 77 
and 154 of exon 9b (Table 3-14). Similarly, RESCUE-ESE detected two 
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different ESE at G77 compared to one at C77 (Figure 3-8). The fact that a 
single nucleotide mutation can change ESE sequence into an ESS or even 
create a new silencer element should be borne in mind (Fairbrother et al., 2002, 
Zhang et al., 2005, Kashima and Manley, 2003). Another important 
observation is that A154 seemed to be a potential binding site for SR-9G8 
when Splicing Rainbow software program was used) (Figure 3-11). This 
protein was detected as a silencer in one study on human tissue, but in other 
studies it was shown to be enhancing transport to the cytoplasm for some viral 
mRNA infecting human body (Hurst et al., 2013, Boyd, 1997, Albuquerque et 
al., 2009). Based on the results found in this study, A154 had a minor effect on 
including exon 9b, but it might have a secondary role to C77 in helping such an 
mRNA transcript to be transported to the cytoplasm for subsequent translation. 
 
3.5.4 The preparation and testing of exon 9b minigene constructs: 
After completing the bioinformatics analysis, the aim was to prepare the two 
alleles of exon 9b. For this purpose, genomic DNA samples from control 
subjects were screened for exon 9b using a specific primer set that anneals to 
exon 9b flanking introns (around 100 bp each side) to generate short exon 9b 
fragment. Furthermore, an additional forward primer was designed upstream of 
exon 9b farther than the first forward designed primer by about 850 bp to 
generate exon 9b long fragments (Table 3-2). 
Only two control subjects were shown to have the two alleles of exon 9b, in 
addition to A549 cells, while the rest of the control subjects were shown to 
express a single heterozygote exon 9b at position 154 and only BE (2)-c cells 
expressed double homozygote exon 9b (Table 3-13). It is worth noting that BE 
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(2)-c cells showed higher expression of CHRNA7 than CHRFAM7A 
transcripts (Figure 2-38, section 2.7.3). The detection of C-A rather suggests 
possible polymorphism at the two base positions of exon 9b (77 & 154).  
These results led to the following question: Are either of these alleles at 
positions 77 and 154 the result of a SNP? Therefore, which allele is the 
original sequence and which one is possibly polymorphic. Moreover, if there 
was a polymorphism, did that SNP change took place before or after CHRNA7 
duplication? This might be explained in part by the detection of C only at 
position 77 in 8 out of 10 control subjects. In addition, BE (2)-c cells expressed 
transcripts from both genes (CHRNA7 and CHRFAM7A) but were expressing 
double homozygote allele at positions 77 and 154 of exon 9b, adding a further 
evidence that the ancestral allele is probably C-A.  
Earlier results in this study showed that the TG at positions 67-68 of exon 6 of 
CHRFAM7A were missing from three cells tested (A549 and PBMC) (as 
mentioned in section 2.8.2). This suggested that the orientation of this gene in 
relation to that of CHRNA7 is in a tail-to-head arrangement (Araud et al., 
2011, Flomen et al., 2008). In addition, each of the cells tested could have no, 
one or both CHRFAM7A copies (Flomen et al., 2006) which might explain the 
different peaks for G-G and C-A alleles at positions 77 and 154 of exon 9b 
(Figure 3-17). This figure summarised the results of sequencing of exon 9b 
short fragment amplified in A549 and BE (2)-c cells in addition to 10 control 
subjects. The C-A peaks for A549 were higher than those of G-G peaks (in a 
ratio of 2:1). This could suggest that there might be only a single copy of 
CHRNA7 in these cells (that is already rarely occurring). The other possible 
explanation is that the C-A was the ancestral allele and that a G-G double 
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mutation within CHRNA7 sequence took place in only one copy of the gene, 
explaining the peak difference. For BE (2)-c cells, the opposite is true and there 
was no mutation at these positions reflecting only one dominant C-A allele 
(earlier results showed that these cells express both CHRFAM7A and 
CHRNA7, but the latter was expressed much more than the former, a finding 
that was opposite to all other tested cells). Regarding the control subjects, they 
were clustered into two main groups:  the double heterozygote exon 9b, with 
the two alleles (G-G and C-A) expressed equally, and the single heterozygote 
exon 9b, with a single peak for C allele at position 77, and a double peak at 
position 154 (higher peak for A than for G in a ratio of 2:1). The double 
heterozygote control subjects showed that they contain almost equal copies of 
the two genes (this was used as a template for subsequent preparation of 
minigene constructs). The single heterozygote group suggested a single 
mutation at position 154 of CHRNA7 took place and involved only one of the 
two gene copies (explained by the small peak height). 
The other differences within intron 9, upstream of exon 9b, that were included 
in long exon 9b fragment (Table 3-12) FRXOGQ¶WEHGHWHFWHGIURPDPSOLILHG57-
PCR products of A549, BE (2)-c cells and two control subjects (representing 
single and double heterozygotes at positions 77 and 154 of exon 9b) (Table 
3-13 & Figure 3-16). This meant the different bases within intron 9 of both 
genes could represent an error in the database. Apart from the two bases at 
positions 77 and 154, the rest on intron 9 part included in exon 9b constructs 
was completely matching between the two alleles. This meant that intronic 
sequences embedded within the databases were less reliable than the coding 
sequences, and possible errors might exist within such sequences. 
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The next step included preparation of the minigene constructs. The double 
heterozygote samples were selected as the target for construct preparation (as 
the two alleles of exon 9b were detected in almost equal proportion). First, 
exon 9b short fragment constructs were prepared, and then exon 9b long 
fragments were prepared. The fragments were then inserted into exon trap 
vector for subsequent transfection assays. The prepared exon 9b alleles were 
inserted into the multiple cloning site of exon trap flanked by intronic 
sequences followed by an exon on both sides. The only difference between the 
short and long exon 9b fragment constructs was about 850 additional bases of 
intronic sequences upstream of exon 9b. However, the transfection results 
showed that all the constructs expressed exon 9b transcripts in both cell lines 
used (A549 and Cos7 cells), although in different ratios (Figure 3-22). The C-A 
allele constructs expressed more exon 9b than the G-G allele highlighting a 
possible effect attributed to the base constitution at these two positions (77 and 
154) of exon 9b.  
Is it position 77 or 154 that has the major influence on exon 9b inclusion? To 
answer this question, site directed mutagenesis was used to generate constructs 
with additional possible exon 9b alleles: G-A and C-G alleles. As there was no 
noticeable difference when comparing exon 9b short and long fragments, the 
former was used as a template for the mutagenesis preparation, targeting the 
nucleotide at position 154. Thus a new set of ex vivo splicing experiments was 
carried out (using the same cell lines used above) and showed similar results, 
with C-A and C-G alleles including more exon 9b than G-G and G-A alleles 
(Figure 3-23). These results suggested a major role for the C-allele at position 
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77 of exon 9b to enhance its inclusion in the mRNA transcript. The DNA 
sequence for the constructs used was identical except at positions 77 and 154. 
 Next, we aimed to test for possible effects of transfection of cells with exon 9b 
minigene constructs on the transcription process within the transfected cells 
using RT-PCR. The results matched those detected earlier on A549 cells, with 
the two main transcripts and the two genes expressed at similar ratios (Figure 
3-24). To quantify exon 9b expression between the different constructs used, 
the UV picture of the gel electrophoresis of the RT-PCR products was 
subjected to densitometric analysis. For this purpose, AlphaDigiDoc1201 
software was used, taking into consideration the density of upper band 
brightness (that included exon 9b) as the comparator. In addition, the density of 
the lower band brightness (with no exon 9b) was used as an internal control, 
and accordingly the ratio of exon 9b-included/excluded transcripts was 
measured and compared across all constructs used. It is worth mentioning that 
exon 9b-included transcripts measured larger than exon 9b-excluded transcripts 
(439 bp sizes compared to 242 bp sizes, respectively). This raised the need for 
using a correction for the size of the two bands accordingly to omit the size 
difference factor that might influence more ethidium bromide chelation with 
larger size products. However, the results were almost matching with and 
without correcting for size difference, with all the results showing again a 
major effect of C-allele at position 77 (Figure 3-25). 
Taking together the ex vivo splicing assays and the In-Silico analysis data, it is 
clear that the potential silencer elements that could bind to G77 can be more 
powerful than the enhancer elements competing for the same site resulting in 
lower overall inclusion ratio of exon 9b G-G allele. Considering the same 
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concept, it is possible to conclude that the absence of potential silencer 
elements binding to C77 is less interfering with C-A allele on exon 9b 
inclusion, increasing its inclusion rate.  
The effect of the inclusion of exon 9b on secondary protein structure was tested 
on secondary protein structure using PSIPRED software analysis (as shown in 
section 2.7.6.2.4). The results showed that inclusion of exon 9b within both 
predicted proteins would have the same effect as missing exon 9 (Figure 2-59, 
C & D), with the protein having three TMDs and an intracellular, rather than an 
extracellular, carboxy terminal end. Surprisingly, the translation was shown to 
be ended by a premature stop codon just before position 77 of exon 9b 
indicating that exon 9b would not be translated completely into the subsequent 
protein. This result shed the light on the importance of such a transcript in the 
control mechanism that CHRFAM7A has under normal conditions to suppress 
expression of CHRNA7 and its protein. 
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3.6 Conclusions 
The results shown in this chapter confirm that the nucleotide base at position 
77 of exon 9b has a dramatic effect on exon inclusion within the mRNA 
transcripts. In the case of the C77 allele, the chances of including the exon 9b 
sequence were increased compared to the G77 allele. These results suggest that 
a C-base at this position favours exon 9b inclusion. Taking into consideration 
that most bio-informatic analysis tools of exon 9b sequences showed that the 
G77 can act as a greater potential enhancer sequence than C77, it is worth 
noting that C77 escaped binding to many silencer sequences. Taking all of 
these results together including the minigene construct transfection results, it 
seems likely that G77 acts as a competition site for enhancer and silencer 
factors which ultimately drive exon 9b G-G allele into a low expression ratio 
that could be undetectable (as evident from earlier results of CHRNA7 
transcripts). In contrast, it seems likely that C77 acts as a more potent site than 
G77 in stabilising the spliceosome on exon 9b (no silencer potential binding 
sites were detected). This indicates that position 77 of exon 9b is crucial for 
inclusion within the mRNA transcripts depending on the nucleotide base 
included. However, there is still a room for suggesting a possible role of this 
transcript in the control mechanism theory of CHRFAM7A over CHRNA7 
during the normal (non-inflammatory) condition. This means that increased 
expression of exon 9b transcripts from CHRFAM7A can interfere wLWK Į
mRNA (from CHRNA7) affecting its expression. 
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4 *HQHUDOGLVFXVVLRQ 
4.1 CHRNA7 and CHRFAM7A transcripts: 
7KHUH LV D UDQJH RI KXPDQ GLVHDVHV WKDW DUH FDOOHG ³FKURQLF LQIODPPDWRU\
GLVHDVHV´ $PRQJ WKHVH LV &KURQLF 2EVWUXFWLYH 3XOPRQDU\ 'LVHDVH &23'
These diseases are characterised by a chronic inflammation that involve one (or 
more) tissues. On the other hand, the immune response in patients with these 
diseases sometimes seems to be defective and not counteracting the 
inflammatory changes. A normal response by the immune system to an injury 
or infection to human body tissues would be in the form of start of 
inflammation (Tracey, 2002). This reaction would involve activation of 
different cells that participate in one way or another to produce inflammatory 
mediators. Such mediators can help to repair the damaged tissues and suppress 
a threatening pathogen. However, this inflammatory response is regulated by 
the Central Nervous System (CNS) to be limited in time and magnitude to 
prevent further tissue damage, spread of inflammation to other body systems, 
and a possible change to chronic inflammatory status. The immune system is 
the active arm of the CNS and can limit the effect of inflammation via many 
SDWKZD\V$PRQJWKHVHLVWKH³FKROLQHUJLFDQWL-LQIODPPDWRU\SDWKZD\´ZKLFK
is mediated by the vagus nerve activation (Borovikova et al., 2000). The vagus 
nerve is well known for innervating a wide range of body organs and thus its 
role in limiting inflammation is vital to prevent progression of inflammation to 
sepsis (Wang et al., 2003, Wang et al., 2004). Although the vagus nerve is the 
key arm of the cholinergic anti-inflammatory pathway, its stimulatory signal 
requires another vital component to be delivered to the target organs. This 
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component is ³WKHDOSKD-QLFRWLQLFDFHW\OFKROLQHUHFHSWRUĮ-nAChR). It was 
shown that the absence of this receptor in an experimental model of 
inflammation could render the vagus nerve ineffective against inflammation 
and subsequent sepsis (Borovikova et al., 2000). The vagus nerve stimulates 
WKH Į-nAChR via acetylcholine (ACh), but nicotine can produce a similar 
effect to ACh and thus suppress inflammation. It was shown that chronic 
exposure to nicotine could lead to suppression of Į-nAChRs, which means 
that the immune response is partially impaired. Such an effect of nicotine was 
suggested to be the basis for a defective anti-inflammatory response in chronic 
smokers and in COPD patients (Kawashima et al., 2012).  
4.1.1 Do Į-nAChRs have a role in preventing lung inflammation?  
7KLV ZDV DQVZHUHG E\ XVLQJ D KXPDQ LQIODPPDWRU\ OXQJ PRGHO ZKHUH Į-
nAChRs were shown to mediate the anti-inflammatory pathway and suppress 
inflammation (Kox et al., 2011) 7KLV PHDQV WKDW IDFWRUV WKDW FDQ DIIHFW Į-
nAChRs expression or function might play a role in the development or 
progression of COPD. For this reason, it was necessary to try to understand the 
PHFKDQLVPV WKDW FRQWURO Į-nAChRs. This receptor is encoded by the 
CHRNA7 gene on chromosome 15, with its partial duplication (CHRFAM7A) 
located 1.6 Mb upstream of it (Gault et al., 1998). The complex regulatory 
mechanism between the two genes was uncovered recently and it shows a 
correlation with inflammation. It was shown that during the resting condition 
(no tissue injury or inflammation), CHRFAM7A is down regulating CHRNA7 
and thus limiting the receptor role in the anti-inflammatory pathway. However, 
once inflammation starts (in response to injury or infection) the released 
inflammatory mediators start down regulating CHRFAM7A and thus allowing 
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for an indirect CHRNA7 up regulation (Araud et al., 2011, Benfante et al., 
2011, de Lucas-Cerrillo AM, 2011). This effect will end up with expression of 
Į-nAChRs and a subsequent suppression of inflammation. This suppression 
would help to limit the effect of inflammation to the tissue involved and 
prevent a possible systemic spread and subsequent sepsis (Wang et al., 2003). 
This effect of CHRNA7 helps in its own regulation, and by suppressing the 
inflammatory mediators that blocked an earlier down regulation of 
CHRFAM7A (on CHRNA7) this would help the tissue to go back to the 
resting condition. 
There are a number of factors that could affect the regulatory role of 
CHRFAM7A on CHRNA7 which may interfere with the anti-inflammatory 
regulation of involved tissues. These include the copy number of both genes 
DQGWKHIDFWRUVWKDWDIIHFWWKHDVVHPEO\DQGIXQFWLRQRIWKHĮ-nAChRs. It was 
shown that CHRFAM7A is a recent evolutionary event that is unique to the 
human species and could not be detected in animals (Locke et al., 2003). 
However, the gene could not always be identified, and some individuals lack 
one or both copies of the gene (Riley, 2002, Araud et al., 2011). It was proved 
in many studies that the locus on chromosome 15 which harbours the 
CHRNA7 and CHRFAM7A (15q13-14) is subjected to a range of deletion and 
duplication events that affected the restructuring of this locus. Deletion and 
duplication events that affected the CHRNA7 helped creating the CHRFAM7A 
(Makoff and Flomen, 2007). Similarly, a whole deletion event might affect one 
both copies of CHRNA7 leading to different neuropsychiatric disorders 
(Shinawi et al., 2009, Hoppman-Chaney et al., 2013). Collectively the resulting 
deletion of either gene could affect the anti-inflammatory pathway. 
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7KH RWKHU IDFWRU WKDW FDQ DIIHFW WKH Į-nAChRs function significantly is a 
defective assembly. This receptor is a homopentamer that form by assembly of 
five subuniWVRIĮ-nAChRs around a central channel pore and changes to this 
architecture can affect the channel function and subsequent effect on 
inflammation (Galzi et al., 1992). The alternative RNA splicing could also 
DIIHFWWKHDVVHPEO\RIWKHĮ-nAChRs possibly by producing different protein 
isoforms of the receptor that could co-assemble with the wild type isoform. 
This can give rise to a somewhat heteropentameric structure of the receptor that 
was proved to affect the receptor and channel functions. Examples of such 
alternative transcripts were missing exon 8 (García-Guzmán et al., 1995), and 
inserted exon 9b (Saragoza et al., 2003). However, the co-expression of GXSĮ 
protein (translated from CHRFAM7A transcripts) gave similar results to co-
expression of alternative transcripts and all lead to a different co-assembly of 
WKHĮ-nAChRs. This effect changed the receptor into a non-functioning status. 
This is not necessarily always true, and the co-expression of transcripts with 
inserted exon 4a did not have an inhibitory effect on the receptor function 
(Severance and Yolken, 2008). Exon 4a transcripts were suggested to have no 
effect on the function of the receptor when co-assembled with the wild type 
subunits.  
Our results showed that CHRNA7 and CHRFAM7A both express a novel 
transcript that is missing exon 9. At the start of the work, we suggested that this 
effect might be due to tissue specific splicing factors that could be inactive and 
thus causing skipping of exon 9. As both genes have almost 100 % similarity in 
the sequences of exons 5-10 (Gault et al., 1998), it might be accepted to 
suggest that exon 9 splicing from both genes is under control of the same 
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splicing factors and SR proteins. If this is true, it might explain the reason for 
detecting missing exon 9 transcripts from both genes in the same cells. 
However, a possible effect due to tissue specific splicing should be ruled out as 
the same transcript missing exon 9 was detected from both genes in different 
human cell lines (A549, BEAS2B, BE (2)-c) and primary human cells 
(PBMC).  
It is important to remember that CHRFAM7A has a dominant negative effect 
on CHRNA7 during the resting condition (non-inflammatory). This effect is 
kept until the start of inflammation, which would reverse the roles of both 
genes ending up with H[SUHVVLRQ RI Į-nAChRs to start localising 
inflammation (Benfante et al., 2011, de Lucas-Cerrillo AM, 2011). Bearing in 
mind this fact, it might be possible to suggest the production of alternative 
transcripts (such as missing exon 9 transcript) as part of the regulatory 
mechanism of CHRFAM7A on CHRNA7. On the other hand, it might be also 
possible to suggest that CHRFAM7A is keeping CHRNA7 down regulated via 
enhancing production of missing exon 9 transcripts. These transcripts have no 
frame shift, and if translated (predicted using software programs, like 
PSIPRED) can form a protein similar to the wild type, except  that they are 
missing TMD 3 and have an intracellular carboxy terminus (rather than 
extracellular one in the wild type). If such transcripts were translated, they are 
expected to co-DVVHPEOHZLWKWKHZLOGW\SHĮSURWHLQDVZDVVKRZQLQother 
studies (discussed above). This could lead to the formation of non-functioning 
receptors and ion channels.  
In the present study, another novel transcript was detected from CHRFAM7A, 
which is inserted exon 9b. This transcript was detected from CHRFAM7A 
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transcripts only and not from those of CHRNA7. By referring to the reference 
sequence of both genes, we showed that exon 9b is actually part of the intron 9 
sequence. Interestingly, there were only two bases within exon 9b sequence (in 
both genes) different between both genes at positions 77 and 154 (from the 5` 
end of the exon). These nucleotide bases were both G in CHRNA7 sequence 
while they were C and A at positions 77 and 154, respectively for 
CHRFAM7A sequence. This meant that the exon 9b allele was G-G in 
CHRNA7 and C-A in CHRFAM7A at these two positions. Considering these 
two bases, these nucleotide bases might affect the spliceosome assembly on 
exon 9b in both genes differently leading to exon 9b expression from 
CHRFAM7A gene only. To test this effect, bio-informatics analysis showed 
that G77 (in CHRNA7) is harbouring more silencer sequence motifs than C77 
(in CHRFAM7A). Following these results, exon 9b minigene constructs were 
prepared to test for effects of the two bases on transcription. Four different 
exon 9b alleles were prepared (G-G, C-A, G-A, C-G) to cover the two bases 
within exon 9b from both genes for a possible splicing enhancer or suppressor 
effect. These constructs were transfected into A549 and Cos7 cells. Our results 
showed that the C-A exon 9b allele was expressed more than G-G allele in both 
cell lines. Further results revealed that the C77 have the superior effect on all 
other nucleotide bases in enhancing exon 9b inclusion in splicing. These results 
showed that a single nucleotide base might affect splicing and change inclusion 
or exclusion of exon 9b. 
It is tempting to suggest that exon 9b transcripts from CHRFAM7A could also 
play a role in the control of CHRNA7 transcripts via interfering with Į
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mRNA. However, all the suggested effects of missing exon 9 or inserted exon 
9b are still a matter of speculation. 
7KH Į-nAChR has a central role in the anti-inflammatory pathway that 
participated in making this receptor the main target for many studies aiming at 
further understanding or treating inflammation. Among these studies is 
targeting the receptor by using nicotine treatment in pancreatitis to decrease the 
incidence of individuals developing type 1 diabetes mellitus (Mabley et al., 
2002)8VLQJ WKH VDPHSULQFLSOH QLFRWLQH WUHDWPHQW WDUJHWLQJ Į-nAChR was 
shown to decrease the incidence of endotoxemia and shock preventing sepsis 
and death (Wang et al., 2004). Similar approach was used by stimulating the 
vagus nerve. This effect is mediated by the production of acetylcholine (ACh) 
that would act as agonist for these receptors and starting anti-inflammatory 
effect (Borovikova et al., 2000, Wang et al., 2003). The same principle was 
used for treatment of chronic inflammatory diseases (Pavlov et al., 2009). 
Recent and ongoing WUHDWPHQWWULDOVWULHGVXFFHVVIXOO\WKHXVHRIĮ-agonists in 
the treatment of inflammatory diseases, such as rheumatoid arthritis (van 
Maanen et al., 2009, Olofsson et al., 2012). Further treatment trials involved 
targeting mild forms of REHVLW\ ZLWK Į-agonist treatment (Cancello et al., 
2012).  
,QWHUHVWLQJO\ Į-nAChR was the focus of interest for understanding 
neuropsychiatric disorders. This might be best presented by the finding of 
decreased CHRNA7 expression in schizophrenia patients versus control 
subjects (Gault et al., 2003) DQGĮ-nAChR was linked with schizophrenia in 
subsequent studies (Araud et al., 2011). One of the theories explaining this link 
ZDVEDVHGRQWKHGHIHFWLYHQHXURQDOWUDQVPLVVLRQPHGLDWHGE\WKHĮ-nAChR) 
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that could affect cognition (Weiland et al., 2000). This was supported by the 
fact that vagus nerve stimulation was approved for the treatment of refractory 
cases of schizophrenia and depression (Ulloa, 2005). 
)LQDOO\H[SORULQJWKHUROHRIĮ-nAChRs in COPD might shed some light on 
the mechanisms that control the development and progression of the disease. 
This is based on the anti-inflammatory role that this receptor could play in a 
chronic inflammatory disease (as COPD). It is worth mentioning that in a 
URGHQWPRGHOIRUDFXWHOXQJLQMXU\Į-nAChRs was detected on the surface of 
alveolar macrophages and neutrophils, and was found to mediate anti-
inflammatory response to the lung injury (Su et al., 2007). 
The findings from my study showed that there is altered mRNA expression of 
CHRNA7 and CHRFAM7A in airway cells, which could affect Į-nAChR 
expression and/or function in these cells. This effect could lead to a 
dysfunction of the cholinergic anti-inflammatory pathway in airway cells and a 
possible exaggerated inflammatory response in COPD. Whether this is true or 
not, these results warrant the need for further studies to explore this 
phenomenon and explain its role in the inflammatory process in COPD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
General discussion                                                                               Chapter 4        
 293 
4.2 Limitations of work:  
This work helped in the detection of many transcripts for both CHRNA7 and 
CHRFAM7A genes, some of which were novel transcripts. However, there are 
still many limitations facing the exploration of transcription for these two 
genes, which is mainly the duplicated part. The fact that exons 5-10 have the 
same sequence in both genes has a major role in interfering with many methods 
aimed at testing each gene transcripts. For instance, it was non-applicable to 
quantify the full-length and missing exon 9 transcripts of CHRNA7 using 
QRT-PCR (as mentioned in section 2.7.4). 
Furthermore, another important obstacle when exploring the intronic part of 
these genes was the errors in the sequences deposited in the main databases. 
These errors can lead to unexpected results if the planned work was greatly 
based on such sequences. 
Another limitation is that I could not test for the functional effect of inserted 
exon 9b or missing exon 9.   
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4.3 Future work: 
From our results, we can conclude the following targets for a future work on 
these two genes: 
1) To test for the cigarette smoke extract (CSE) work on airway epithelial 
cells to detect the effect of smoking on inflammatory mediators in the 
presence or absence of NQRFNHGGRZQĮUHFHSWRUV 
2) Generate plasmid constructs from the full length mRNA of both genes 
(CHRNA7 & CHRFAM7A). Such constructs could be used in 
transfection studies that involve inflammatory models lacking Į
receptors (such as Cos7 cells). Additional plasmid constructs could be 
generated from the full length ones that are matching missing exon 9 
and with inserted exon 9b to test for their effects on anti-inflammatory 
response. 
3) To test a group of COPD patients and control subjects for CHRNA7 
and CHRFAM7A main transcripts to correlate the expression of 
transcripts missing exon 9 or with inserted exon 9b from both genes. 
The transcript expression could be correlated with inflammatory 
mediator levels and with the disease severity. 
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5 $SSHQGL[ 
Part of our work was not completed due to the limitation of time. This part 
included the start of functional analysis for the effects of CHRNA7 and 
CHRFAM7A in inflammatory models of airway epithelial cells. For this 
purpose, A549 cells were used as inflammatory model. The cells were grown 
on plates as mentioned in section 2.6.1. The initial optimization steps included 
testing for the effect of apoptosis on the cells. Different concentrations of 
cigarette smoke extract (CSE) were prepared for incubation with A549 cells. 
Similar work was applied by using CSE on alveolar macrophages (Kojima et 
al., 2013). This was followed by testing first for semi-quantitative RT-PCR (as 
mentioned in section 2.6.10). The initial results showed similar results for 
expression of full length and missing exon 9 transcripts from A549 after 
stimulation with 1, 5 and 10 % CSE for 0, 8 and 24 hr. Due to limitation of 
time, these results could not be replicated and further inflammatory mediators 
measurements were suspended. 
5.1 Methods and results: 
5.1.1 Cigarette smoke extract (CSE) preparation: 
Using CSE-preparation apparatus, CSE was prepared (Figure 5-1). 
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Figure 5-1: CSE-apparatus. 
For preparing CSE, one cigarette, 10 ml of phenol-red free and 50 ml syringe were 
attached together using rubber tubes and three-way valve. The valve helped control 
aspirating smoke from the cigarette at a step and then pushing the smoke to the 
medium in the next step. These steps were repeated until the whole cigarette was 
completed. 
 
 
The method included the lighting up of a single cigarette at a time. The smoke 
of the cigarette is then aspirated and introduced into a medium to make it 
dissolve within. This preparation step was applied using a three-way valve tube 
system that connects between the cigarette, medium used and a 50-ml syringe. 
The syringe helps to aspirate the smoke from the cigarette and then push it to 
the medium for subsequent dissolution. The medium used was phenol red-free 
DMEM (similar to that used with A549, mentioned in section 2.6.1) to avoid 
interfering with Nanodrop spectrometric measurements. Following the 
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preparation, different dilutions of the prepared conditioned smoke-medium 
(CSM) were prepared and optical densities were detected using Nanodrop 
spectrometer (using protein A-280 property, at 320 nm wave length). From the 
dilution readings (that represents their CSE saturation status), an optical 
density of 0.15 was considered as equal to 100% CSE concentration (Figure 5-
2). 
This calculation was used to prepare 100% CSE, which can be diluted later to 
the required CSE concentrations (1, 5 & 10%).  
 
Figure 5-2: CSE dilutions Nanodrop spectrometric readings. 
Several dilutions from the prepared CSM were prepared and optical densities 
were measured using Nanodrop spectrometry (using protein-A280 property at 
wavelength 320 nm). The dilutions tested were 5, 10, 20, 30, 50, and 100% of 
the prepared CSM. Note the increase in intensities with increased CSM 
concentrations. 
 
5.1.2 Cell counting: 
The A549 cells were prepared and grown as mentioned in section 2.6.1. To 
ensure that relatively equal number of cells was used in each stimulatory 
condition, cell counting proceeded adding the prepared CSE. This was applied 
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by adding 1*106 cells/flask used. The aim of cell counting was, in addition to 
ensuring the comparison of equal cell numbers within different CSE % used, is 
to test for possible apoptosis effect with increased time. This was tested using 
trypan blue dye to stain (that can permeate dead but not live cells) following 0, 
8 and 24 hr of incubation at conditions used for A549 cells (as mentioned in 
section 2.6.1). The zero time was regarded as a control status of the cells at the 
start of seeding and the next two time points (8 & 24 hr) were compared with 
the former one. The final calculations used were total cell, live cell an dead cell 
numbers and percentages (Figure 5-3). 
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Figure 5-3: The average percentages of live and dead A549 cells. 
Top: average percentage of live cells grown over different time points and using 
different CSE %. Bottom: corresponding percentages for dead cells. Note that the cell 
numbers were almost equal at 0% CSE for all time points. However, for 8h incubation 
with CSE preps, cells shifted towards proliferation and fewer dead cells could be 
detected. When incubation time was increased to 24 hr, fewer  live cells and more 
dead cells were detected at 5% & 10% CSE preps used (compared to corresponding 8h 
results). The error bars represent SEM for two sets of experiments. 
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The next step included extracting RNA from the A549 cells in different time 
points and CSE conditions (as mentioned in section 2.6.2) and generating 
cDNA (as mentioned in section 2.6.3) for testing with RT-PCR (as mentioned 
in section 2.6.10). The results were similar to those shown with non-stimulated 
A549 cells (as shown in section 2.7.5). However, these results are based on 
single run, and thus no complete interpretation could be based by using these 
results. 
However, further work on measurement of inflammatory mediators was not 
completed due to limitation of time. 
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